Armed YB-1 dependent oncolytic adenoviruses for combined virotherapy and suicide gene therapy by Kostova, Youlia
  
 
 
 
 
Dissertation zur Erlangung des Doktorgrades  
der Fakultät für Chemie und Pharmazie  
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
Armed YB-1 dependent oncolytic adenoviruses for combined 
virotherapy and suicide gene therapy 
 
 
Youlia Kostova 
aus 
Kardzhali, Bulgarien 
 
2014 
  
  
 
Erklärung 
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 
von Herrn Prof. Dr. Christian Plank betreut und von Herrn Prof. Dr. Ernst Wagner von der 
Fakultät für Chemie und Pharmazie vertreten.  
 
Eidesstattliche Versicherung 
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. 
 
München, 08.08.2014  
                                                                               
 
 
                                                                              .......................................................... 
                                                                                              Youlia Kostova 
 
 
 
 
 
 
 
 
Dissertation eingereicht am: 11.08.2014 
1. Gutachter: Prof. Dr. Ernst Wagner  
2. Gutachter: Prof. Dr. Christian Plank  
Mündliche Prüfung am: 27.01.2015
TABLE OF CONTENTS I 
 
TABLE OF CONTENTS 
 
1. INTRODUCTION ................................................................................................................. 1 
1.1. Glioblastoma multiforme ......................................................................................................... 1 
1.1.1. Pathology ......................................................................................................................... 1 
1.1.2. Standard therapy ............................................................................................................. 1 
1.1.3. Strategies for targeting cellular molecules ...................................................................... 2 
1.2. Limitations of current glioma therapy ..................................................................................... 3 
1.2.1. Defence mechanisms of GBM against therapies ............................................................. 3 
1.2.2. Mechanisms of drug resistance ....................................................................................... 3 
1.3. Suicide gene therapy ................................................................................................................ 4 
1.3.1. HSV1-TK/GCV suicide system .......................................................................................... 4 
1.3.2. Bystander effect .............................................................................................................. 6 
1.3.3. HSV1-TK isoforms ............................................................................................................ 7 
1.3.4. Clinical application of HSV1-TK/GCV gene therapy for cancer ........................................ 8 
1.3.5. Other suicide gene systems ............................................................................................. 9 
1.4. Reporter genes for non-invasive imaging in cancer therapy ................................................... 9 
1.5. Adenoviruses .......................................................................................................................... 11 
1.5.1. Adenoviral structure ...................................................................................................... 11 
1.5.2. Adenoviral infection and life cycle ................................................................................ 12 
1.5.3. Adenoviral genome organisation .................................................................................. 12 
1.6. Adenoviral vectors for gene therapy ..................................................................................... 14 
1.7. Oncolytic adenoviruses .......................................................................................................... 15 
1.7.1. Nature and modifications .............................................................................................. 15 
1.7.2. In vitro 3D tumour models to explore oncolytic adenoviruses ..................................... 16 
1.7.3. Clinical application of oncolytic virotherapy ................................................................. 17 
1.8. Arming oncolytic adenoviruses with suicide and reporter genes .......................................... 18 
1.9. YB-1 dependent oncolytic adenoviruses................................................................................ 19 
1.9.1. The multifunctional protein YB-1 .................................................................................. 19 
1.9.2. Regulation of adenoviral replication by YB-1 and YB-1 dependent virotherapy .......... 19 
1.10. Aims of the thesis ................................................................................................................... 22 
2. MATERIALS ..................................................................................................................... 23 
2.1. Laboratory equipment ........................................................................................................... 23 
2.2. Consumables .......................................................................................................................... 24 
2.3. Chemicals ............................................................................................................................... 24 
2.4. Biochemical reagents and commercial available substances ................................................ 25 
2.5. Prepared buffers and solutions.............................................................................................. 26 
2.6. Kits .......................................................................................................................................... 27 
2.7. Enzymes ................................................................................................................................. 27 
2.8. Antibodies .............................................................................................................................. 28 
2.9. Primers and oligonucleotide probes ...................................................................................... 28 
2.10. Plasmids ................................................................................................................................. 29 
TABLE OF CONTENTS II 
 
2.11. Prodrugs, cytostatic drugs and radiolabelled compounds .................................................... 30 
2.12. Cell culture media and supplements ..................................................................................... 30 
2.13. Cell lines ................................................................................................................................. 31 
2.14. Adenoviruses .......................................................................................................................... 32 
2.15. Software and databases ......................................................................................................... 34 
3. METHODS ....................................................................................................................... 35 
3.1. Cell culture ............................................................................................................................. 35 
3.1.1. 2D monolayer cell culture ............................................................................................. 35 
3.1.2. 3D spheroid cell culture................................................................................................. 35 
3.2. Adenovirus amplification and purification ............................................................................ 36 
3.3. Determination of viral titre .................................................................................................... 37 
3.3.1. Infectious units .............................................................................................................. 37 
3.3.2. Plaque forming units ..................................................................................................... 37 
3.3.3. Viral particle number and aggregate formation ........................................................... 37 
3.4. Adenovirus infections ............................................................................................................ 38 
3.4.1. 2D cell culture ................................................................................................................ 38 
3.4.2. 3D spheroid culture ....................................................................................................... 38 
3.5. DNA isolation ......................................................................................................................... 39 
3.5.1. Viral DNA isolation ......................................................................................................... 39 
3.5.2. Extraction of cellular DNA ............................................................................................. 39 
3.6. RNA isolation and reverse transcription ................................................................................ 39 
3.6.1. Isolation of cellular RNA ................................................................................................ 39 
3.6.2. Reverse transcription from RNA into cDNA .................................................................. 40 
3.7. Determination of DNA and RNA concentration ..................................................................... 40 
3.7.1. Measurement of optical density ................................................................................... 40 
3.7.2. PicoGreen assay for DNA quantification ....................................................................... 40 
3.8. Agarose gel electrophoresis ................................................................................................... 40 
3.9. Southern blot ......................................................................................................................... 41 
3.10. Polymerase chain reaction ..................................................................................................... 42 
3.11. Real-time quantitative PCR analysis ...................................................................................... 43 
3.11.1. Absolute DNA quantification ......................................................................................... 43 
3.11.2. Relative mRNA quantification ....................................................................................... 44 
3.12. Protein analysis ...................................................................................................................... 45 
3.12.1. Extraction of cellular proteins ....................................................................................... 45 
3.12.2. Protein quantification.................................................................................................... 45 
3.12.3. TCA precipitation ........................................................................................................... 45 
3.12.4. SDS-polyacrylamide gel electrophoresis and Western blot .......................................... 45 
3.13. Cytotoxicity assays ................................................................................................................. 46 
3.13.1. SRB staining ................................................................................................................... 46 
3.13.2. XTT assay ....................................................................................................................... 46 
3.14. Preparation of cryosections and immunofluorescence staining ........................................... 47 
3.15. [18F]-FHBG radiotracer uptake ............................................................................................... 47 
3.16. Statistical analysis .................................................................................................................. 48 
TABLE OF CONTENTS III 
 
4. RESULTS .......................................................................................................................... 49 
4.1. Characterisation of adenoviral vectors .................................................................................. 49 
4.1.1. Verification of crucial genetic modifications ................................................................. 49 
4.1.2. Control for contamination with wild-type Ad5 recombinants ...................................... 50 
4.2. Induction of cytopathic effect by YB-1 dependent oncolytic adenoviruses in tumour cell  
lines ........................................................................................................................................ 52 
4.3. Replication competence of YB-1 dependent oncolytic adenoviruses ................................... 53 
4.3.1. Replication of oncolytic adenoviruses in tumour cells .................................................. 53 
4.3.2. Release of newly synthesised adenoviral particles ....................................................... 55 
4.3.3. Oncolytic adenoviruses produce infectious progeny .................................................... 56 
4.4. Expression of adenovirus-delivered HSV1-sr39TK in tumour cells ........................................ 57 
4.5. Analysis of growth, cellular migration and infectivity of glioma spheroids ........................... 60 
4.5.1. Spheroids exhibit tumour-like growth pattern ............................................................. 60 
4.5.2. Migration potential of cells from spheroids .................................................................. 61 
4.5.3. Spheroids allow for adenoviral infections ..................................................................... 61 
4.6. Overlapping time- and dose-dependent HSV1-sr39TK/GCV-mediated cytotoxicity and 
oncolytic effect ...................................................................................................................... 63 
4.7. Bystander effect of viral oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity ................ 67 
4.8. Enhancement of the oncolytic potential of YB-1 dependent adenoviruses by TMZ ............. 69 
4.9. Improved cell killing by the combination of oncolytic potential, TMZ and HSV1-sr39TK/GCV-
mediated cytotoxicity ............................................................................................................ 72 
4.9.1. Combined cell killing in 2D glioma culture .................................................................... 72 
4.9.2. Combined cell killing in 3D glioma spheroids ................................................................ 76 
4.10. Enhancement of replication of YB-1 dependent adenoviruses by TMZ ................................ 79 
4.10.1. Enhancement of replication in 2D glioma culture ......................................................... 79 
4.10.2. Enhancement of replication in 3D glioma spheroids .................................................... 80 
4.11. Release and infectivity of newly synthesised viral particles from infected and drug-treated 
3D glioma spheroids .............................................................................................................. 81 
4.12. Adenovirus dissemination and HSV1-sr39TK expression in 3D glioma spheroids ................. 83 
4.13. Uptake of [18F]-FHBG by HSV1-sr39TK-expressing glioma cells ............................................. 87 
4.13.1. [18F]-FHBG accumulation in 2D glioma culture .............................................................. 87 
4.13.2. [18F]-FHBG accumulation in 3D glioma spheroids ......................................................... 88 
5. DISCUSSION .................................................................................................................... 92 
5.1. Application of YB-1 dependent oncolytic adenoviruses to address limitations of GBM 
therapy ................................................................................................................................... 92 
5.2. Genetic stability and quality of adenoviruses is crucial for their application as anti-tumour 
agents ..................................................................................................................................... 92 
5.3. Efficient replication and oncolytic potential of YB-1 dependent adenoviruses .................... 94 
5.4. Stable expression of HSV1-sr39TK from replication-competent adenoviral vectors ............ 95 
5.5. Multicellular 3D glioma spheroids as a feasible model to explore anti-tumour treatment .. 96 
5.6. Mutual potentiation of adenoviral oncolysis and HSV1-sr39TK/GCV-mediated effect......... 97 
5.7. Potentiation of viral oncolysis by HSV1-sr39TK/GCV-mediated bystander effect ................ 99 
5.8. Potentiation of YB-1 dependent viral oncolysis by TMZ and benefit of viral dissemination in 
3D ......................................................................................................................................... 100 
TABLE OF CONTENTS IV 
 
5.9. Relevance of 3D spheroids for exploring potential in vivo effects of the HSV1-sr39TK/GCV 
suicide system ...................................................................................................................... 103 
5.10. Combined effect of YB-1 dependent virotherapy, TMZ and HSV1-sr39TK/GCV suicide system 
against GBM ......................................................................................................................... 104 
5.11. Suitability of HSV1-sr39TK-armed YB-1 dependent oncolytic adenoviruses for non-invasive 
reporter gene imaging ......................................................................................................... 106 
5.12. Outlook and future perspectives of combined YB-1 dependent virotherapy and HSV1-
sr39TK/GCV suicide gene system ......................................................................................... 107 
6. SUMMARY ..................................................................................................................... 110 
7. ZUSAMMENFASSUNG ..................................................................................................... 112 
8. REFERENCES ................................................................................................................... 114 
9. APPENDIX ...................................................................................................................... 130 
9.1. Abbreviations ....................................................................................................................... 130 
9.2. Publications .......................................................................................................................... 134 
9.2.1. Original articles ............................................................................................................ 134 
9.2.2. Posters ......................................................................................................................... 134 
9.2.3. Oral presentations ....................................................................................................... 134 
10. ACKNOWLEDGEMENTS ................................................................................................... 135 
 
 
 
INTRODUCTION  1 
 
1. INTRODUCTION  
 
1.1. Glioblastoma multiforme 
1.1.1. Pathology  
Gliomas are a group of low-grade and high-grade brain tumours that originate from glia (from Greek 
for “glue”), the brain tissue providing support functions to neural cells [1]. The cells of origin for the 
development of gliomas are currently unknown. A major theory has been established that neural 
stem cells or neural progenitor cells undergo transformation events during development [2, 3]. 
Another hypothesis refers to the mutation-induced dedifferentiation of mature brain cells like 
astrocytes and oligodendrocytes as the origin of gliomas [4].  
According to the World Health Organisation (WHO), gliomas are classified as grade I to IV. Grade I 
and II gliomas are generally benign, with low proliferative and infiltrative potential, whereas grade III 
and IV gliomas are characterised by a high proliferative activity, marked infiltration into surrounding 
tissue and a very low median survival rate [5, 6]. Grade III and IV malignant gliomas account for 80 % 
of all primary malignant tumours of the brain and the central nervous system (CNS) [7].    
The most common malignant glioma subtype is grade IV astrocytoma, also known as glioblastoma 
multiforme (GBM) [6]. The high aggressiveness and recurrence rate of GBM characterise this glioma 
subtype as the most common deadly primary brain tumour [1, 8]. GBM represents 45.2 % of all 
primary malignant brain tumours and has an incidence rate of 3.19 per 100,000 inhabitants of the 
United States. Despite state-of-the-art therapy, less than 5 % of GBM patients survive within five 
years post diagnosis [7]. Currently there are over 150 ongoing clinical trials for GBM, including 
standard and alternative treatment [9]. 
1.1.2. Standard therapy 
Conventional treatment of GBM comprises surgical intervention, radiotherapy and chemotherapy. 
While surgery and radiotherapy have proven only limited efficacy as monotherapies [8, 10, 11], the 
administration of the chemotherapeutic temozolomide (TMZ, Temodal®) is considered as the most 
important progress in malignant glioma therapy [6]. Median survival times of all patients with newly 
diagnosed GBM improved from 8.1 months in 2000–2003 to 9.7 months in 2005–2008 due to the 
introduction of TMZ [12]. TMZ is an orally available DNA-alkylating agent of the imidazotetrazine 
group. Under physiological conditions TMZ spontaneously decomposes to the active substance 
monomethyltriazene 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). MTIC further 
releases a highly reactive methyldiazonium cation that mediates the cytotoxic activity of TMZ mainly 
through methylation at the O6 position of guanine residues in guanine-rich regions of the DNA [13, 
14]. Although TMZ affects non-specifically rapidly dividing cells, the benefits of the drug are good oral 
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tolerance and efficient penetration of the blood-brain barrier [15] that renders TMZ an attractive 
therapeutic agent for GBM. 
TMZ was established as the standard of care chemotherapy against malignant glioma and GBM after 
a study of Stupp et al. [6, 16]. In a randomised phase III clinical trial they demonstrated that the 
median survival of patients with newly diagnosed GBM significantly improved from 12.1 to 14.6 
months by combined TMZ treatment and postoperative radiation, and the 2 year survival rates 
increased to 26 %, in comparison to radiation therapy alone. A follow-up clinical trial revealed a 10 % 
survival rate after 5 years with adjuvant TMZ treatment versus only 2 % with radiation therapy alone 
[17]. Recent clinical trials with GBM pointed out that concomitant and adjuvant TMZ treatment with 
radiation therapy was beneficial for survival outcome [18, 19].     
1.1.3. Strategies for targeting cellular molecules 
Because of the poor prognosis of GBM despite the application of state-of-the-art therapy, novel 
treatment approaches against cellular targets are being evolved in order to inhibit angiogenesis and 
tumour growth or to stimulate anti-tumour immune responses.  
A promising therapeutic strategy to prevent angiogenesis of malignant glioma and thus to arrest 
neoplasm expansion is the human recombinant monoclonal antibody bevacizumab, which targets 
vascular endothelial growth factor (VEGF), a crucial mediator of tumour angiogenesis [20, 21]. 
Bevacizumab was approved in 2009 in the United States for the treatment of recurrent GBM based 
on encouraging response rates [22-24] and led to improved median survival in combination with 
protracted TMZ [25] and radiotherapy [26].  
Further cellular targets for GBM therapy are cell surface growth factor receptors and signalling 
molecules. Overexpression of epidermal growth factor receptor (EGFR) is common in about 40 % of 
the GBM cases [27]. However, it was shown that small-molecule EGFR inhibitors such as gefitinib and 
erlotinib could not prolong survival of GBM patients in clinical trials substantially [28, 29].  
Several approaches to target aberrant signalling pathways in GBM through inhibition of effector 
molecules have been investigated. Attractive molecular targets are the mammalian target of 
rapamycin (mTOR) from the phosphatidylinositide 3-kinase/protein kinase B/mTOR (PI3K/Akt/mTOR) 
pathway [30-32] or protein kinase C (PKC) [33-35].  
Targeting the immune system has been considered a promising future experimental modality for 
treatment of cancer, including malignant gliomas. A panel of approaches are being currently 
investigated in clinical trials for GBM, including immunotherapy with cytokines, dendritic cells and 
autologous stimulated lymphocytes, as well as tumour- or peptide-based vaccines [9].  
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1.2. Limitations of current glioma therapy  
1.2.1. Defence mechanisms of GBM against therapies  
Despite recent survival prolongation of GBM patients by combined TMZ treatment and radiotherapy, 
and despite the development of novel approaches for molecular targeting, the long-term benefit of 
current therapy for GBM remains debatable. A critical factor hampering the eradication of GBM is 
the highly invasive and dispersive nature of GBM cells, leading to dissemination of the tumour and 
thus making complete resection impossible [36, 37]. The immune privilege of the CNS facilitates the 
immune evasion of tumour cells and thus contributes to the immunological ignorance towards GBM 
antigens [38, 39]. These factors limit the efficacy of immunotherapies. The variability of molecular 
aberrations and dysregulated signalling pathways within GBM cases, but also within tumours in 
general, is a considerable obstacle for the development of sustained targeted therapies. Moreover, 
combinations of targeted molecular drugs result in additive toxicity and drug efficacy is diminished 
due to insufficient penetration into the tumour tissue [1]. Finally, the presence of a self-renewable 
CD133+ tumour stem-like cell population that is resistant to chemo- and radiotherapy, is another 
major challenge contributing to tumour recurrence and dismal long-term survival prognosis [40].  
1.2.2. Mechanisms of drug resistance 
1.2.2.1. Resistance to alkylating agents 
Drug-resistance in glioma can often arise from aberrant DNA repair mechanisms [41]. The most 
thoroughly explored DNA repair protein in GBM, associated with poor prognosis and drug-resistance, 
is mediated by the enzyme O6-methylguanine-DNA methyltransferase (MGMT). MGMT is capable of 
removing the O6-methylguanine adducts formed by alkylating agents and high level of the enzyme 
reduces the efficacy of these agents [42]. Hegi et al. showed that MGMT promoter 
hypermethylation, which was detected in 40-50 % of GBM cases, prevents MGMT gene expression 
and is associated with better response to the alkylating drug TMZ and radiation, resulting in longer 
survival [43]. In contrast, overexpression of MGMT due to unmethylated promoter was associated 
with resistance to alkylating drugs in clinical trials [44, 45]. To circumvent resistance to alkylating 
agents resulting from MGMT overexpression, therapeutic approaches using the inhibitor of MGMT 
O6-benzylguanine (O6-BG) were investigated in combination with alkylating agents as nitrosoureas or 
TMZ, however with limited success [46-48].  
1.2.2.2. Multidrug resistance 
Many tumours can become resistant not only to the specific cytostatic drug applied as a current 
therapy, but also to other agents. This cross-resistance is also called multidrug resistance and is 
caused by multiple mechanisms [49]. The first identified factor mediating multidrug resistance is 
overexpression of the multidrug resistance 1 (MDR1) gene that encodes for the MDR1/P-
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glycoprotein (P-gp) or ABCB1, a member of the adenosine triphosphate (ATP)-binding cassette (ABC) 
transporter family [50]. ABC-transporters mediate a drug efflux that leads to decrease in cellular 
accumulation of cytostatic compounds [49]. Multidrug-resistant cells become insensitive not only to 
structurally unrelated cytostatic drugs such as anthracyclines, vinca alkaloids, and taxanes, but also 
to other compounds such as antiviral drugs and antibiotics, which are transported by P-gp [50]. The 
classical P-gp-mediated as well as alternative mechanisms of multidrug resistance have been 
extensively studied in different cancer cell lines with an established multidrug-resistant phenotype 
[51-53]. However, it has still to be investigated if alternative therapeutic compounds or gene therapy 
approaches using specific prodrugs for example, are also hampered by multidrug resistance 
mediated by P-gp.   
 
Promising tools to circumvent the above described limitations for a successful therapy of GBM are 
alternative tumour-targeting approaches as suicide gene therapy and oncolytic virotherapy. 
Oncolytic viruses have the ability to replicate in and selectively kill tumour cells. To increase their 
killing potential, oncolytic viruses can be equipped with suicide genes that mediate cytotoxicity as a 
part of a suicide gene system. Suicide gene therapy and oncolytic virotherapy have already 
demonstrated their efficacy in tumour eradication, as described in the following.  
 
1.3. Suicide gene therapy   
Suicide gene therapy, also termed gene-directed enzyme prodrug therapy, describes the delivery of a 
gene that encodes an enzyme, which is able to convert a non-toxic prodrug into a metabolite that 
exerts cytotoxic effects in target cells. Prodrugs are inert compounds that can be transformed into 
toxins by suicide gene-encoded enzymes specific for certain tissue or overexpressed in tumours as a 
result of gene delivery [54]. Prodrug-mediated suicide gene systems are therefore convenient tools 
for the application in cancer therapy. Due to its minimal toxicity in healthy tissue, suicide gene 
therapy is designed to address the limitations of conventional chemotherapy, such as severe adverse 
effects and lack of specificity. 
1.3.1. HSV1-TK/GCV suicide system  
The most extensively studied suicide gene strategy in cancer therapy is the Herpes simplex virus 1 
thymidine kinase (HSV1-TK) gene in combination with the prodrug Ganciclovir (GCV) [55]. The HSV1-
TK enzyme is a homodimer with a subunit molecular mass of 45 kDa [56] and is responsible for the 
phosphorylation of its natural substrate deoxythymidine to deoxythymidine triphosphate, which is 
incorporated into nascent DNA of HSV1 [57]. Thus, HSV1-TK is involved in the reactivation of HSV1 
from ganglionic neurons during the latent stage of its life-cycle [58]. HSV1-TK exhibits a broad 
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specificity to other nucleosides, such as deoxycytidine, deoxythymidylate and various pyrimidine and 
guanosine analogues [56]. Of them, the guanosine analogue GCV is metabolised by HSV1-TK with a 
1000-fold higher efficiency compared to mammalian thymidine kinases [59] and this property 
provides the basis for the application of GCV in combination with the suicide gene HSV1-TK for 
cancer gene therapy [57]. Moreover, HSV1-TK exhibits better catalytic properties for GCV than for 
Acyclovir (ACV), a GCV-related guanosine analogue [60, 61]. The prodrug GCV is initially 
phosphorylated by HSV1-TK to GCV-monophosphate, which is further phosphorylated to GCV-di- and 
-triphosphate by cellular enzymes, such as guanylate kinase and nucleoside diphosphokinase [56, 62, 
63]. The toxic metabolite GCV-triphosphate competes with deoxyguanosine triphosphate for the 
incorporation into nascent DNA of dividing cells and inhibits the cellular DNA polymerase, causing 
double strand destabilisation that leads to abrogation of DNA synthesis and subsequently to cell 
death [61, 62, 64] (figure 1.1). In addition, GCV exerts potent anti-viral activity against viruses of the 
herpesvirus family [65] and against hepatitis B virus variants [66].   
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Mode of action of the HSV1-TK/GCV suicide system. After transfection or viral transduction of 
target cells with HSV1-TK-bearing vectors, the HSV1-TK enzyme is expressed and translocated to the cytoplasm. 
HSV1-TK phosphorylates its specific prodrug Ganciclovir (GCV) to GCV-monophosphate (-P), which is further 
phosphorylated to GCV-di-P and GCV-tri-P by cellular kinases. The toxic metabolite GCV-tri-P incorporates into 
the DNA of dividing cells, causing double strand destabilisation, and inhibits the cellular DNA polymerase, 
resulting in termination of DNA synthesis and cell death.      
 
 
It has been suggested that the mode of cell death elicited by the HSV1-TK/GCV system in tumours 
involves both apoptotic [67-70] and non-apoptotic mechanisms [71, 72], depending on the tumour 
cell type. The regulation of the mitochondrial death pathway by B cell lymphoma-2 (Bcl-2) family 
proteins was suggested as the most probable mechanism of HSV1-TK/GCV-mediated apoptotic death 
[68-70]. Death of some tumour cell lines after HSV1-TK/GCV activation can also be caused by 
HSV1-TK
OH
H
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H H
O
O
N
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apoptosis in the G1 phase of the cell cycle combined with late apoptotic or necrotic sub-G1 DNA 
fragmentation [73]. 
1.3.2. Bystander effect 
The efficacy of the HSV1-TK/GCV suicide gene system is greatly facilitated by the so called bystander 
effect. The principle of the bystander effect was first demonstrated in a mosaic co-culture of 
untransfected and HSV1-TK transfected cells, in which the untransfected cells, surrounded by 
transfected cells, became sensitive to GCV [55]. This finding showed the existence of a bystander 
effect that contributes to the eradication of neighbouring non-HSV1-TK-borne cells, even if there is 
only a small subpopulation of HSV1-TK-bearing cells. Considering the low transduction efficiency of 
some gene delivery vehicles for HSV1-TK, the bystander effect is essential for successful tumour 
eradication by prodrug-mediated suicide systems. The basic principle of the bystander effect is the 
transport of GCV-monophosphate, GCV-diphosphate and GCV-triphosphate into adjacent cells, 
where GCV-monophosphate and GCV-diphosphate are further phosphorylated by cellular kinases 
and accumulated GCV-triphosphate directly leads to cytotoxicity [74, 75] (figure 1.2). It has been 
shown that, when only 10 % of cell culture had been transduced to express HSV1-TK, the treatment 
with GCV could result in 100 % cell killing. Corresponding in vivo tumour models, including glioma, 
also confirmed that treatment with GCV induced a complete tumour regression, when 10-50 % of the 
cell population was HSV1-TK positive [76-80].  
One main drawback of the HSV1-TK/GCV system is that, in contrast to the prodrug, the 
phosphorylated GCV metabolites are highly charged and thus unable to passively diffuse throughout 
the cellular lipid membranes and into neighbouring cells [57, 75]. Therefore, the transfer of 
phosphorylated GCV between HSV1-TK positive cells and neighbouring cells was shown to be 
accomplished through direct intercellular contact, mediated by gap junctions [81-83]. Another 
mechanism for a local bystander effect might be the phagocytosis of apoptotic bodies, generated 
from HSV1-TK-modified cells, by adjacent unmodified tumour cells [77].  
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Figure 1.2: Basic principle of the HSV1-TK/GCV-mediated bystander effect. In a population of HSV1-TK-
transduced and untransduced cells, the metabolites GCV-P, GCV-di-P and GCV-tri-P produced by HSV1-TK and 
cellular enzymes in HSV1-TK-transduced cells, are transported to neighbouring untransduced cells through gap 
junctions. GCV-P and GCV-di-P are phosphorylated to GCV-tri-P by kinases of the untransduced cells. Finally, 
accumulated GCV-tri-P induces cytotoxicity in both HSV1-TK-transduced and untransduced cells [75].     
  
       
1.3.3. HSV1-TK isoforms  
Considering that the Michaelis constant (Km) value of HSV1-TK for GCV is about 100-fold higher than 
its Km value for deoxythymidine [61, 84], the enzyme has a higher affinity for deoxythymidine and 
therefore, both molecules compete for the active site of HSV1-TK. Because of this competition, high 
clinically relevant doses of GCV are needed to be applied, but they often cause undesirable side 
effects in patients [54, 56]. In order to overcome unspecific toxicity mediated by GCV, novel mutant 
variants of HSV1-TK with improved specificity towards GCV have been developed and already used in 
preclinical investigations [85-88].  
The most extensively studied mutant is the HSV1-TK variant sr39TK, derived by semi-random 
sequence mutagenesis of amino acid residues within the putative active site of the enzyme [86]. 
Among seven HSV1-TK variants, HSV1-sr39TK was identified as the most sensitive to GCV. This 
mutant contains five amino acid substitutions (table 1.1) that confer a 43-fold greater sensitivity to 
GCV as well as a 20-fold increased sensitivity to ACV than the wild-type HSV1-TK and better efficiency 
in tumour ablation than the wild-type enzyme [85, 86]. The observed low half maximal inhibitory 
concentration (IC50) of 0.017 µM for GCV with HSV1-sr39TK enabled a drastic reduction of the 
prodrug dose applied in vitro and favoured a 10-fold lower GCV concentration to efficiently inhibit 
the growth of HSV1-sr39TK-expressing glioma xenograft models in comparison to GCV with wild-type 
HSV1-TK-transduced cell untransduced cell
GCV
GCV-tri-P
GCV-di-P
GCV-P
GCV
HSV1-TK
GCV-tri-P
GCV-di-P
GCV-P
cellular kinases
cellular kinases
cell death
GCV-tri-P GCV-tri-P
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HSV1-TK [86]. HSV1-sr39TK in combination with GCV was shown to be more efficient in in vitro and in 
vivo studies against metastatic prostate cancer [89], as well as against various tumour cell lines [90], 
compared to wild-type HSV1-TK or other variants.  
 
Table 1.1: Deduced amino acid sequence of the HSV1-TK semi-
random mutant sr39TK. Mutated residues conferring increased 
sensitivity towards GCV and/or ACV are displayed [86].  
     
 Amino acid residues 159-161 and 168-169 
HSV1-TK (wt) L             I             F                   A             L 
sr39TK (mutant) I             F             L                   F             M 
 
A: Alanine; F: Phenylalanine; I: Isoleucine; L: Leucine; M: Methionine  
 
 
1.3.4. Clinical application of HSV1-TK/GCV gene therapy for cancer  
The success of the HSV1-TK/GCV suicide system in preclinical studies encouraged the conduction of 
several clinical trials towards various tumour types. Beneficial for the therapeutic outcome in cancer 
are the minimal adverse effects of the suicide gene system, due to the preferential killing of rapidly 
dividing cells such as tumour cells, but not of normal tissue [56]. Clinical phase I/II trials towards 
various cancer types, including ovarian cancer [91, 92], metastatic melanoma [93], prostate cancer 
[94, 95] and malignant glioma [96], demonstrated a good safety profile of the HSV1-TK/GCV suicide 
therapy, associated with moderate to encouraging efficacy.  
Given the in chapter 1.2. described limitations of current therapy against glioma, the strategy of 
HSV1-TK/GCV suicide gene therapy is being under investigation as an alternative treatment of these 
neoplasms. Since the HSV1-TK/GCV system exerts its cytotoxic effect only in dividing cells, HSV1-TK 
and GCV are suitable for specific local targeting of the highly proliferating GBM cells [39]. Moreover, 
the immune privilege of the brain hampers the immune recognition of cellular cytotoxic processes 
and favours the transduction of the tumour with viral delivery vectors. Several encouraging phase I 
and II clinical trials towards malignant glioma, using retroviral [97, 98] and adenoviral [96, 99] 
delivery of HSV1-TK, pointed out the safety and feasibility of this suicide gene therapy. Rainov et al. 
reported minimal toxicity of adjuvant HSV1-TK gene therapy in GBM patients in a phase III clinical 
trial, but the limiting factor was the poor transduction efficiency of the retroviral delivery vector 
[100]. Though more encouraging than the trial of Rainov et al., the improvement of overall survival in 
a recent phase III GBM trial, using adenovirus-mediated gene therapy with HSV1-TK and GCV 
administration, was only minor [101]. In order to circumvent resistance of HSV1-TK-expressing cells 
to GCV, a combination of the HSV1-TK/GCV system with conventional chemo- and radiotherapy 
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became a necessary and successful treatment option, as it was shown in preclinical trials that HSV1-
TK could sensitise glioma cells to radiation and cytostatic drugs like TMZ [102, 103].  
1.3.5. Other suicide gene systems  
It is of advantage to develop a broad range of suicide genes/prodrug combinations for cancer 
therapy, because not all cancers respond equally to the same prodrug and, in case of treatment 
failure with one suicide gene, it can be substituted by alternative suicide genes, against which there 
is no pre-existing immune response [56]. Over twenty suicide genes with different kinetic and 
cytotoxic properties are identified by now [57]. Besides HSV1-TK, other examples of widely used 
suicide gene systems include the enzymes cytosine deaminase (CD) and cytochrome P450. The CD 
enzyme, found in bacteria (bCD) and yeast (yCD), catalyses the conversion of the prodrug 5-
fluorocytosine (5-FC) to the toxic metabolite 5-fluorouracil (5-FU) [104]. Cytochrome P450 enzymes 
are drug-metabolising enzymes of mammals, responsible for the conversion of the prodrugs 
ifosphamide (IFO) and cyclophosphamide (CPA) into their 4-hydroxy-forms, which induce cytotoxic 
effects [105]. Both CD/5-FU and cytochrome P450/IFO and CPA suicide gene systems have been 
investigated as approaches against cancer [106, 107]. 
 
1.4. Reporter genes for non-invasive imaging in cancer therapy 
Non-invasive imaging with reporter genes in tumour therapy is applied for monitoring of delivery, 
distribution, expression and persistence of a therapeutic gene within a tumour, for visualising the 
therapeutic success as well as tumour regression or growth in living organisms. Non-invasive imaging 
can be performed e.g. by means of positron emission tomography (PET) with radionuclide probes. 
PET displays a higher sensitivity and spatial resolution than single photon emission computed 
tomography (SPECT). With its ability to detect about 10-10 M of a radiolabelled probe, PET allows the 
direct quantitation of tracer amounts of radiolabelled substrates within cells [108].  
The most commonly applied reporter gene for non-invasive tumour imaging in experimental settings 
is HSV1-TK. The principle of non-invasive imaging with HSV1-TK as a reporter gene is based on the 
enzymatic conversion of various specific radiotracer substrates, such as the acycloguanosine 
derivative [18F]-labelled 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine (FHBG) or the uracil nucleoside 
derivative [124I]- and [131I]-labelled 2’-fluoro-2’-deoxy-5-iodo-1-β-D-arabinofuranosyl (FIAU) by the 
expressed HSV1-TK protein after gene transduction. The phosphorylated radiolabelled metabolites 
produced by this conversion are then trapped within the cell and can be visualised by PET ([18F]-
FHBG, [124I]-FIAU) or SPECT ([131I]-FIAU) imaging [109, 110] (figure 1.3). Crucial for the choice of the 
radiolabelled tracer FHBG and FIAU as reporter probes for HSV1-TK is that HSV1-TK and HSV1-sr39TK 
exhibit greater substrate specificity for these compounds than does mammalian TK [110].  
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Figure 1.3: Principle of reporter 
gene imaging with HSV1-TK. The 
HSV1-TK enzyme, which is 
expressed after gene 
transduction of target cells, 
converts its specific 
radiolabelled substrates (e.g. 
[*I]-FIAU, [18F]-FHBG) into 
phosphorylated metabolites. 
These cannot diffuse throughout 
the cell membrane and 
accumulate within the cell, 
enabling non-invasive imaging of 
HSV1-TK-transduced cells by 
means of PET and SPECT. *I: 
[124I]- or [131I]-FIAU. 
      
 
Early investigations of hepatic reporter gene delivery have shown that adenoviral transfer of HSV1-TK 
or HSV1-sr39TK is promising for in vivo reporter gene PET imaging using radiolabelled 
acycloguanosines [111-113]. Some in vitro and in vivo studies of cardiovascular imaging [114-116] or 
tumour imaging [117-119] showed that HSV1-TK is more sensitive to [14C]-FIAU and [124I]-FIAU than 
to [18F]-FHBG. In contrast, HSV1-sr39TK showed greater sensitivity to [18F]-FHBG than to FIAU probes 
and the HSV1-sr39TK/[18F]-FHBG combination yielded more radiotracer accumulation over time and 
higher imaging contrast for PET than the combination of HSV1-sr39TK and FIAU. Therefore, HSV1-
sr39TK and [18F]-FHBG have been used as an optimal combination of reporter gene and probe for 
non-invasive PET imaging. Non-invasive imaging with HSV1-sr39TK and [18F]-FHBG in a dedicated 
small animal scanner with greater sensitivity than clinical PET scanners, termed microPET, was 
feasible for monitoring the HSV1-sr39TK/GCV-mediated effect in tumour xenografts [120-123]. The 
feasibility of FIAU-/FHBG-based HSV1-TK nuclear reporter gene imaging, its application for assessing 
the safety of transgene delivery vectors and for predicting the therapeutic response in cancer, was 
also demonstrated in several phase I and II clinical trials [124-127]. 
Another example of a widely used nuclear reporter gene is the human sodium-iodide symporter gene 
(hNIS). It mediates the uptake of radioisotopes suitable for imaging with scintigraphic techniques, 
such as 123I, 131I, and 99mTc-pertechnetate (99mTc), or with PET, as 124I and 94mTc [128]. hNIS was applied 
for non-invasive imaging of the response of tumours to radioiodine therapy [129, 130]. Nuclear 
reporter genes can also code for extracellular receptors like human somatostatin receptor subtype 2 
(hSSTR2) [131] or human dopamine 2 receptor (hD2R) [132].    
 
 
HSV1-TK
radiolabelled
substrate:
[*I]-FIAU
[18F]-FHBG
P
PET
SPECT
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1.5. Adenoviruses 
1.5.1. Adenoviral structure 
Human adenoviruses belong to the family of Adenoviridae and the genus of Mastadenoviruses. They 
were first isolated from human adenoids in 1953 by Rowe et al. [133]. Adenoviruses mainly cause 
infections of the respiratory tract that range from mild and self-limited to life threatening, associated 
with acute respiratory disease in immunocompromised patients [134-136]. Over 60 serotypes of 
human adenovirus, which are divided into seven species (A-H), have been identified so far [137].  
Adenoviruses are non-enveloped viruses that have a capsid diameter of over 90 nm and a size of 150 
MDa. Their genome consists of linear, double-stranded DNA of about 36 kb length [138, 139]. The 
mature adenovirus particle is composed of an outer capsid and an inner core that contains the viral 
DNA (figure 1.4). Recently, the visualisation of adenoviruses by X-ray crystallography [140] or 
cryoelectron microscopy [141] enabled the nearly atomic resolution of all structure components of 
the virion. The icosahedral virus capsid is composed of 240 pseudo-hexagonal homotrimers of hexon, 
the major capsid protein, on the faces and edges of the capsid and of a pentagon-shaped penton 
located on each of the 12 fivefold apices. Each penton consists of a covalent complex between the 
homopentameric penton base and a homotrimeric fiber protein [142-144]. Four minor capsid 
proteins (IIIa, VI, VIII and IX) are also involved in capsid assembly [141, 145]. The virus core contains 
six structural proteins, five of which are associated with the viral genome (V, VII, µ, IVa2 and the 
terminal protein). The sixth core protein, the 23K cysteine protease, plays a role in virion assembly 
[138, 144].    
 
  
 
 
 
 
 
 
 
 
Figure 1.4: Adenovirus assembly. The adenovirus capsid is composed of the major capsid proteins hexon and 
penton (built up of penton base and fiber), and the minor capsid proteins IIIa, VI, VIII and IX. The core proteins 
V, VII, µ, the terminal protein and IVa2 stabilise the viral DNA. The viral protease plays a role in virion assembly 
(modified from [144]). 
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1.5.2. Adenoviral infection and life cycle 
The initial contact between the adenovirus and the target cell is mediated by the interaction of the 
viral fiber protein with the coxsackie and adenovirus receptor (CAR), a cell membrane protein [146]. 
However, dependent on species, adenoviruses can also utilise alternative cell surface receptors for 
cell entry, e.g. CD46, CD80, CD86, sialic acid receptors or heparin sulphate glycosoaminoglycans [138, 
144]. The virus-host interaction is further accomplished by the binding of an arginine-glycine-aspartic 
acid (RGD) peptide on the viral penton base to cellular ανβ3/ανβ5 integrins [147]. This binding triggers 
the internalisation of viral particles by clathrin-mediated endocytosis [148]. The delivery of the virus 
into an acidic endosome mediates the viral escape from the endosome and the transport of the virus 
towards the nucleus [149]. After docking to the nuclear pore complex, the viral particle disassembles 
and its DNA is imported into the nucleus, where the transcription of viral genes is initiated [150]. 
1.5.3. Adenoviral genome organisation 
The linear DNA of the adenovirus is flanked by inverted terminal repeats (ITR) that contain the origins 
of DNA replication and, located close to the left ITR, the encapsidation signal [151, 152]. The viral 
genome is divided into transcription units defined as early and late according to the onset of their 
transcription [153] (figure 1.5). The early elements (E1-4) are the first to be transcribed shortly after 
infection and their gene products have regulatory functions. The E1 region codes for the early region 
1A (E1A) and early region 1B (E1B) proteins. E1A are the first proteins of the adenovirus that are 
expressed after infection. Crucial for mediating the regulatory functions of E1A are two transcripts of 
12S and 13S mRNA, derived by alternative mRNA splicing, that encode proteins of 243 amino acid 
(aa) and 289 aa, respectively. E1A contains four conserved regions (CR1-4). The functional difference 
between the 289 aa and the 243 aa proteins arises from the lack of CR3 in the 243 aa protein. In the 
289 aa protein, CR3 codes for a C4 zinc finger motif that acts as a transcriptional activator crucial for 
the transactivation of the delayed early E2-4 genes and of some cellular genes [154-157]. A further 
function of the E1A proteins is the deregulation of the host cell cycle in order to facilitate adenoviral 
replication. Both splice variants of E1A bind to cellular retinoblastoma proteins (pRb) and inhibit their 
cell cycle suppressive activity by destroying pRb-E2F complexes. The released cellular transcription 
factor E2F mediates transition of the host cell cycle from G0/G1 into the S phase [156, 158]. 
Moreover, E1A proteins can directly target the cell division cycle 25 homolog a (cdc25a) phosphatase 
and thus force S phase entry [159].              
The E1B protein family is subdivided into the proteins E1B55K and E1B19K. The E1B55K protein forms 
in cooperation with the E4 encoded protein E4orf6 an ubiquitin-ligase complex that targets p53 and 
inhibits p53-mediated cell cycle arrest and apoptosis [160]. The E1B55K and E4orf6 complex is also 
responsible for the export of viral mRNA transcripts from the nucleus into the cytoplasm for the 
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biosynthesis of viral proteins. In addition, E1B55K and E4orf6 downregulate host protein synthesis 
[161]. The E1B19K protein is a homologue of the Bcl-2 protein and exerts anti-apoptotic effects in 
host cells [162].    
The E2 transcription unit, including the E2A and E2B genes, encode the viral DNA polymerase and 
other proteins that are directly involved in adenoviral DNA replication, DNA elongation, transcription 
control, mRNA stability, protection of viral DNA from degradation and prevention of DNA integration 
into the host genome [163, 164]. At the end of adenoviral replication, up to 106 new DNA molecules 
have been synthesised within 48 h after infection of human cells, which almost correlates with the 
cellular DNA content [152].     
The gene products of the E3 transcription unit are involved in mediation of lytic viral release from the 
infected cells and in adenovirus-mediated immune escape. The E3 encoded adenovirus death protein 
(ADP, formerly E3 11.6K) facilitates host cell lysis and the release of newly synthesised viral particles 
at late stages of infection [165]. E3 encoded proteins with immunomodulatory functions prevent 
detection of virus-infected cells by the host immune system by blocking MHC class I antigen 
presentation and inflammatory responses induced by cytokines [166].   
The E4 gene products are derived by alternative splicing of a primary mRNA transcript. Proteins 
expressed by the E4 region exhibit diverse functions in viral DNA replication, RNA splicing, synthesis 
of late viral proteins, as well as in modulation of transcription, cell cycle, DNA repair and cell 
signalling [167].                  
Gene expression from the late regions L1-5 is initiated about 8 h post infection. The late genes 
encode the viral structural proteins described in chapter 1.5.1. [168]. Besides its role in virion 
assembly [144], the L3-coded 23K proteinase cleaves the cellular cytokeratin network, thus rendering 
the host cell susceptible to lysis and release of newly synthesised viral particles [169]. An indication 
for cell lysis is the cytopathic effect (c.p.e.) that describes the typical swelling and rounding of 
adenovirus-infected cells, occurring one to two days after infection [170].   
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Figure 1.5: Organisation of the adenoviral genome. Location of the early (E1-4) and late (L1-5) gene regions in 
the adenoviral genome and their crucial gene functions.    
 
 
1.6. Adenoviral vectors for gene therapy 
Adenoviruses can be applied as vehicles for the delivery of therapeutic genes and adenovirus-based 
gene therapy is a promising alternative treatment for cancers that are refractory to conventional 
therapies. The advantages of adenoviral vectors in gene therapy are their broad host range and their 
ability to infect proliferating as well as quiescent cells, enabling efficient gene transfer. Moreover, 
they display low pathogenicity in humans and the non-integrative character of their genome allows 
for transient transgene expression and minimises the risk of mutagenesis. Finally, adenoviral vectors 
can be easily purified achieving high titres [168, 171]. The packaging capacity of adenoviral vectors 
for foreign DNA can be up to 105 % of the wild-type adenoviral genome size, which equals to an 
insert size of only about 2 kb, without impairing the genetic stability of the vectors [172]. In order to 
maximise the vector capacity for inserts, first generation vectors with deletions of the E1 and/or E3 
regions that enable insertions of about 8 kb foreign DNA have been constructed, providing safe and 
efficient transgene delivery [153, 168, 173].  
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1.7. Oncolytic adenoviruses 
1.7.1. Nature and modifications  
Oncolytic viruses are biological therapeutic agents that are genetically modified to selectively kill 
tumour cells while sparing healthy tissue. The concept of cancer virotherapy is based on the ability of 
the viral agent to replicate in tumour cells and to spread its progeny throughout the tumour with the 
aim to eliminate the tumour burden completely [171, 174]. The strategy of oncolytic killing utilises 
the replicative and lytic life cycle of the viruses and its regulation by tumour-specific factors [174, 
175]. According to the paradigm of virotherapy, viral oncolysis might also stimulate a systemic 
immune response against residual tumour cells [175]. There are some viruses with natural tropism 
for cancer cells, including reovirus [176], autonomous parvovirus [177], Newcastle disease virus [178, 
179], mumps virus [180] and murine leukemia virus [181]. In contrast, viruses, such as adenovirus, 
measles virus, vesicular stomatitis virus, vaccinia virus and HSV need to be engineered to make them 
tumour specific [175].  
Oncolytic adenoviruses are designed to overcome the limitations of replication-deficient vectors such 
as insufficient infectivity of solid tumours and impaired virus spread [171, 182]. Furthermore, all the 
benefits of attenuated adenoviral vectors, as listed in chapter 1.6., are applicable for oncolytic 
vectors [183]. Due to their ability to transduce also quiescent cells, oncolytic adenoviruses are 
suitable agents against cancer stem cell populations, which show a low proliferation rate [184-186].  
In contrast to the non-selective replication of wild-type adenovirus, oncolytic adenoviruses are 
genetically modified to replicate exclusively in tumour cells. There are two major strategies to 
generate replicative adenoviral vectors with specific tumour tropism. The first strategy involves the 
introduction of loss-of-function mutations in adenoviral genes essential for viral replication in normal 
cells. These mutated viral genes are compensated by aberrant oncogenes, tumour suppressor genes 
or transcription factors in tumour cells, as p53, pRb or Y-box binding protein 1 (YB-1). The adenoviral 
replication is therefore restricted to tumour cells with dysfunctional gene expression [171, 174]. One 
of the most prominent examples for conditionally replicating adenoviruses with introduced 
mutations is ONYX-015 (formerly dl1520), which carries deletions of the E1B55K gene. It was 
originally proposed that this virus replicates selectively in tumour cells with a mutated p53 tumour 
suppressor gene and an aberrant p53-p14ARF pathway, because the p53-binding protein E1B55K is 
not at disposal for inactivation of p53 and lack of p53 expression in tumours enables viral replication 
[187-189]. The p53-dependency of ONYX-015 is however rejected, as another study has stated that 
the replication of the virus does not depend on p53 or p14ARF [190] and probably other mechanisms 
are involved. Another mutated conditionally replicating adenovirus is AdΔ24 that contains a 24 bp 
deletion of the CR2 of E1A, rendering the expressed protein unable to bind to pRb and to stimulate S 
phase entry. The virus can therefore replicate only in cancer cells with mutated pRb [191].  
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In the second strategy for generation of conditionally replicative adenoviral vectors, so called 
transcriptional targeting, viral promoters are replaced by cancer-specific promoters that restrict viral 
replication to tumour cells expressing specific transcription factors [171, 174, 183]. Several oncolytic 
adenoviruses that utilise transcriptional targeting have been designed using cancer-specific 
promoters of genes encoding for example prostate-specific antigen [192], α-fetoprotein [193] or 
human telomerase reverse transcriptase (hTERT) [194].    
In order to augment the anti-tumour efficacy of conditionally replicating adenoviruses, several 
attempts to improve their cell targeting and delivery to the tumour, as well as their intratumoural 
spread, were performed. The rapid clearance of adenoviruses from blood by liver Kupffer cells [195] 
is a considerable obstacle especially for the targeting of disseminated cancers. Therefore, capsid 
modifications were performed in order to prevent the interaction of adenoviruses with hepatocytes 
and to increase adenovirus persistence in blood [174]. Although oncolytic adenoviruses are 
characterised by a high transduction efficiency in vivo [182], many tumours do not express CAR 
receptors sufficiently and adenoviral infection is therefore limited [196]. To enhance viral delivery 
and spread in CAR-deficient tumour cells significantly, an integrin-binding RGD motif [197] or a 
polylysine sequence [198] can be inserted into the adenoviral fiber knob gene. These fiber 
modifications increase both the CAR-independent tumour tropism and the oncolytic potential of the 
viruses [198-200]. A strategy to augment intratumoural spread of oncolytic adenoviruses by 
enhancing viral particle release is the deletion of the anti-apoptotic E1B19K gene [201] or the 
maintenance of the ADP protein [165]. Finally, the use of immune suppressive drugs can prevent 
recognition of oncolytic adenoviruses by the host adaptive immune response and can thus improve 
viral anti-tumour efficacy [175].  
The potency of oncolytic adenoviruses can be further enhanced by arming them with suicide genes, 
as described in chapter 1.8., or transgenes that enhance intratumoural spread of the virus [202], 
modify the tumour microenvironment [203] and modulate immune responses in favour of tumour 
destruction [204].  
1.7.2. In vitro 3D tumour models to explore oncolytic adenoviruses  
Three-dimensional (3D) multicellular spheroids are convenient and feasible models for performing 
preliminary investigations of in vivo effects. A benefit of spheroids is that their complexity is 
intermediate between the conventional two-dimensional (2D) cell culture in vitro and tumours in 
vivo. The use of spheroids represents an approach to mimic micrometastases in order to study the 
biology of tumour microregions [205]. Because they resemble tumour tissue with regard to growth 
kinetics and metabolism [205], multicellular spheroids can be applied for the study of treatment 
efficacy and for drug screening in cancer therapy [206-209]. Spheroids are also a relevant and 
promising 3D model for exploring adenoviral replication, oncolysis, distribution and spread [210]. 
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They were successfully applied in various preclinical analyses of conditionally replicating and tropism-
modified oncolytic adenoviruses prior to in vivo application [211-213]. Moreover, spheroids derived 
from tumour cell lines were used as a convenient in vitro model to assess changes in cellular 
metabolism by means of imaging techniques after treatment with oncolytic adenoviruses [214].  
1.7.3. Clinical application of oncolytic virotherapy  
Modern oncolytic virotherapy undergoes a promising development towards clinical application, 
based on the recent success of some clinical trials. An adenoviral vector with similarity to ONYX-015, 
termed Oncorine (H101), was the first oncolytic adenovirus that was approved as a therapy of head 
and neck squamous cell carcinoma (HNSCC) in China in 2005 [215, 216]. A milestone in the 
development of oncolytic virotherapy was achieved with the first demonstration of significant anti-
cancer efficacy by an attenuated oncolytic HSV-1, termed OncoVEXGM-CSF (talimogene laherparepvec), 
encoding the immunostimulatory cytokine granulocyte macrophage colony-stimulating factor (GM-
CSF) [217, 218]. Another notable clinical development of virotherapy was achieved by the study of 
JX-594, an oncolytic vaccinia virus armed with GM-CSF [219, 220]. Among oncolytic adenoviruses, 
some phase I and II clinical trials showed promising results by applying ONYX-015 with or without 
chemotherapy against various cancer types, including head and neck cancer [221, 222], ovarian 
cancer [223], solid tumours [224], pancreatic carcinoma [225], colorectal cancer [226, 227] and 
malignant glioma [228]. In addition, an oncolytic adenovirus under the control of the hTERT 
promoter and the RGD-modified version of AdΔ24 were tested in phase I trials against solid tumours 
[229] and ovarian cancer [199, 200], respectively.  
HSV has been for a long time the vector of choice for oncolytic virotherapy against brain cancer [175, 
230]. However, recombinant oncolytic HSV have shown only limited efficacy in clinical trials for 
malignant glioma probably due to deletions of crucial viral genes [231-233]. Oncolytic adenoviruses 
have emerged in the focus of malignant glioma therapy, as this tumour type provides favourable 
conditions for viral replication and spread. Malignant gliomas rarely metastasise and the viral load 
can be safely injected intratumourally. Moreover, the blood-brain barrier and the lack of tumour-
specific antigen drainage to the cervical lymph nodes cause an immune privilege of the brain [234, 
235]. ONYX-015 was tested as an adjuvant therapy in a phase I trial for recurrent malignant gliomas 
and demonstrated good viral tolerance and absence of severe anti-viral effects. This therapy was 
safe, but achieved no significant anti-tumour efficacy [228].  
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1.8. Arming oncolytic adenoviruses with suicide and reporter genes   
Although clinical trials have demonstrated their good safety profile, oncolytic adenoviruses are not 
able to improve the outcome of the disease significantly, as described above. Due to the 
heterogeneous expression of cell surface receptors [236] and tumour-specific promoters from one 
tumour type to the other, a treatment with a single oncolytic adenovirus has often not the desired 
efficacy. Oncolytic adenoviruses can be therefore combined with suicide and reporter genes in order 
to improve cell killing and to directly monitor the viral distribution, spread and therapeutic efficacy in 
living systems.  
The HSV1-TK/GCV suicide system was shown to enhance the oncolytic activity of HSV1-TK-armed 
conditionally replicating [237-239] and non-conditionally replicating [240] adenoviruses and thus to 
improve the treatment efficacy in different preclinical tumour models compared to virus treatment 
only. Other studies demonstrated a potent anti-tumour synergistic effect of HSV1-TK-expressing 
conditionally replicating adenoviruses driven by the hTERT promoter and the HSV1-TK/GCV suicide 
system [241, 242].  
Further improvement of armed virotherapy includes the development of oncolytic adenoviruses 
containing bCD/HSV1-TK or yCD/HSV1-sr39TK fusion genes, which allow the concomitant delivery of 
both suicide gene types to tumours [243, 244]. Encouraging results from phase I clinical trials 
demonstrated the potential therapeutic benefit and safety of the combined approach using viral 
oncolysis, activity of both CD/5-FC and HSV1-TK/GCV suicide systems and radiation therapy for 
prostate cancer [245-247]. Oncolytic adenoviruses expressing HSV1-sr39TK [244] or a mutant of 
HSV1-TK that incorporates an 8 aa-domain derived from the Tat protein of the human 
immunodeficiency virus (Tat8TK) [248] can facilitate in vivo PET imaging of viral distribution, 
transgene activity and of the progress of combined anti-tumour oncolytic- and suicide gene therapy. 
Furthermore, the delivery of the hNIS reporter gene to conditionally replicating adenoviruses [249, 
250] or to tropism-modified replication-selective adenoviruses [251-253] was proven to be effective 
for non-invasive imaging of the combined potential of oncolytic virotherapy and hNIS-mediated 
radioiodine treatment against cancer.  
Besides HSV1-TK/HSV1-sr39TK and CD, there are further suicide genes delivered by replication-
competent adenoviruses that were shown to enhance the oncolytic potential of their delivery 
vectors in cancer. One example thereof is the suicide gene FCU1, encoding a bifunctional chimeric 
protein that combines the enzymatic properties of yCD and uracil phosphoribosyl transferase (FUR1 
or UPRT) and catalyses the conversion of 5-FC [254]. Another example is the novel suicide gene 
deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK), which sensitises mammalian cells 
to the prodrugs (E)-5-(2-bromovinyl)-20-deoxyuridine (BVDU) and 2’,2’-difluoro-deoxycytidine (dFdC) 
[255].  
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1.9. YB-1 dependent oncolytic adenoviruses 
1.9.1. The multifunctional protein YB-1  
The Y-box binding protein 1 (YB-1) is a protein with multiple functions, concerning the regulation of 
various biological processes. It belongs to the superfamily of the cold-shock proteins and contains a 
highly conserved nucleic-acid-binding motif [256]. Whereas YB-1 is barely present in healthy cells, 
except in certain embryonic tissues [257], it is overexpressed in various cancer types and is located 
mostly in the nucleus of tumour cells [258, 259]. The pleiotropic functions of YB-1 arise from the 
localisation of the protein either in the nucleus or in the cytoplasm of cells. In the cytoplasm, YB-1 is 
involved in regulation of mRNA translation and transport of mRNA to polysomes [260, 261]. 
Translocation of YB-1 into the nucleus of highly proliferating or tumour cells results from 
environmental stressors like chemotherapy [258], UV irradiation [262], hyperthermia [263] or takes 
place at the G1/S phase transition of the cell cycle [264]. YB-1 also accumulates in the nucleus of 
adenovirus-infected cells [259, 265]. Following accumulation in the nucleus, YB-1 binds with its cold-
shock domain to an inverted CCAAT element within a gene promoter region, termed Y-box [264, 
266], and functions as a transcription factor that regulates a variety of genes, associated with cancer 
malignancy [264, 267-272]. YB-1 also promotes an epithelial-mesenchymal transition that 
contributes to the metastatic potential of tumours [273]. It has also been shown that YB-1 is 
associated with the transactivation of genes responsible for tumour proliferation and relapse [274, 
275]. YB-1 directly interacts with p53 or represses the transcription of p53, thus reducing its pro-
apoptotic activity [276, 277]. Evidence exist that many tumours exhibit multidrug-resistant 
phenotype as a result of the transactivation of MDR1 and multidrug resistance-related protein 
(MRP1) gene expression by nuclear accumulated YB-1 [258, 263, 266, 278]. Due to its multiple 
functions in tumourigenesis, nuclear localisation of YB-1 is a prognostic factor for poor clinical 
outcome of many malignancies, including amongst others pediatric GBM [279], breast cancer [280], 
ovarian cancer [281], non-small cell lung cancer [282], HNSCC [283]. Furthermore, high levels of YB-1 
mRNA are observed in GBM [284]. The pleotropic functions of YB-1 as a regulator of genes and 
signalling pathways responsible for development of cancer and malignant phenotype turn this 
protein into an oncogenic factor and an excellent therapeutic target against cancer [285].  
1.9.2. Regulation of adenoviral replication by YB-1 and YB-1 dependent virotherapy 
The adenoviral DNA replication depends on viral replication factors encoded by the adenoviral E2 
region, as described in chapter 1.5.3. The expression of the E2 genes is controlled by the E2-early and 
E2-late promoters [286]. The interaction of the CR1 and CR2 of E1A with pRb releases the host cell 
factor E2F from the pRb-E2F complex, leading amongst others to activation of the E2-early promoter 
by E2F [156, 287]. In contrast, the activity of the E2-late promoter does not depend on E1A or E2F 
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and is required for the accomplishment of adenoviral replication [265]. It was demonstrated that YB-
1 is translocated to the nucleus of adenovirus-infected cells by the adenoviral proteins E1B55K and 
E4orf6. Following nuclear accumulation, YB-1 binds to the proximal Y-boxes of the adenoviral E2-late 
promoter and activates the E2 gene transcription [259, 265]. As mentioned in chapter 1.5.3., E1B55K 
and E4orf6 are expressed after transactivation by the CR3-containing E1A 289 aa protein (E1A 13S 
mRNA) [156]. Interestingly, after infection of tumour cells with adenoviruses that do not produce the 
E1A 289 aa protein as a result of deletion in the CR3 transactivation domain, YB-1 can relocate into 
the nucleus independently of E1A, E1B55K and E4orf6 and can activate the E2-late promoter, leading 
to adenoviral replication [259, 288] (figure 1.6). Therefore, this YB-1-based strategy can be applied 
for the development of conditionally replicating E1A-mutated adenoviruses that replicate in the 
presence of YB-1, which is already accumulated in the nucleus of tumour cells due to overexpression 
[284] or environmental stress [258, 262, 263]. In this context, YB-1 dependent adenoviruses showed 
efficient E1A-independent replication and oncolytic potential in multidrug-resistant cancer cells with 
nuclear localisation of YB-1 [288], as YB-1 induces MDR1 gene expression [258].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Concept of YB-1 dependent oncolytic adenoviruses. The DNA replication of adenoviruses is 
activated by adenoviral E1A proteins, which disrupt the pRb-E2F complex and enable binding of E2F to the E2-
early promoter. However, the E2-late promoter plays the main role in the activation of E2 gene transcription. 
The E1A 289 aa protein, encoded by the E1A 13S mRNA transcript of wild-type adenoviruses (left), 
transactivate the expression of E1B55K and E4orf6. YB-1 is translocated by E1B55K and E4orf6 to the cell 
nucleus and activates the E2-late promoter. In adenoviruses that do not produce E1A 13S mRNA (right), gene 
transactivation is dysfunctional and E1B55K and E4orf6 are consequently not at disposal for nuclear transport 
of YB-1. The replication of these adenoviruses is YB-1 dependent, because the E2-late promoter is activated 
only in tumour cells with already nuclear accumulated YB-1. The transport of YB-1 to the nucleus of these 
tumour cells is induced by stress responses or overexpression of YB-1 (modified from [265]).   
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Several studies demonstrated the relation between chemotherapeutic stress, nuclear localisation of 
YB-1 and adenoviral replication. Among them, a study showed that YB-1 dependent oncolytic 
adenoviruses cause oncolysis and downregulation of MDR1 and MRP1 gene expression, leading to 
resensitization of multidrug-resistant tumour cells to chemotherapy [265]. It was also demonstrated 
that genotoxic stress induced by chemotherapy or radiation enhances the nuclear accumulation of 
YB-1 and augments the replication and oncolytic potential of YB-1 dependent adenoviruses [289-
292].  
A novel oncolytic adenovirus that is based on the concept of YB-1 dependent virotherapy is the 
vector Ad-delo3-RGD [291]. The structure of this adenovirus is partly based on the genome of the 
adenoviral vector dl520 and accordingly, Ad-delo3-RGD contains a deletion of 11 bp in CR3 of E1A 
[293]. Because of this deletion, the adenovirus does not express the 289 aa E1A protein containing 
the transactivation domain encoded by CR3. The E1A deletion renders the virus conditionally 
replicating in the presence of YB-1 [291]. Ad-delo3-RGD also carries a deletion in the E1B19K gene, 
resulting in improved viral spread [201]. A deletion of most of the E3 region enables transgene 
insertion for future applications. Finally, the viral fiber was modified with a RGD motif in order to 
improve infectivity [197]. Ad-delo3-RGD was shown to replicate YB-1 dependently and to exert 
selective oncolytic killing of tumour cells in vitro and in vivo in xenograft models of pancreatic cancer 
and malignant glioma [291, 292]. The oncolytic activity of the virus against pancreatic cancer cells 
was augmented after combination of oncolytic virotherapy with paclitaxel treatment [291]. In 
malignant glioma cells, treatment with TMZ enhanced nuclear accumulation of YB-1, which resulted 
in significant increase in viral replication and in potentiation of the viral anti-tumour effect [292]. 
Encouraging therapeutic efficacy has been obtained recently by the combination of Ad-delo3-RGD 
and TMZ in brain cancer stem cells, suggesting that YB-1 based virotherapy could be promising 
against this subset of cells [294].  
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1.10. Aims of the thesis 
Standard and alternative molecular therapies for GBM and malignant glioma are currently facing 
limited success. Promising strategies to address existing limitations of anti-GBM and anti-cancer 
therapy in general represent suicide gene therapy and oncolytic virotherapy. Oncolytic adenoviruses 
modified to replicate selectively in tumour cells that express the oncogenic factor YB-1 have already 
demonstrated anti-tumour efficacy in vitro and in vivo, also in combination with chemotherapy.  
Based on the finding that YB-1 is overexpressed in GBM, it is of special interest to develop a novel 
targeted approach against GBM, combining YB-1 dependent virotherapy with a HSV1-sr39TK/GCV-
mediated suicide and reporter gene strategy, and TMZ therapy. The aim of this work is first to 
characterise an E1-mutated YB-1 dependent oncolytic adenovirus armed with the suicide and 
reporter gene HSV1-sr39TK with respect to viral replication, release and dissemination, as well as 
induction of oncolytic effect and transgene expression in GBM cells in vitro. Furthermore, the 
combined oncolytic effect and HSV1-sr39TK/GCV-mediated cytotoxicity of the vector is to be 
analysed, regarding the timing of GCV addition and induction of bystander killing effect. Considering 
that YB-1 is accumulated within the cell nucleus upon chemotherapy-induced stress, a further goal of 
this work is to evaluate the influence of TMZ on adenoviral replication and oncolytic effect in GBM 
cells. In addition, the potential synergy between TMZ, viral oncolysis and HSV1-sr39TK/GCV-
mediated cytotoxicity is to be analysed. The application of HSV1-sr39TK in the context of viral 
oncolysis for non-invasive nuclear PET imaging is also to be examined in vitro. The oncolytic, 
cytotoxicity-mediating and imaging properties of the armed vector are to be compared to other YB-1 
dependent oncolytic adenoviruses and a HSV1-sr39TK-expressing replication-deficient adenoviral 
vector, as well as to be analysed in an in vitro 3D multicellular spheroid model. The data obtained in 
this thesis are fundamental for future preclinical investigations in vivo.                
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2. MATERIALS 
 
2.1. Laboratory equipment 
Table 2.1: Laboratory equipment 
Laboratory equipment Manufacturer 
Analytical balances: 
PCE-LSM 2000 
Research RC210P 
 
PCE GmbH, Meschede, Germany 
Sartorius AG, Göttingen, Germany 
Centrifuges: 
Biofuge fresco 
EBA 12 R 
Megafuge 2.0 R 
Ultracentrifuge OptimaTM LE-80K 
 
Heraeus Instruments, Hanau, Germany 
Hettich GmbH & Co.KG, Tuttlingen,Germany   
Heraeus Instruments, Hanau, Germany 
Beckman Coulter GmbH, Krefeld, Germany 
CO2 incubator HERAcell 150i Thermo Scientific Inc., Rockford, IL, USA 
Concentrator 5301 Eppendorf AG, Hamburg, Germany 
Cross-linker UV Stratalinker 2400 Stratagene, La Jolla, CA, USA 
Cryostat microtome HM 560 Microm GmbH, Walldorf, Germany 
Electrophoresis power supply PowerPac 300 Bio-Rad, Munich, Germany 
Gamma-counter Wallac 1480-011  PerkinElmer LAS GmbH, Rodgau, Germany 
Gel electrophoresis units: 
Mini horizontal submarine unit HE33 
Sub-Cell GT system 
 
Amersham Biosciences, Buckinghamshire, UK 
Bio-Rad, Munich, Germany 
Hybridisation oven Personal Hyb Stratagene, La Jolla, CA, USA 
INVEON PET/CT System Siemens Healthcare, Erlangen, Germany 
Microscopes: 
Axiovert 25 and 135 with AxioCam MRc 
Eclipse TE2000-S 
 
Carl Zeiss GmbH, Jena, Germany 
Nikon Instruments, Melville, NY, USA 
Microtiter shaker MTS 2/4 IKA Werke GmbH, Staufen, Germany 
Minishaker MS2 IKA Werke GmbH, Staufen, Germany 
Multilabel counter Wallac Victor2 1420 PerkinElmer LAS GmbH, Rodgau, Germany 
Neubauer cell counting chamber  Brand GmbH, Wertheim, Germany 
Pipettes (10/20/200/1000 µl) Eppendorf AG, Hamburg, Germany 
Pipette controller Accu-jet® Brand GmbH, Wertheim, Germany 
Real-time PCR Sequence Detection System ABI 
7900HT 
Applied Biosystems®, Life Technologies GmbH, 
Darmstadt, Germany 
SDS-PAGE unit Mini-PROTEAN 3 Cell  Bio-Rad, Munich, Germany 
Spectrophotometer DU 640 Beckman Coulter GmbH, Krefeld, Germany 
Sterile bench Hera Safe HS 12 Heraeus Instruments, Hanau, Germany 
Thermal cyclers for PCR: 
Mastercycler® 
PTC-100TM 
 
Eppendorf AG, Hamburg, Germany 
MJ Research Inc., Watertown, MA, USA 
Thermomixer comfort Eppendorf AG, Hamburg, Germany 
UV gel documentation system LTF Labortechnik GmbH, Wasserburg, Germany 
UV transilluminator Biotec-Fischer GmbH, Reiskirchen, Germany 
Water bath Memmert GmbH, Schwabach, Germany 
Western blot: Image Station 440CF Kodak Digital Science, Rochester, NY, USA 
Western blot: Transphor Electrophoresis unit Hoefer Inc., San Francisco, CA, USA 
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2.2. Consumables 
Table 2.2: Consumables 
Consumable Manufacturer 
Cell culture dishes (6, 10 and 15 cm) TPP AG, Trasadingen, Switzerland 
Cell culture test plates (6-, 24-, 96-well) TPP AG, Trasadingen, Switzerland 
Cell lifter Corning Inc., Corning, NY, USA 
Centrifuge tubes, conical (15 and 50 ml) TPP AG, Trasadingen, Switzerland 
Cover slips (24 x 50 mm) G. Menzel GmbH, Braunschweig, Germany 
Cryomold Intermediate (15 x 15 x 5 mm) Sakura Finetek, Torrance, CA, USA 
Cryopreservation tubes CryoPure (1.6 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Dialysis Cassette Slide-A-Lyzer®, 10K Molecular 
Weight Cut-Off (MWCO) 
Pierce Biotechnology Inc., Rockford, IL, USA 
Disposable scalpel Feather Co., Osaka, Japan 
GeneScreen Hybridisation Transfer Membrane PerkinElmer LAS GmbH, Rodgau, Germany 
Micro Amp® Optical 96-well real-time PCR 
Reaction Plate with Optical Adhesive Film 
Applied Biosystems®, Life Technologies GmbH, 
Darmstadt, Germany 
Microscope slides Superfrost Plus G. Menzel GmbH, Braunschweig, Germany 
Needles, sterile (18G x 1½”) MicrolanceTM 3 BD Biosciences, Heidelberg, Germany 
Pipette tips Axygen® Corning Inc., Corning, NY, USA 
Polystyrene Reagent Reservoir (50 ml) Corning Inc., Corning, NY, USA 
Precise Protein Gels (10 %) Thermo Scientific Inc., Rockford, IL, USA 
Polyvinylidene fluoride (PVDF) membrane Millipore, Merck KGaA, Darmstadt, Germany 
Reaction tubes (0.5, 1.5 and 2 ml) Josef Peske GmbH, Aindling, Germany 
Serological pipettes (1, 2, 5, 10, 25, 50 ml) Greiner Bio-One GmbH, Solingen, Germany 
Syringe filter, sterile (0.22 µm) TPP AG, Trasadingen, Switzerland 
Syringes, sterile B. Braun Medical Inc., Melsungen, Germany 
Ultra-clear centrifuge tubes (16 x 102 mm) Beckman Coulter GmbH, Krefeld, Germany 
UV-Cuvette micro with caps Brand GmbH, Wertheim, Germany 
Whatman paper Schleicher & Schuell Bioscience GmbH, Dassel, 
Germany 
 
2.3. Chemicals 
Table 2.3: Chemicals 
Chemical Manufacturer 
Acetic acid  Merck KGaA, Darmstadt, Germany 
Acetone Pharmacy of Klinikum rechts der Isar, Munich, 
Germany 
Ammonium acetate (NH4C2H3O2) Merck KGaA, Darmstadt, Germany 
Bromophenol blue  Sigma-Aldrich GmbH, Steinheim, Germany  
Calcium chloride (CaCl2) Fluka GmbH, Neu-Ulm, Germany 
Cesium chloride (CsCl) Serva, Heidelberg, Germany 
Chloroform  Merck KGaA, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich GmbH, Steinheim, Germany 
Ethanol Merck KGaA, Darmstadt, Germany 
Ethylenediamine-tetraacetic acid (EDTA) Merck KGaA, Darmstadt, Germany 
Glycerol  Merck KGaA, Darmstadt, Germany 
Glycine Sigma-Aldrich GmbH, Steinheim, Germany 
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Hydrochloric acid (HCl) 37 % Merck KGaA, Darmstadt, Germany 
Isopropyl alcohol Pharmacy of Klinikum rechts der Isar, Munich, 
Germany 
Magnesium chloride (MgCl2) Merck KGaA, Darmstadt, Germany 
Maleic acid Sigma-Aldrich GmbH, Steinheim, Germany 
β-Mercaptoethanol Sigma-Aldrich GmbH, Steinheim, Germany 
Methanol  Merck KGaA, Darmstadt, Germany 
Phenol:Chloroform:Isoamyl Alcohol 
25:24:1 
Sigma-Aldrich GmbH, Steinheim, Germany 
Potassium chloride (KCl) Sigma-Aldrich GmbH, Steinheim, Germany 
Potassium dihydrogen phosphate (KH2PO4) Merck KGaA, Darmstadt, Germany 
Sodium acetate (C2H3NaO2) Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium chloride (NaCl) Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium citrate dihydrate Merck KGaA, Darmstadt, Germany 
Sodium deoxycholate Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium dodecyl sulfate (SDS)    SERVA Electrophoresis GmbH, Heidelberg, Germany 
Sodium hydrogen carbonate (NaHCO3) Fluka GmbH, Neu-Ulm, Germany 
Sodium hydroxide (NaOH) Merck KGaA, Darmstadt, Germany 
Sodium phosphate (Na2HPO4) Sigma-Aldrich GmbH, Steinheim, Germany 
Sulforhodamine B (SRB), sodium salt  Sigma-Aldrich GmbH, Steinheim, Germany 
Trichloroacetic acid (TCA) Sigma-Aldrich GmbH, Steinheim, Germany 
Tris base Carl Roth GmbH, Karlsruhe, Germany 
Triton-X 100 Sigma-Aldrich GmbH, Steinheim, Germany 
Trizol Reagent Invitrogen GmbH, Karlsruhe, Germany 
Tween 20 Sigma-Aldrich GmbH, Steinheim, Germany 
 
2.4. Biochemical reagents and commercial available substances 
Table 2.4: Biochemical reagents and commercial available substances 
Substance Manufacturer 
Agar noble, ultrapure Affymetrix, Cleveland, USA 
Agarose Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Bovine Serum Albumin Fraction V (BSA), pH 5.2 Carl Roth GmbH, Karlsruhe, Germany 
Cresol red Sigma-Aldrich GmbH, Steinheim, Germany 
Distilled water (DNase/RNase free) Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
DNA ladder (1 kb) InvitrogenTM, Life Technologies GmbH, 
Darmstadt, Germany 
DNA loading dye (6x) Sigma-Aldrich GmbH, Steinheim, Germany 
ECLTM Western Blotting Detection Reagent GE Healthcare GmbH, Munich, Germany 
Embedding compound Tissue-Tek® O.C.T.TM  Sakura Finetek, Torrance, CA, USA 
Ethidium bromide (10 mg/ml) Sigma-Aldrich GmbH, Steinheim, Germany 
Glycogen Sigma-Aldrich GmbH, Steinheim, Germany 
High-Range Rainbow Molecular Weight Marker for 
SDS-PAGE 
GE Healthcare GmbH, Munich, Germany 
MgCl2 for PCR Fermentas GmbH, St. Leon-Rot, Germany 
Milk powder AppliChem GmbH, Darmstadt, Germany 
PCR dNTP mix (10 mM each) Roche Diagnostics, Mannheim, Germany 
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PreDeveloped TaqMan Assay Reagent Human 18S 
rRNA 
Applied Biosystems®, Life Technologies 
GmbH, Darmstadt, Germany 
Protease inhibitor cocktail tablets  Roche Diagnostics, Mannheim, Germany 
Protein Assay (Dye reagent) Bio-Rad, Munich, Germany 
qPCR Master Mix Plus Eurogentec s.a., Seraing, Belgium 
qPCR Master Mix Plus for SYBR® Assay I Eurogentec s.a., Seraing, Belgium 
Recombinant green fluorescent protein (rGFP)  MP Biomedicals, Heidelberg, Germany 
Taq buffer with (NH4)2SO4 Fermentas GmbH, St. Leon-Rot, Germany 
Trypan blue (0.4 %) Sigma-Aldrich GmbH, Steinheim, Germany 
Vectashield mounting medium containing 4´,6´-
diamidino-2-phenylindole (DAPI) 
Vector Laboratories, Burlingame, CA, USA 
Western blot: BupHTM Tris-HEPES-SDS Running 
Buffer 
Thermo Scientific Inc., Rockford, IL, USA 
 
2.5. Prepared buffers and solutions 
Table 2.5: Prepared buffers and solutions 
Buffer or solution Composition 
CsCl, ρ 1.25 g/cm3 33.75 g CsCl in 100 ml 10 mM Tris, pH 8.0 
CsCl, ρ 1.35 g/cm3 47.57 g CsCl in 100 ml 10 mM Tris, pH 8.0 
Digestion buffer for DNA isolation 100 mM NaCl, 25m M EDTA (pH 8.0), 10 mM Tris (pH 
8.0), 0.5 % SDS 
GCV 50 mg/ml stock, dissolved in dH2O 
Lysis buffer 250 mM Tris (pH 8.0), 0.1 % Triton X-100 
Radio-Immunoprecipitation Assay (RIPA) 
buffer 
50 mM Tris (pH 7.2), 150 mM NaCl, 0.1 % SDS, 0.5 % 
Na-deoxycholate, 1 % Triton X-100, 1x Protease 
inhibitor cocktail  
TMZ 100 mM stock, dissolved in DMSO 
Tris (1 M) 121.1 g Tris base dissolved in 1l dH2O, pH adjusted 
with 37 % HCl 
PCR master mix 1 x Taq buffer, 1.5 mM MgCl2, 0.4 mM dNTPs, 5 U Taq 
polymerase 
Phosphate Buffered Saline (PBS), 20x 200 mM Na2HPO4, 2.8 M NaCl, 36 mM KH2PO4, 54 mM 
KCl (pH 7.4) 
PBS2+ 1 x PBS, 0.68 mM CaCl2, 0.49 mM MgCl2 
PBS/Tween 1 x PBS, 0.05 % Tween 20 
Precipitation buffer for DNA isolation I 94 % ethanol, 588 mM NH4C2H3O2  
Precipitation buffer for DNA isolation II 97 % ethanol, 300 mM C2H3NaO2 
SDS-Pronase buffer for DNA isolation 10 mM Tris (pH 7.5), 10 mM EDTA (pH 8.0), 0.5 % SDS, 
0.5 mg/ml Pronase 
Sodium chloride-sodium citrate buffer 
(SSC), 20x 
3 M NaCl, 0.3 M sodium citrate  
SRB staining solution 0.5 % (w/v) SRB in 1 % acetic acid 
Tris-acetate-EDTA (TAE) buffer  40 mM Tris (pH 8.0), 1 mM EDTA (pH 8.0), 0.1% acetic 
acid 
Western blot: blocking buffer  5 % (w/v) milk powder, 50 mM Tris (pH 7.5), 150 mM 
NaCl 
Western blot: blotting buffer (10x) 250 mM Tris base, 1.92 M Glycin, 1 % SDS, 20 % 
Methanol   
Western blot: Laemmli buffer (5x) 300 mM Tris (pH 6.8), 1.5 g SDS, 50 % Glycerol, 12.5 % 
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β-Mercaptoethanol, 100 mg Bromophenol blue 
Immunofluorescence: blocking buffer 1 % BSA (w/v) in 1 x PBS, 0.05 % Tween 20 
Southern blot: denaturation solution 0.5 M NaOH, 1.5 M NaCl  
Southern blot: neutralisation solution 0.5 M Tris (pH 7.5), 1.5 M NaCl 
Southern blot (detection): maleic acid 
buffer 
0.1 M maleic acid, 150 mM NaCl, adjust to pH 7.5 with 
solid NaOH  
Southern blot (detection): detection 
buffer 
0.1 M Tris, 0.1 M NaCl, adjust to pH 9.5 with solid 
NaOH, 0.3 % Tween 20 
Southern blot (detection): washing buffer 0.1 M maleic acid, 150 mM NaCl, adjust to pH 7.5 with 
solid NaOH 
Southern blot: stripping buffer 0.2 M NaOH, 0.1 % SDS 
 
2.6. Kits 
Table 2.6: Kits 
Kit Manufacturer 
Adeno-XTM Rapid Titer Kit Clontech Laboratories, Mountain View, CA, USA 
DNA Blood and Tissue Kit Qiagen GmbH, Hilden, Germany 
DIG High Prime DNA Labelling and Detection 
Starter Kit II 
Roche Diagnostics, Mannheim, Germany 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems®, Life Technologies GmbH, 
Darmstadt, Germany 
QIAquick Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
Quant-iTTM PicoGreen® dsDNA Assay Kit InvitrogenTM, Life Technologies GmbH, Darmstadt, 
Germany  
XTT Cell Proliferation Kit II Roche Diagnostics, Mannheim, Germany 
 
2.7. Enzymes 
Table 2.7: Enzymes 
Enzyme Manufacturer 
Benzonase Nuclease (25 U/µl) Novagen, San Diego, USA 
Pronase Boehringer, Mannheim, Germany 
Proteinase K  Qiagen GmbH, Hilden, Germany 
Restriction enzymes New England Biolabs GmbH, Frankfurt am Main, Germany 
(PvuI with buffer R+: Fermentas GmbH, St. Leon-Rot, Germany) 
RNase A Roche Diagnostics, Mannheim, Germany 
Taq DNA polymerase Fermentas GmbH, St. Leon-Rot, Germany 
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2.8. Antibodies 
Table 2.8: Antibodies 
Target Isotype, host Conjugate Manufacturer Application 
anti-goat IgG, donkey HRP Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
WB 
anti-mouse IgG, goat polyclonal FITC Serotec, Oxford, UK IF 
anti-rabbit IgG-H&L, goat polyclonal Texas Red Abcam, Cambridge, UK IF 
Hexon IgG, mouse  Clontech Laboratories, 
Mountain View, CA, USA 
IF 
HSV1-TK  IgG, rabbit polyclonal   Prof. William Summers, 
Yale University, USA 
IF 
HSV1-TK (N-
terminus) *  
IgG, goat polyclonal  Santa Cruz 
Biotechnology, Inc., 
Heidelberg, Germany 
WB 
 
Abbreviations: Fluorescein isothiocyanate (FITC), Horseradish peroxidase (HRP), Immunofluorescence (IF), 
Western blot (WB). 
* Supplied together with a blocking peptide (0.2 µg/µl; Santa Cruz Biotechnology, Inc., Heidelberg, Germany) 
for competition studies.  
 
2.9. Primers and oligonucleotide probes 
Table 2.9: Primer and probe sequences 
Target gene Sequence Tm Application 
Adenoviral E1A  fw: 5’-ATG GCC GCC AGT CTT TTG-3’ 
rev: 5’-GCC ATG CAA GTT AAA CAT TAT C-3’ 
56°C 
60°C 
PCR 
Adenoviral E2 fw: 5’-GGC TGC TCT GCT CGG AAG AC-3’ 
rev: 5’-GTA ATT AAC AAC CGT TCC GAG G-3’ 
65°C 
60°C 
PCR 
Adenoviral E1A-pIX   fw: 5’-GGG AAA ACT GAA TAA GAG G-3’ 
rev: 5’-AAC GAG TTG GTG CTC ATG G-3’ 
52.4°C 
56.7°C 
PCR 
Adenoviral E3 fw: 5’-CGA GCT CAG CTA CTC CAT C-3’ 
rev: 5’-GTA ATT AGC ATA GCA GTG CAG C-3’ 
60°C 
64°C 
PCR 
HSV1-sr39TK fw: 5’-ATC AAC ACG CGT CTG CGT TCG-3’  
rev: 5’-TCA GTT AGC CTC CCC CAT CTC-3’  
61.8°C 
61.8°C 
PCR 
Adenoviral Fiber 5 fw: 5’-AAG CTA GCC CTG CAA ACA TCA-3’  
rev: 5’- CCC AAG CTA CCA GTG GCA GTA-3’ 
59°C 
63°C 
real-time PCR 
HSV1-sr39TK fw: 5’-GTA CCC GAG CCG ATG ACT TAC T-3’ 
rev: 5’-CCC GGC CGA TAT CTC A-3’ 
61°C 
58°C 
real-time PCR 
Probe: 6-FAM – 5‘-CTT CCG AGA CAA TCG CGA 
ACA TCT ACA CC-3’ – TAMRA 
 
 
All primers applied for Polymerase chain reaction (PCR) analysis and the adenoviral Fiber 5 primers 
used in real-time PCR analysis were purchased from Metabion International AG, Martinsried, 
Germany. They were dissolved in dH2O to obtain a stock concentration of 100 µM. The adenoviral 
E1A-pIX primers amplify a sequence located between E1A and the gene coding for minor capsid 
protein IX (pIX). The HSV1-TK primers and probe applied for real-time PCR analysis were designed 
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according to Ebeling et al. [295] and were obtained from Applied Biosystems®, Life Technologies 
GmbH, Darmstadt, Germany. The primers were diluted in 1 mM Tris-HCl, pH 8.0/0.01 mM EDTA to a 
stock concentration of 10 µM. The specific HSV1-TK probe, coupled to the 5’ reporter dye 6-
carboxyfluorescein (FAM) and the 3’ quencher dye 6-carboxytertramethylrhodamine (TAMRA), was 
supplied at a concentration of 100 µM.   
   
2.10. Plasmids 
pXC1 
pXC1 is a cloning vector that contains the left terminal 16 % of human adenovirus 5 (Ad5) DNA [296]. 
It was used within this thesis as a positive reference for detection of adenoviral E1A in the test of 
adenovirus preparations for contamination with wild-type adenovirus. 
pBHGlox∆E1,3 Cre 
The plasmid pBHGlox∆E1,3 Cre is an E1- and E3-deleted Ad5 backbone vector for adenovirus 
construction and transgene expression. It contains a loxP-site (locus of X-over of P1) and a coding 
sequence for Cre recombinase (cyclization recombinase), enabling vector construction by means of 
the Cre-loxP recombination system [297]. pBHGlox∆E1,3 Cre was used within this thesis as a positive 
reference for detection of adenoviral E2 region in the test of adenovirus preparations for 
contamination with wild-type adenovirus. 
pBHG10 
The E1- and E3-deleted Ad5 backbone plasmid pBHG10 is used for adenovirus construction by means 
of homologue recombination [173]. The vector was used within this thesis for the derivation of 
template-specific DNA hybridisation probe for detection of adenoviral E2 region. 
pDC316sr39TK 
The plasmid pDC316sr39TK is a transfer vector used for adenovirus construction containing the 
transgene HSV1-sr39TK. The vector was used within this thesis for the generation of a template-
specific DNA hybridisation probe for detection of HSV1-sr39TK.  
The plasmids pXC1, pBHGlox∆E1,3 Cre and pBHG10 were obtained from Microbix Biosystems, 
Toronto, Canada. The plasmid pDC316sr39TK was constructed in the laboratory of Dr. Martina 
Anton, Klinikum rechts der Isar, Munich, Germany.  
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2.11. Prodrugs, cytostatic drugs and radiolabelled compounds 
GCV 
GCV (Cymeven®) is a prodrug that is converted by HSV1-TK into the toxic metabolite GCV-
triphosphate, which induces cytotoxicity through inhibition of DNA synthesis [61, 62, 64]. GCV was 
purchased from Hoffmann-La Roche, Grenzach-Wyhlen, Germany and a stock solution was prepared 
as described in table 2.5. 
Daunorubicin  
The cytostatic drug daunorubicin (daunoblastin) is a member of the group of anthracyclines. As a 
DNA intercalator, it inhibits DNA and RNA synthesis [298]. The drug was used within this thesis as a 
substrate for P-gp in order to maintain the multidrug-resistant phenotype of the cell line EPP85-
181RDB. Daunorubicin was purchased from Sigma-Aldrich GmbH, Steinheim, Germany. 
TMZ 
The cytostatic drug TMZ is a DNA alkylating agent, which exerts its cytostatic effect through 
formation of a reactive methyldiazonium cation and DNA methylation of guanine at the O6 position 
[13, 14]. TMZ was purchased from Sigma-Aldrich GmbH, Steinheim, Germany and a stock solution 
was prepared as described in table 2.5. 
[18F]-FHBG 
[18F]-FHBG is a radiolabelled GCV analogue, converted by HSV1-TK into an insoluble metabolite that is 
trapped within the cell and can be detected by a gamma-counter or a PET system [109]. The 
radiotracer was synthesised at the Department of Nuclear Medicine, Klinikum rechts der Isar, 
Munich, Germany [114, 299], yielding [18F]-FHBG at an average specific activity of 33.4 GBq/µmol. 
 
2.12. Cell culture media and supplements 
Table 2.10: Cell culture media and supplements 
Cell culture medium or supplement Manufacturer 
Eagle’s Minimum Essential Medium (MEM) 
with Earle’s salts and 2 mM L-glutamine 
Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
Dulbecco's Modified Eagle’s Medium (DMEM) Biochrom AG, Berlin, Germany 
D-glucose Merck KGaA, Darmstadt, Germany 
Fetal bovine serum (FBS) PAN-Biotech GmbH, Aidenbach, Germany 
Fetuin Sigma-Aldrich GmbH, Steinheim, Germany 
Fungizone® Antimycotic Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
Horse serum (HS) Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
L-alanyl-L-glutamine Biochrom AG, Berlin, Germany 
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Leibovitz’s L-15 medium BioWhittakerTM, Lonza GmbH, Cologne, 
Germany 
MEM-vitamins, 100x Biochrom AG, Berlin, Germany 
NaHCO3, pH 7.5 Fluka GmbH, Neu-Ulm, Germany 
Non-essential amino acids (NEAA) Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
Transferrin Sigma-Aldrich GmbH, Steinheim, Germany 
Trasylol Pharmacy of Klinikum rechts der Isar, Munich, 
Germany 
Trypsin/EDTA (0.25 %/0.02 %)  Biochrom AG, Berlin, Germany 
Opti-MEM® I + GlutaMAXTM I  Gibco®, Life Technologies GmbH, Darmstadt, 
Germany 
PBS-Dulbecco, 1x  Biochrom AG, Berlin, Germany 
Penicillin/Streptomycin (PS), 100x  Biochrom AG, Berlin, Germany 
 
DMEM was supplemented with 10 % FBS and 2 mM L-glutamine. The culture medium of adenovirus-
infected HEK293 cells consisted of DMEM supplemented with 5 % HS and 2 mM L-glutamine. Eagle’s 
MEM with Earle’s salts and 2 mM L-glutamine was supplemented with 10 % FBS and 1 % NEAA. U87-
MG spheroid growth medium consisted of Eagle’s MEM with Earle’s salts and 2 mM L-glutamine 
supplemented with 10 % FBS, 1 % NEAA, 1 % PS, 1 % NaHCO3 (0.22 µm filtered) and 0.25 µg/ml 
Fungizone®. The L-15 medium was replenished with 10 % FBS, 1 mM L-glutamine, 1 g/l glucose (0.22 
µm filtered), 1,1 g/l NaHCO3 (0.22 µm filtered), MEM-vitamins (1x), 6.25 mg/l fetuin, 2.5 mg/l 
transferrin and 20,000 kIU (Kallikrein Inhibitor Units)/l  Trasylol.  
 
2.13. Cell lines 
HEK293 
The human embryonic kidney (HEK) cell line 293 (Microbix Biosystems, Toronto, Canada) is used for 
the production and titration of adenoviruses. The HEK293 cells are stably transformed with 4.5 kb of 
the left end of the Ad5 genome, enabling a transcomplementation of the E1 region and rendering the 
cell line permissive for Ad5 infection [300]. In this thesis, all adenoviruses were produced within this 
cell line. HEK293 cells were maintained in DMEM with supplements.   
U87-MG 
U87-MG (wt-p53) is a human, epithelial glioblastoma-astrocytoma (grade IV) cell line, derived from 
malignant glioma of a Caucasian 44-year-old woman and first characterised by J. Ponten [301]. U87-
MG (HTB-14) were purchased from American Type Culture Collection (ATCC), Rockville, MD, USA and 
cultured in Eagle’s MEM with Earle’s salts and 2 mM L-glutamine with supplements. The cell line is 
characterised by a high expression level and partial nuclear localisation of YB-1 [290].  
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EPP85-181RDB 
The human pancreatic carcinoma cell line EPP85-181RDB (RDB: resistant to daunoblastin) is 
characterised by a multidrug-resistant phenotype and was derived as a subclone from the parental, 
drug-sensitive cell line EPP85-181, established by Hermann Lage [51]. The cell line EPP85-181RDB 
was kindly provided by PD Dr. Per Sonne Holm, Klinikum rechts der Isar, Munich, Germany and 
cultured in L-15 medium with supplements. Its classical multidrug-resistant phenotype, conferred by 
overexpression of MDR1/P-gp, was maintained by addition of 2.5 µg/ml daunorubicin to the culture 
medium every two weeks [51]. Nuclear distribution of YB-1 had been already verified [288].    
 
2.14. Adenoviruses 
Ad-delo3-RGD  
The structure of the oncolytic adenovirus Ad-delo3-RGD (chapter 1.9.2.) is partially based on the 
genome of the Ad5-derived dl520 [293]. In this context, dl520 DNA from SspBI (Ad5 wild-type 
position nt193) to MunI (Ad5 wild-type nt3925) was subcloned into the shuttle plasmid of the AdEasy 
system (Qbiogene). This fragment carries an 11 bp deletion in the CR3 region of the E1A gene, 
resulting in lack of expression of the transactivating 289 aa protein by the E1A13S splice variant. Ad-
delo3-RGD contains also a partial deletion of E1B19K due to restriction with EcoNI (Ad5 wild-type 
position nt1715) and BstEII (Ad5 wild-type position nt1916), which abrogates E1B19K expression. The 
open reading frame of E1B55K has not been affected. The vector carries also a deletion of the E3 
region. Ad-delo3-RGD as well as the following oncolytic vectors were derived by homologous 
recombination with a RGD-modified [197] AdEasy backbone [291]. All oncolytic vectors were 
constructed and kindly provided by PD Dr. Per S. Holm and Klaus Mantwill, Klinikum rechts der Isar, 
Munich, Germany (figure 2.1).     
Ad-delo-sr39TK-RGD 
The Ad5-based, oncolytic adenovirus Ad-delo-sr39TK-RGD (Ad-delo2-sr39TK-RGD) contains the same 
deletions of E1A13S and E1B19K as Ad-delo3-RGD. However, the ADP gene was retained and the 
transgene HSV1-sr39TK, controlled by a human cytomegalovirus (CMV) promoter and a simian virus 
40-polyadenylation (SV40-poly(A)) recognition sequence, was inserted into the otherwise deleted E3 
region of the RGD-modified backbone of Ad-delo-sr39TK-RGD (figure 2.1). 
Ad-delo-shMGMT-RGD 
Ad-delo-shMGMT-RGD is an Ad5-based oncolytic vector containing the same deletion of E1A13S as 
Ad-delo3-RGD and Ad-delo-sr39TK-RGD, but without ablation of the E1B19K gene. The partially 
deleted E3 region expresses a short hairpin RNA (shRNA) insert, which is processed into a small 
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interfering RNA (siRNA) sequence against the cellular MGMT gene, and contains also the ADP gene 
and the RGD motif (figure 2.1). 
Ad-sr39TK 
Ad-sr39TK is a replication-deficient, E1- and E3-deleted adenovirus. The vector was derived by 
homologous recombination of a transfer vector, containing the human CMV promoter-controlled 
transgene HSV1-sr39TK together with a SV40-poly(A) recognition sequence, with an adenoviral 
packaging plasmid [113]. The transgene was thereby inserted into the deleted E1 region of the 
packaging plasmid. Ad-sr39TK was kindly provided by Prof. Dr. Sanjiv S. Gambhir, University of 
California School of Medicine, Los Angeles, CA, USA (figure 2.1).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Structure of YB-1 dependent oncolytic adenoviruses and of HSV1-sr39TK-armed replication-
deficient adenovirus. Mutations of the oncolytic vectors Ad-delo3-RGD (A), Ad-delo-sr39TK-RGD (B) and Ad-
delo-shMGMT-RGD (C), as well as of the replication-deficient vector Ad-sr39TK (D) are described in detail in 
chapter 2.14. Blue bars indicate insertions.   
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Ad5-wt 
Ad5-wt (wild-type) denotes the wild-type adenovirus of serotype 5. Ad5-wt DNA was applied as a 
reference for the verification of the genetic structure of the oncolytic adenoviruses and was kindly 
provided by Klaus Mantwill, Klinikum rechts der Isar, Munich, Germany.   
Ad-mCMVeGFP 
The replication-deficient, E1- and E3-deleted adenovirus contains the murine CMV (mCMV) 
promoter-controlled transgene enhanced green fluorescent protein (eGFP) inserted into the deleted 
E3 region. Ad-mCMVeGFP was produced by Cre-loxP recombination of a transgene-containing 
transfer vector with the adenoviral packaging vector pBHGlox. The virus was applied as an indicator 
of adenoviral infectivity of U87-MG-derived spheroids. The vector was constructed in the laboratory 
of Dr. Martina Anton, Klinikum rechts der Isar, Munich, Germany. 
 
2.15. Software and databases 
Table 2.11: Software and databases 
Software or database Application Company or URL 
EndNote citation management Thomson Reuters, New York City, 
NY, USA 
GraphPad Prism data analysis, statistics GraphPad Software, San Diego, CA, 
USA 
Image J image processing National Institutes of Health, 
Bethesda, MD, USA 
INVEON Acquisition and 
Research Workplace 
PET data analysis Siemens Healthcare, Erlangen, 
Germany 
Microsoft Office word processing, data analysis Microsoft GmbH, Unterschleißheim, 
Germany 
National Center for 
Biotechnology 
Information (NCBI) 
literature, gene and protein 
database 
http://www.ncbi.nlm.nih.gov 
 
SDS2.2 real-time PCR analysis Life Technologies GmbH, Darmstadt, 
Germany 
Universal Protein 
Resource 
Knowledgebase 
(UniProtKB) 
protein database http://www.uniprot.org 
 
VectorNTI gene sequence analysis Life Technologies GmbH, Darmstadt, 
Germany 
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3. METHODS 
 
3.1. Cell culture  
3.1.1. 2D monolayer cell culture 
All cell lines were cultured in appropriate culture medium at 37°C in a humidified atmosphere 
containing 5 % CO2. The cells were passaged, when reaching 70-80 % confluence, by detaching the 
cell monolayer with Trypsin and resuspending it in fresh culture medium. When used for 
experiments, the number of living cells for plating was determined by a Neubauer cell counting 
chamber and the total number of living cells was calculated according to following equation: average 
number of cells per one large square x 104 x dilution factor = cell number per ml. To exclude dead 
cells from counting, the cell suspension was stained in a 1:1 ratio with Trypan blue. The anionic diazo 
dye of Trypan blue passes through the leaky membranes of non-living cells and is microscopically 
visible after accumulation within the cell lumen. Dead cells can thus be excluded from counting.  
For freezing, cells were detached as described above, centrifuged at 1200 rpm for 3 min at room 
temperature (RT) and resuspended in 90 % FBS and 10 % DMSO per 1-2 x 106 cells. The cell 
suspension was immediately frozen in an isopropyl alcohol containing freezing container at -80°C and 
was transferred to the vapour phase of liquid nitrogen for long-term storage after 24 h. Cryo-
conserved cells were thawed in a 37°C water bath and immediately transferred into fresh culture 
medium. When the cells had attached to the culture dish, the medium was changed to remove traces 
of DMSO and the cells were cultured as described above.     
3.1.2. 3D spheroid cell culture  
Spheroids of U87-MG cells were cultured at 37°C in a humidified atmosphere containing 5 % CO2 and 
were established as described by Leske et al. [302]. Accordingly, 4000 cells per well were dissociated 
and seeded into wells of a 96-well plate coated with 60 µl of 1 % noble agar dissolved in PBS, using 
the appropriate culture medium. Spheroids formed within 24 h and were allowed to grow for three 
days, before performing experiments. For long-term cultivation of spheroids, culture medium was 
changed three times a week. Spheroid diameter was measured with an inverted microscope and 
their volumes were calculated using the equation  ? = ?
?
???. The migration of cells from spheroids, 
formed as described above and attached to an uncoated well of a 24-well plate, was microscopically 
monitored 24 h to 7 days after attachment. Migration distance was measured using transmitted light 
microscopy.  
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3.2. Adenovirus amplification and purification 
All infections of HEK293 cells with adenoviruses during the adenoviral amplification process were 
performed as described in chapter 3.4. When first signs of c.p.e. of the assembled adenoviruses 
occurred, cell supernatants containing released viral particles were collected and several small-scale 
viral amplification steps were performed. During all expansion steps, adenoviruses were released 
from the producer cells by three freezing and thawing steps of the virus-containing supernatant or 
cell suspension. After an expansion step in 8 x 15 cm culture dishes of HEK293 cells, the scraped cells 
were harvested about 48 h post infection by centrifugation at 2700 rpm and RT for 20 min and the 
pellet was resuspended in 6-10 ml PBS2+ (table 2.5). The viral titre was determined by End-point 
dilution assay as described in chapter 3.3.2. This suspension, so called “crude stock”, was applied for 
large-scale adenovirus expansion. For expansion to a large format prior to adenovirus purification, 
20-30 x 15 cm culture dishes of HEK293 cells were infected with the “crude stock” at a multiplicity of 
infection (MOI) of 10 (pfu/cell, see chapter 3.3.2). When c.p.e. was almost complete, usually after 
about 48 h, the cells were harvested by centrifugation at 2700 rpm and RT for 20 min and the pellet 
was resuspended in 10-15 ml of 0.1 M Tris, pH 8.0. To separate the viral particles from the cell debris, 
the suspension was centrifuged for 10 min at 2000 rpm and RT and once again in an ultracentrifuge 
for 15 min at 8000 rpm and RT. The supernatant was incubated with 200 units of Benzonase 
Nuclease for 45 min, in order to degrade remaining cellular nucleic acids. The adenoviruses were 
then purified by two subsequent CsCl step-gradient centrifugations at 30,000 rpm and 10 °C. The first 
gradient consisted of CsCl (ρ 1.35 g/cm3), overlaid with CsCl (ρ 1.25 g/cm3). The viral suspension was 
applied on top of the gradient and centrifuged for 3 h. The viral band from the first step-gradient was 
then added to a second gradient, consisting of CsCl with a density of 1.35 g/cm3 and centrifuged for 
16-24 h. Afterwards, the virus was pooled from the ultracentrifuge tube with a syringe and a needle, 
and purified by three consecutive dialysis steps against PBS in a Slide-A-Lyzer® dialysis cassette. The 
purified virus was stored in PBS2+ supplemented with 10 % glycerol at -80 °C.   
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3.3. Determination of viral titre 
3.3.1. Infectious units 
The number of infectious units (ifu) per ml of adenoviral preparations was determined in HEK293 
cells by Adeno-XTM Rapid Titer Kit according to manufacturer’s instructions.    
3.3.2. Plaque forming units              
Adenoviral particles cause c.p.e. in infected cells, which results in detachment of the adherent cell 
layer and formation of clear spots, so called “plaques”. The number of viral plaque forming units 
(pfu) per ml was determined by End-point dilution assay, according to Clontech’s titration protocol 
based on the Spearman-Karber method (Clontech Laboratories, USA). To perform the titration, 
HEK293 cells were seeded into a 96-well plate and infected with serial dilutions of the virus solution, 
either in form of CsCl-purified stocks, “crude stocks” or supernatants of infected U87-MG cells or 
spheroids containing released viral particles. The infected HEK293 cells were incubated in a 
humidified atmosphere for 10 days at 37°C. The fraction of c.p.e.-positive wells for each of the serial 
dilutions was determined and viral titre (pfu/ml) was calculated according to the following formula:  
Titre (pfu/ml) = 10(x + 0.8)  
x = the sum of the fractions of c.p.e.-positive wells  
3.3.3. Viral particle number and aggregate formation     
The amount of viral particles (VP) was determined by optical densitometry. The virus stock was 
diluted 1:20 in a 0.1 % SDS solution in order to inactivate the functional virus and the optical density 
(OD) in nm was measured by a spectrometer. The amount of VP/ml was calculated according to 
OD260 x 1.1 x 1012 VP/ml [303]. An OD260/OD280 ratio about 1.4 indicated optimal purity.  
To test adenoviruses for aggregation, viral solutions were diluted 1:50 in CsCl (ρ 1.35 g/cm3) prior to 
desalting in a dialysis cassette and OD260, OD320 and OD340 were determined. Ratios of OD320/OD260 and 
OD340/OD260 below 0.26 ensured that the viral stock was not aggregated. 
According to the above described measurements, the adenoviral stocks applied in this thesis had an 
optimal purity and were not aggregated.   
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3.4. Adenovirus infections 
The total MOI for all infections, referred to as either ifu or pfu, was derived by multiplication of the 
required MOI (ifu/cell or pfu/cell) with the cell number to be infected.  
3.4.1. 2D cell culture 
Infections of HEK293 cells were performed by diluting the virus at the required MOI (pfu/cell) in 
PBS2+ and applying the viral solution onto the cell monolayer. After incubation in a humidified 
atmosphere at 37°C for 30 min, HEK293 culture medium for infections was added to the cells. U87-
MG and EPP85-181RDB cells were infected with viruses at the required MOI (ifu/ml) in Opti-MEM® I 
+ GlutaMAXTM I. U87-MG and EPP85-181RDB cells were incubated for 30 min and 1 h at 37°C, 
respectively, and cultured subsequently in growth medium for a period of time dependent on 
experiment. Morphological changes of the cells and the occurrence of c.p.e. was monitored by 
transmitted-light microscopy.  
3.4.2. 3D spheroid culture  
3.4.2.1. Infection  
U87-MG-derived spheroids with a volume of 0.1-0.18 mm³ were infected three days after formation 
in 50 µl Opti-MEM® I + GlutaMAXTM I for 30 min in a humidified atmosphere at 37°C without 
removing the spheroids from the coated wells and cultured in growth medium for a period of time, 
dependent on experiment. The cell number per spheroid was extrapolated from a spheroid growth 
curve with known initial number of cells and the MOI (ifu/cell) per spheroid was calculated 
accordingly. Spheroid growth was monitored at different time points and their volume was 
calculated as described in chapter 3.1.2.   
3.4.2.2. Determination of infectivity  
The infectivity of spheroids was explored by infections with Ad-mCMVeGFP at different MOIs 
(pfu/cell) as described above. The fluorescent signal intensity of eGFP was detected microscopically. 
In addition, spheroids were digested with 10 µl lysis buffer (table 2.5) for 15 min at RT. The lysates 
were used to quantify the fluorescent signal according to a standard consisting of serial dilutions with 
known concentrations of rGFP. The protein amount in the spheroid samples was determined by Bio-
Rad Protein Assay as described in chapter 3.12.2. The fluorescent signal intensity of eGFP was 
measured in a black 96-well plate using a multilabel counter with excitation at 485 nm and emission 
at 535 nm wavelength. The amount of eGFP in the samples was calculated by extrapolation from the 
standard curve and normalised to the protein amount.    
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3.5. DNA isolation 
3.5.1. Viral DNA isolation  
DNA from purified virus stocks was isolated by phenol-chloroform extraction. 200 µl digestion buffer 
(table 2.5) was added to 10 µl of the virus together with 0.6 mAU (milli-arbitrary unit) proteinase K to 
degrade the viral capsid. After incubation for 1 h at 50°C, equal volume of phenol-chloroform-isoamyl 
alcohol was added to the suspension and centrifuged for 15 min at 14,000 rpm and 4°C. An equal 
volume of chloroform was added together with cresol red to the upper, aqueous phase containing 
the DNA for removal of phenol residuals and centrifuged again. The DNA from the aqueous phase 
was precipitated by addition of the 4.25-fold volume of precipitation buffer I (table 2.5) with 35 
µg/ml of glycogen as a DNA carrier and collected by centrifugation for 30 min at 14,000 rpm and 4°C. 
The DNA pellet was washed from remaining salts with 70 % ethanol, air dried and resuspended in 
dH2O. DNA concentration was determined by Quant-iTTM PicoGreen® dsDNA Assay Kit as described in 
chapter 3.7.2. 
3.5.2. Extraction of cellular DNA  
In order to perform adenoviral replication analysis by Southern blot or by real-time quantitative PCR, 
infected U87-MG or EPP85-181RDB cells were lysed over night at 37°C by 500 µl SDS-Pronase buffer 
(table 2.5) for DNA extraction. The cell lysates were then mixed with an equal volume of phenol-
chloroform-isoamyl alcohol and centrifuged for 15 min at 15°C and 14,000 rpm. The DNA from the 
aqueous phase was precipitated by addition of precipitation buffer II (table 2.5) and mixing by 
inversion until a visible DNA filament was formed. After three washing steps with 70 % ethanol, the 
DNA was air dried and resuspended in dH2O. The DNA concentration was determined by optical 
densitometry as described in chapter 3.7.1.  
  
3.6. RNA isolation and reverse transcription 
3.6.1. Isolation of cellular RNA 
For RNA isolation infected U87-MG or EPP85-181RDB cells were lysed by incubation for 5 min with 1 
ml Trizol reagent/1 x 106 cells. 200 µl chloroform per ml Trizol was then applied to the cell lysates, 
mixed well and centrifuged for 15 min at 13,000 rpm and 4°C. The RNA from the upper aqueous 
phase was precipitated by addition of one volume of isopropyl alcohol and, after an incubation step, 
centrifugation for 10 min at 13,000 rpm and 4°C. The RNA pellet was washed out from residual salts 
with 80 % ethanol, centrifuged for 5 min at 7600 rpm and 4°C and air dried. The pellet was finally 
resuspended in nuclease-free water, followed by denaturation of the RNA at 65°C for 10 min. The 
RNA concentration was determined by optical densitometry. The integrity of RNA was verified by 
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electrophoretic separation in a 1 % agarose gel as described in chapter 3.8. Extracted RNA was stored 
at -80°C.      
3.6.2. Reverse transcription from RNA into cDNA 
The reverse transcription of RNA into complementary DNA (cDNA) was performed using the High 
capacity cDNA reverse transcription kit according to manufacturer’s instructions. 1 µg RNA per 
reaction was reverse transcribed in a thermal cycler (PTC-100TM). The cDNA was stored at -20°C. 
 
3.7. Determination of DNA and RNA concentration 
3.7.1. Measurement of optical density 
DNA and RNA concentration was determined by optical densitometry of OD260/OD280 in a 
spectrophotometer. Provided that the path length of light, passing through a sample, is 1 cm, an 
OD260 of 1.0 corresponds to a concentration of 50 μg/ml for double-stranded (ds)DNA or 40 μg/ml for 
single-stranded (ss)RNA according to the Beer-Lambert law. Thus, the concentration was calculated 
as follows:  
dsDNA (µg/ml): 50 μg/ml × OD260 × dilution factor 
ssRNA (µg/ml): 40 μg/ml × OD260 × dilution factor  
An OD260/OD280 ratio of about 1.8 for DNA and of 1.8-2 for RNA is indicative for maximal purity.   
3.7.2. PicoGreen assay for DNA quantification  
In case of low DNA yield the concentration of DNA was determined using Quant-iTTM PicoGreen® 
dsDNA Assay Kit. The DNA was labelled by the fluorescent nucleic acid stain PicoGreen and 
fluorescence was measured at 538 nm after excitation at 485 nm in a multilabel counter. The DNA 
amount was quantified by means of a standard curve with bacteriophage λ-DNA (provided by the 
kit), treated as the unknown samples.   
    
3.8. Agarose gel electrophoresis 
DNA and RNA fragments were subjected to electrophoretic gel separation in order to determine the 
length of DNA fragments, to isolate DNA fragments of interest or to analyse the integrity of RNA. The 
agarose gels were prepared by melting of 1 % or, when large fragments were analysed, 0.8 % agarose 
in 1 x TAE. Prior to polymerisation, 0.5 μg/ml of ethidium bromide was added to the gel. DNA or RNA 
reactions were mixed in a ratio of 1:6 with 6 x DNA loading dye and loaded next to a DNA ladder on 
the gel. Electrophoresis was run in gel units with power supply at 90 V or at 20-30 V depending on 
experiment. Because of the intercalation with ethidium bromide, the DNA emits visible light after 
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excitation with UV light at 366 nm and the DNA fragments can be visualised in an UV gel 
documentation system or transilluminator. 
 
3.9. Southern blot  
Southern blot is a method for transferring electrophoretic separated DNA fragments from a gel to a 
solid support in order to detect a gene or DNA region of interest with a specific fluorescent or 
radiolabelled DNA probe. The probe hybridises to the complementary DNA fragments and can be 
visualised in a chemiluminescent or autoradiographic reaction [304].   
In order to perform adenoviral replication analysis by Southern blot, DNA from infected and/or GCV-
treated U87-MG cells was extracted as described in chapter 3.5.2. 1 µg DNA was digested with 10 U 
PvuI in a 20 µl reaction mix of 1 x buffer R+ and 10 µg RNase A for 90 min at 37°C. The restriction was 
terminated by incubation of the reaction for 5 min at RT with 5 µg pronase. DNA fragments, which 
were in a range from 1.67 to 13.81 kb depending on virus, were obtained by electrophoretic 
separation on a 0.8 % agarose gel over night at 20-30 V. The separated DNA fragments on the gel 
were then exposed to 250 mM HCl for 10-20 min, followed by incubation in denaturation solution 
and subsequently in neutralisation solution (table 2.5) for 2 x 15 min, each. The exposal to weak acid 
results in partial depurination of the DNA and the strong base in the denaturation solution 
hydrolyses the phosphodiester backbone at the sites of depurination. The resulting about 1 kb 
fragments can then be transferred from the gel with high efficiency [305]. The DNA fragments were 
blotted onto a GeneScreen Hybridisation Transfer Membrane by capillary transfer overnight at RT. 20 
x SSC was used to elute the DNA from the gel and a weight on top of the transfer system was applied 
to ensure tight connection between the layers of material used within it. The DNA was immobilised 
on the membrane by UV irradiation at 120 mJ in a Cross-linker.  
Probe generation, hybridisation of template DNA with specific DNA probes and signal detection were 
performed according to DIG High Prime DNA Labelling and Detection Starter Kit II. To generate a 
complementary DNA probe for the detection of a template in the E2 region, a 1669 bp fragment was 
obtained by PvuI-restriction (nt6149/nt7818) of the adenoviral backbone plasmid pBHG10. A specific 
1146 bp probe for detection of the HSV1-sr39TK gene was derived by restriction of the shuttle 
plasmid pDC316sr39TK with EcoRI (nt993) and HindIII (nt2139). Both probes were purified using 
QIAquick Gel Extraction Kit and their concentration was determined by Quant-iTTM PicoGreen® 
dsDNA Assay Kit (chapter 3.7.2). The probes were labelled with the steroid hapten digoxigenin (DIG) 
coupled to 2´-deoxyuridine 5´-triphosphate (dUTP). The optimal hybridisation temperature of the 
probes was based on their melting temperature (Tm) and was calculated following the 
METHODS 42
 
manufacturer’s instructions. The labelling efficiency of the probes was determined in a preliminary 
experiment to be sufficient to label 1-3 pg/µl of template DNA.  
After hybridisation of the template DNA with its complementary DNA probes, signals were detected 
in a chemiluminescent reaction at 477 nm by a Kodak image station. All buffers used within the kit 
for immunological detection are listed in table 2.5. If it was necessary for the DNA blot to be re-
probed, the first DNA probe was removed by washing the transfer membrane in Stripping buffer 
(table 2.5), following the manufacturer’s instructions of the DIG High Prime kit. The template DNA 
was hybridised with a second DIG-labelled DNA probe and detected as described above.  
    
3.10. Polymerase chain reaction  
PCR analysis of adenoviral DNA as a control to exclude an unintentional contamination with wild-type 
adenovirus was performed using PCR master mix (table 2.5), 0.2 µM of each forward and reverse 
E1A- and E2-specific primers (table 2.9) and 50 ng adenoviral template DNA, isolated as described in 
chapter 3.5.1, in a total reaction volume of 50 µl. The plasmids pXC1 and pBHGlox were used as 
positive amplification controls for E1A and E2, respectively. DNA was amplified on a thermal cycler 
according to table 3.1. PCR analysis for verification of the genetic modifications of the adenoviral 
vectors was performed as described above with 0.2 µM of each forward and reverse E1A-pIX-, E3- 
and HSV1-sr39TK-specific primers (table 2.9). Amplifications were carried out on a thermal cycler as 
described in table 3.1.  
 
Table 3.1: PCR cycling conditions    
            Target 
PCR step  Adenoviral E1A/E2 Adenoviral E1A-pIX/E3 HSV1-sr39TK 
Initial denaturation 94 °C     2 min    1x 94 °C       2 min    1x 94 °C     2 min    1x 
Denaturation 94 °C   45 sec   35x 94 °C     45 sec    30x 94 °C   45 sec   35x 
Annealing 57 °C   45 sec   35x 50 °C     45 sec    30x 57 °C   45 sec   35x 
Extension 72 °C     1 min  35x 72 °C       5 min   30x 72 °C     1 min  35x 
Final extension 72 °C   10 min    1x 72 °C     10 min     1x 72 °C   10 min    1x 
 
The length of the PCR products was determined by electrophoretic separation on a 1 % agarose gel 
at 90 V as described in chapter 3.8. 
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3.11. Real-time quantitative PCR analysis   
Real-time quantitative PCR (qPCR) is a method for monitoring the amplification throughout the PCR 
process in real time and provides a powerful tool to quantify gene replication or expression. The 
quantity of PCR products correlates with the time point when the target amplification is first 
detected. This value is defined as cycle threshold (Ct), the cycle in which the fluorescence intensity of 
the target is greater than background fluorescence. The greater the quantity of initial target DNA, the 
faster a fluorescent signal exceeds the background level, resulting in a lower Ct [306].  
Two real-time qPCR data analysis types can be discriminated: absolute and relative quantification. 
Absolute quantification is used to determine the input copy number of a sample, interpolating it 
from a standard curve. The standard curve enables a linear correlation between Ct and initial amount 
of nucleic acids, allowing quantification of unknown samples based on their Ct values [306]. Relative 
quantification is applied to determine changes in gene expression of a target sample in relation to a 
reference (calibrator). Target gene expression is normalised to an endogenous control, usually a 
housekeeping gene or ribosomal RNA (rRNA). In this thesis, relative gene expression was calculated 
by the comparative Ct (2-ΔΔCt) method, which determines changes in gene expression as a relative fold 
difference between a target and reference sample [307].  
Real-time qPCR can be performed with different detection chemistries, as SYBR green dye or 
TaqMan® hydrolysis probes. The fluorescent cyanine dye SYBR green binds to the minor groove of 
dsDNA and emits fluorescence at 524 nm [308]. Thus, increase of fluorescence intensity correlates 
directly with dsDNA accumulation. The group of TaqMan® probes comprises sequence-specific 
oligonucleotides containing a fluorescent reporter dye on the 5´ end and a quencher dye on the 3´ 
end [306]. The quencher dye reduces the fluorescence emitted by the reporter dye by fluorescence 
resonance energy transfer [309], when the probe is intact. When annealed to the target sequence, 
the probe is cleaved by the 5´ exonuclease activity of Thermus aquaticus (Taq) DNA polymerase 
during the extension step of the PCR, the quencher is separated from the reporter and fluorescence 
emission increases [306, 310].       
3.11.1. Absolute DNA quantification  
In order to perform absolute quantification of Fiber 5 and HSV1-sr39TK genes, a standard of known 
copy number was generated by extraction of DNA from a highly concentrated purified Ad-delo-
sr39TK-RGD-stock using DNeasy Blood and Tissue Kit according to manufacturer’s instruction. The 
copy number of the DNA per µl was calculated by means of its concentration and molecular weight 
and serial dilutions were prepared in order to derive a standard curve. Each standard dilution was 
mixed with 5 ng of genomic (U87-MG) DNA to mimic an “in vivo” adenoviral infection. DNA from 
infected cells was isolated (chapter 3.5.2) and DNA concentration was determined as described in 
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chapter 3.7.1. DNA from 100 µl of virus-containing cellular supernatants was extracted according to 
DNeasy Blood and Tissue Kit and the DNA concentration was determined by Quant-iTTM PicoGreen® 
dsDNA Assay Kit (chapter 3.7.2). The absolute qPCR of Fiber 5 was performed using 12.5 µl of the 
qPCR Master Mix Plus for SYBR® Assay per reaction, 0.4 µM of each specific forward and reverse 
primers (table 2.9) and 2-2.5 ng of template DNA in a total reaction volume of 25 µl. The absolute 
qPCR of HSV1-sr39TK was performed with 12.5 µl of qPCR Master Mix Plus, 300 nM of each primer, 
200 nM of the probe (table 2.9) and 5 ng of template DNA in a total reaction volume of 25 µl. The 
template DNA was amplified in a real-time PCR sequence detection system according to the cycling 
conditions listed in table 3.2 and table 3.3. The amount of gene copies was calculated by means of 
the standard curve using SDS 2.2 software.  
 
Table 3.2: Real-time qPCR cycling conditions for SYBR® Green assay 
 Stage Temperature (°C) Time Cycles 
1. Initial denaturation 95 15 min   1 
2. Denaturation 95 15 sec 40 
 Annealing 58 15 sec  40 
 Extension 72 15 sec 40 
3. Dissociation (melting curve analysis) 95 
60 
95 
15 sec 
15 sec 
15 sec 
  1 
  1 
  1 
 
 
Table 3.3: Real-time qPCR cycling conditions for TaqMan® assay 
 Stage Temperature (°C) Time Cycles 
1. Initial denaturation 50   2 min   1 
2. Denaturation 95 10 min   1 
3. Annealing 95 15 sec  40 
 Extension 60   1 min 40 
 
 
3.11.2. Relative mRNA quantification  
For the relative quantification of HSV1-sr39TK mRNA expression, total RNA was isolated from 
infected U87-MG or EPP85-181RDB cells (chapter 3.6.1) and reverse transcribed into cDNA (chapter 
3.6.2). The qPCR was performed with master mix, primers and probe as described in chapter 3.11.1, 
using 5 ng of cDNA per reaction. cDNA from uninfected cells served as a reference. The transgene 
expression was normalised to the expression of the endogenous control 18S rRNA, which was 
detected in parallel using PreDeveloped TaqMan Assay Reagent Human 18S rRNA in 1 ng cDNA per 
reaction. The amplification was performed according to table 3.3. 
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3.12. Protein analysis  
3.12.1. Extraction of cellular proteins  
For analysis of HSV1-sr39TK protein expression, infected and/or GCV-treated U87-MG or EPP85-
181RDB cells were harvested by centrifugation at 2700 rpm for 10 min, when cells infected with 
oncolytic adenoviruses showed indication of c.p.e. After two washing steps with 1 x PBS, cells were 
lysed in 500 µl/1 x 106 cells ice-cold RIPA buffer (table 2.5) for 30 min on ice. DNA was removed from 
the lysates by centrifugation for 30 min at 10,000 rpm and 4°C. Supernatants containing the 
extracted cellular and viral proteins were stored at -80°C.  
3.12.2. Protein quantification  
Protein concentration was quantified by the Bio-Rad Protein Assay, which is based on the method of 
Bradford [311]. Accordingly, the absorbance maximum for an acidic solution of Coomassie® Brilliant 
Blue G-250 dye, included in the dye reagent, shifts from 465 nm to 595 nm when forming complexes 
with proteins. For quantification, protein standard consisting of BSA (stock solution 1.45 mg/ml in 20 
% RIPA buffer) was prepared by serial dilutions. The protein sample and the standard dilutions were 
mixed 1:4 with dye reagent and incubated for 20 min. The absorbance at 590 nm was measured in a 
multilabel counter and protein concentration was calculated according to the standard curve.     
3.12.3. TCA precipitation  
Samples containing a low protein amount, mostly because of c.p.e., were concentrated by TCA 
precipitation. For this purpose, protein extracts were treated with ¼-fold volume of 50 % ice-cold 
TCA and incubated for 15 min on ice. After centrifugation for 15 min at 14,000 rpm and 2°C, the 
pellets were resuspended in 500 µl ice-cold acetone to remove residual TCA and centrifuged again 
for 15 min at 2°C and 14,000 rpm. Pellets were vacuum-dried in a concentrator and resuspended in 5 
x Laemmli buffer (table 2.5). 
3.12.4. SDS-polyacrylamide gel electrophoresis and Western blot   
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is applied in order to separate proteins according 
to their size, using SDS as a detergent [312]. SDS acts as an anionic, denaturing detergent that binds 
to proteins directly proportional to their molecular weight and enables their motility in an electric 
field through its negative charge.  
Prior to subjecting proteins to SDS-PAGE, precipitated and in Laemmli buffer diluted samples were 
boiled at 95°C for 5 min to further denature the proteins by breaking up secondary and tertiary 
structures. 150 µg of the protein samples were loaded together with a molecular weight marker on 
10 % polyacryamid gels and separated according to their size by electrophoresis at 25 mA per gel, 
using BupHTM Tris-HEPES-SDS Running Buffer (table 2.4). 
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Proteins were then blotted onto a PVDF membrane by electrophoretic transfer in a transfer unit 
filled with blotting buffer (table 2.5) for 1 h at 400 mA. The membrane was blocked to avoid 
unspecific antibody binding by incubation in blocking buffer (table 2.5) for 30 min at RT. The primary 
antibody against HSV1-TK (table 2.8) was diluted 1:1000 in blocking buffer and incubated for 
overnight at 4°C onto the membrane. In a parallel reaction, the primary antibody (1:1000) was 
incubated with 1 µg/ml of a blocking peptide (table 2.8) against the HSV1-TK-specific antibody for 30 
min at RT to test the specificity of the antibody. The antibody-blocking peptide complex was then 
applied to a protein sample on the membrane and incubated overnight at 4°C. The antibody that is 
neutralised by the blocking peptide is no longer able to bind to the epitope of its target protein and 
thus no signal is detected. After three washing steps with PBS/Tween (table 2.5) for 10 min, a 1:3000 
dilution of the secondary antibody (table 2.8) in blocking buffer was applied for 1 h at RT. Following 
four washing steps of 15 min with PBS/Tween and one with PBS, protein detection was performed 
using the ECLTM ("Enhanced Chemiluminescence") detection reagent. The enzyme HRP coupled to the 
secondary antibody catalyses the oxidation of luminol and generates chemiluminescence at 425 nm 
wavelength. Signals were detected by an image station. Mean intensity was quantified using Image J 
software.    
 
3.13. Cytotoxicity assays 
3.13.1. SRB staining  
In order to quantify c.p.e., HSV1-sr39TK/GCV-mediated cytotoxicity or the combined cell killing effect 
of adenoviral infection, TMZ and the HSV1-sr39TK/GCV-system, cell staining with SRB was performed 
[313]. SRB is a fluorescent aminoxanthene dye that binds to basic amino acid residues of cellular 
proteins under mild acetic conditions. Hence, SRB staining enables quantification of cell survival after 
treatment. The remaining adherent cells were first fixed in 10 % cold TCA solution (50 µl/well, 96-
well plate) overnight at 4°C. After rinsing of TCA by five washing steps with distilled water, cells were 
stained by SRB staining solution (table 2.5; 50 µl/well, 96-well plate) for 10 min at RT. Subsequently, 
the dye was removed by five times washing with 1 % acetic acid and the stained cells were air dried. 
In addition, images of SRB-stained cells were taken. To quantify cell survival, dried SRB dye was 
dissolved in 10 mM non-buffered Tris (100 µl/well, 96-well plate) for 1 h and the OD at 590 nm was 
measured in a multilabel counter.  
3.13.2. XTT assay 
Metabolic activity of cells or U87-MG-derived spheroids, subjected to viral infections or GCV and TMZ 
treatment, was verified using the XTT Cell Proliferation Kit II according to the manufacturer’s 
instructions. Briefly, cells or spheroids were incubated in growth medium with XTT solution for 4-24 
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h. The solution contains the yellow tetrazolium salt XTT that is cleaved by metabolically active cells to 
form an orange formazan dye [314, 315]. As this conversion occurs only in viable cells, the amount of 
orange formazan formed correlates with the increase in viability and can be quantified 
spectrometrically in a multilabel counter at absorbance of 490 nm with background correction at 630 
nm. The number of viable cells in 2D monolayer culture was determined by means of an equally 
treated standard curve, consisting of serial dilutions with known cell number.  
In contrary to SRB staining, the XTT assay enables the quantification of metabolically active cells, 
whereas SRB detects intact cells, regardless of functional metabolism.   
 
3.14. Preparation of cryosections and immunofluorescence staining 
For immunofluorescence analysis of adenoviral distribution, infected and drug-treated U87-MG-
derived spheroids were fixed 48 h post infection in acetone/methanol (1:1) for 20 min at -20°C and 
embedded in Cryo Tissue Tek medium for cryosectioning. Cryosections of 14 µm thickness were 
generated using a cryostat microtome and mounted onto microscope slides. Prior to 
immunostaining, frozen sections at -20°C were warmed to RT and fixed for permeabilisation of cells 
in acetone/methanol (1:1) for 10 min at RT. After washing with 1 x cold PBS, unspecific antibody 
binding was avoided by incubation of the sections in blocking buffer (table 2.5) for 30 min RT. The 
slides were washed once with PBS/Tween (table 2.5) and incubated simultaneously with 1:1000 
dilutions of the primary anti-Hexon or anti-HSV1-TK antibodies (table 2.8) overnight at 4°C. After 
three times rinsing with 1 x PBS, the sections were treated with 1:50 dilutions of the corresponding 
FITC- and Texas Red-coupled secondary antibodies (table 2.8) for 1 h at RT. After three times rinsing 
with 1 x PBS, the sections were air dried and mounted in Vectashield mounting medium containing 
DAPI. Fluorescent signals were analysed on a Nikon Eclipse fluorescence microscope. 
  
3.15. [18F]-FHBG radiotracer uptake 
The radiotracer uptake activity of HSV1-sr39TK as an indicator of the enzymatic function of HSV1-
sr39TK was analysed by in vitro uptake of [18F]-FHBG in infected and/or treated U87-MG cells or 
spheroids. For uptake analysis, 1 x 105 cells and spheroids containing approximately 1 x 105 cells were 
washed once with 1 x PBS and labelled with 0.1 MBq [18F]-FHBG. All probes were incubated for a 
minimum of 1 h at 37°C and washed twice with ice-cold PBS, before the accumulated radiotracer was 
released from the cells by addition of 1 ml 1 M NaOH. A standard curve, containing serial dilutions of 
the [18F]-FHBG solution, was prepared in order to determine the uptake dose of the samples. The 
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radiotracer activity per 1 x 105 cells was measured as counts per minute (cpm) using a gamma-
counter and decay-corrected. 
To measure the spatial accumulation of radiotracer without disrupting the spheroid morphology, 
infected and/or treated spheroids consisting of 4 x 105 cells were labelled with [18F]-FHBG as 
described above. After labelling, spheroids were transferred to a 24-well plate, containing one 
spheroid per well, and radioactivity was detected on a combined small-animal positron emission 
tomography (PET)/computed tomography (CT) system. The analysis of the regions of interest (ROI) 
was performed with INVEON Research Workplace software using the statistical iterative 
reconstruction algorithm of ordered subset expectation maximisation (OSEM 3D) with attenuation 
correction/scatter correction (ACSC). Decay correction was performed and the measured activity was 
validated by means of a standard curve with serial radiotracer dilutions. 
 
3.16. Statistical analysis 
Statistical analysis of TMZ-enhanced adenoviral replication was performed by using Student’s t-test 
(paired, two-sided). The criterion for statistical significance was taken as p < 0.05. To analyse 
spheroid growth after subjection to viral infections and TMZ or GCV treatment in a time-course, two-
way ANOVA at 5 % level of significance (alpha value of 0.05) was performed. Correction of alpha 
error level was subsequently conducted by Tukey’s multiple comparison test (95 % confidence 
interval) for the significance of multiple independent groups. Metabolic activity of spheroids after 
treatment was analysed by Student’s t-test (paired, two-sided, p < 0.05). The radiotracer uptake 
studies were evaluated by one-way ANOVA at a 5 % level of significance (alpha value of 0.05) with 
Tukey’s multiple comparison test (95 % confidence interval) as described above. 
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4. RESULTS 
 
4.1. Characterisation of adenoviral vectors 
The adenoviral vectors (figure 2.1) applied in this work were characterised in order to verify their 
correct genetic structure prior to the beginning of all experiments. Additionally, the adenoviral 
preparations were examined for potential contamination with wild-type adenovirus.  
4.1.1. Verification of crucial genetic modifications 
The integrity of essential mutated adenoviral regions and the maintenance of the transgene HSV1-
sr39TK in Ad-delo-sr39TK-RGD were verified after virus production and compared to respective gene 
regions of a HSV1-sr39TK-armed and non-armed adenovirus. The verification was performed by 
means of PCR analysis of DNA extracted from CsCl-purified adenovirus preparations. The expected 
PCR products are summarised in table 4.1 and the derived PCR signals are depicted in figure 4.1.  
The E1 region-specific primers amplify a DNA fragment, which comprises the E1A, E1B19K and 
E1B55K genes. This fragment was detected in its full length in Ad5-wt DNA. The vectors Ad-delo-
sr39TK-RGD and Ad-delo3-RGD contain an 11 bp deletion in the CR3 region of the E1A gene and a 
201 bp deletion in the E1B19K gene (chapter 2.14.). Because of these two manipulations, a shorter 
PCR product than the one in Ad5-wt was derived from Ad-delo-sr39TK-RGD and Ad-delo3-RGD, as 
expected. In the replication-deficient adenovirus Ad-sr39TK, the detected fragment in the E1 region 
is for the most part deleted and replaced by the transgene HSV1-sr39TK (chapter 2.14.). The specific 
amplification resulted therefore in a PCR product shorter than that of Ad5-wt and the oncolytic 
adenoviruses. 
The E3 region-specific primers amplified a sequence located in the E3 region of Ad5-wt. In Ad-delo-
sr39TK-RGD, this part of the E3 region is replaced by the 1131 bp insertion of the HSV1-sr39TK gene. 
This insertion resulted in a larger PCR product, compared to Ad5-wt, when detected with E3-specific 
primers. No respective PCR signal was obtained in the E3-deleted Ad-delo3-RGD vector. A fragment, 
localised outside of the deletion in the E3 region and corresponding to the respective PCR sequence 
derived from Ad5-wt, was detected in Ad-sr39TK DNA.  
Both Ad-delo-sr39TK-RGD and Ad-sr39TK yielded a positive amplification signal for the transgene 
HSV1-sr39TK. The vectors armed with the transgene HSV1-sr39TK were also verified by sequencing 
(data not shown). The oncolytic vector Ad-delo-shMGMT-RGD had already been verified previously. 
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Table 4.1: Expected PCR products after specific detection of adenoviral E1/E3 region and HSV1-sr39TK. 
Virus PCR product (size in bp)  
 E1 E3 HSV1-sr39TK 
Ad5-wt 3345 796  n.a. 
Ad-delo-sr39TK-RGD 3163   2147  1070 
Ad-delo3-RGD 3163  - n.a. 
Ad-sr39TK 2935 796  1112 
Ad5-wt: wild-type adenovirus 5; n.a.: not analysed   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Verification of key adenoviral modifications. DNA was isolated by phenol-chloroform extraction 
from CsCl-purifications of the indicated adenoviruses and subjected to PCR analysis with specific primers for 
the amplification of adenoviral E1A-pIX region (left), E3 region (middle) and HSV1-sr39TK gene (right). Lane 1: 1 
kb DNA ladder with DNA bands of indicated length. - : negative control.  
 
 
4.1.2. Control for contamination with wild-type Ad5 recombinants 
Recombinant replication-competent adenoviruses (RCA) arise from the recovery of E1 sequences 
during accidental homologous recombination between E1-deleted or E1-mutated adenoviruses and 
the wild-type E1 sequence provided by the producer cell line HEK293 [316]. In order to exclude 
possible contamination of the adenoviruses with wild-type Ad5 RCA, the adenoviral vectors were 
examined by specific PCR amplification of DNA extracted from CsCl-purified adenovirus preparations.  
If the PCR analysis with specific primers for E1A is positive in replication-deficient, E1A-deleted 
adenoviruses, the virus of interest is contaminated with RCA. However, oncolytic adenoviruses like 
Ad-delo-sr39TK-RGD, Ad-delo3-RGD and Ad-delo-shMGMT-RGD, which contain an 11 bp deletion in 
the CR3 region of the E1A gene, yield a positive amplification signal despite being devoid of 
contamination with wild-type recombinants. The results of the PCR analysis for wild-type RCA 
contamination are summarised in table 4.2 and the signals derived by the PCR are depicted in figure 
4.2. Amplification of all oncolytic vectors with E1A-specific primers resulted in the expected PCR 
products, which are 11 bp shorter than the respective product of the Ad5-derived vector pXC1. 
However, due to the similar length of the PCR products derived from the oncolytic vectors and of 
those derived from the Ad5-vector pXC1, a potential wild-type RCA contamination of the oncolytic 
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vectors could not be definitely excluded. Absence of RCA contamination was therefore verified by 
the distinctive PCR signals of the oncolytic vectors in figure 4.1. No PCR signal was derived by E1A-
specific amplification of Ad-sr39TK. The sensitivity of the amplification was high, given that the 
detection limit of the E1A-specific PCR had been proved to be 10 fg of pXC1 DNA that corresponds to 
912 DNA copies (Dr. Martina Anton, personal communication). The presence of adenoviral DNA was 
verified by successful E2-specific PCR amplification, using the vector pBHGlox as a positive reference.  
 
Table 4.2: Expected PCR products after specific detection of fragments in adenoviral E1A and E2 regions for 
proof of contamination with wild-type RCA. 
Virus PCR product (size in bp) 
 E1A E2 
pXC1 1042 n.a. 
pBHGlox n.a. 631 
Ad-sr39TK - 631 
Ad-delo-sr39TK-RGD 1031 631 
Ad-delo-shMGMT-RGD 1031 631 
Ad-delo3-RGD 1031 631 
n.a.: not analysed     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Control of contamination with wild-type RCA. DNA was isolated by phenol-chloroform extraction 
from CsCl-purifications of the indicated adenoviruses and subjected to PCR analysis with specific primers for 
the amplification of adenoviral E1A (left) and E2 region (right). Plasmid DNA of pXC1 and pBHGlox was used as 
a positive control for E1A and E2 amplification, respectively. Lane 1: 1 kb DNA ladder showing relevant DNA 
bands. - : negative control. 
 
The results described in 4.1.1. and 4.2.1. demonstrate that Ad-delo-sr39TK-RGD contains the correct 
modifications of its genome and that the replication-deficient adenovirus Ad-sr39TK was devoid of 
any detectable wild-type RCA contamination. Due to the presence of the E1A region, the lack of RCA 
contamination in the oncolytic adenovirus preparations was only partially confirmed. The 
adenoviruses could be applied in the subsequent experiments. 
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4.2. Induction of cytopathic effect by YB-1 dependent oncolytic adenoviruses 
in tumour cell lines        
Cytopathic effect (c.p.e.) is a characteristic of infection with replicating adenoviruses and a 
prerequisite for lysis of infected cells. The ability of oncolytic adenoviruses to induce c.p.e. is 
therefore a crucial step for efficient tumour cell eradication. The vectors Ad-delo-sr39TK-RGD, Ad-
delo3-RGD and Ad-delo-shMGMT-RGD were rendered YB-1 dependent by deleting the CR3 domain 
of E1A (figure 2.1). Thus, it was of interest to examine the potential of YB-1 dependent oncolytic 
adenoviruses in mediating c.p.e in the glioma cell line U87-MG and in the multidrug-resistant 
pancreatic cell line EPP85-181RDB as a reference. The replication of YB-1 dependent oncolytic 
adenoviruses is stimulated by nuclear accumulated YB-1 [259, 265]. In this context, the U87-MG cell 
line had been characterised by a high expression level and partial nuclear localisation of YB-1 [290]. 
Nuclear distribution of YB-1 in EPP85-181RDB cells had also been verified [288].  
As shown in figure 4.3, c.p.e. was microscopically visible as colonies of rounded cells detached from 
the cell monolayer. Ad-delo-sr39TK-RGD was able to induce complete c.p.e. in U87-MG cells at MOI 
of 100 ifu/cell already 48 h after infection. At MOI of 10 ifu/cell, Ad-delo-sr39TK-RGD could induce 
c.p.e. in only about 50-70 % of the cell population 72 h after infection (data not shown). The c.p.e. 
elicited by Ad-delo3-RGD 48 h after infection was as strong as that of the armed virus, but started 
with a delay of one day compared to Ad-delo-sr39TK-RGD, when a MOI of 10 ifu/cell was applied 
(data not shown). Ad-delo-shMGMT-RGD induced a similar c.p.e. as Ad-delo-sr39TK-RGD and Ad-
delo3-RGD, regarding its strength and onset time-point. C.p.e. was absent after infection of the 
tumour cells lines with Ad-sr39TK. In EPP85-181RDB, all oncolytic adenoviruses were able to mediate 
c.p.e. successfully and at the same level as in U87-MG cells, but 72 h after infection.  
 
 
 
 
 
 
 
 
 
Figure 4.3: Induction of c.p.e. by YB-1 dependent oncolytic adenoviruses in tumour cell lines. U87-MG and 
EPP85-181RDB cells (5 x 105) were infected with the indicated adenoviruses at MOI of 100 ifu/cell and analysed 
in an inverted microscope for occurrence of c.p.e. 48 h (U87-MG) or 72 h (EPP85-181RDB) after infection. Scale 
bar: 100 µm.    
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Taking the above described results into account, all YB-1 dependent adenoviruses successfully 
induced c.p.e. and thus oncolytic effect in tumour cells. As a next step, the contribution of viral 
replication to c.p.e. was explored. 
   
4.3. Replication competence of YB-1 dependent oncolytic adenoviruses  
4.3.1. Replication of oncolytic adenoviruses in tumour cells  
Given that adenoviral replication is a prerequisite for successful induction of c.p.e. and oncolytic 
effect in target cells, it was of interest to examine the replication capacity of oncolytic adenoviruses. 
Moreover, it was analysed whether the replication kinetics of the transgene HSV1-sr39TK in Ad-delo-
sr39TK-RGD correlated with the replication potential of the virus. These examinations were 
performed by Southern blot and real-time qPCR analyses. 
In accordance with their strong induction of c.p.e., the oncolytic adenoviruses replicated efficiently in 
U87-MG cells, as shown by Southern blot detection of viral DNA (figure 4.4 A). A time-dependent and 
cumulative increase of the DNA amount of all oncolytic viruses was observed from 24 h up to 96 h 
after infection. HSV1-sr39TK gene replication also increased slightly from 24 h to 96 h after infection 
with Ad-delo-sr39TK-RGD. The transgene was not detected in the DNA of Ad-delo3-RGD and Ad-delo-
shMGMT-RGD. No DNA replication was observed after infection with Ad-sr39TK. Addition of GCV to 
infected U87-MG cells immediately after infection resulted in absence of Ad-delo-sr39TK-RGD DNA 
replication, even when high viral doses (MOI of 100 ifu/cell) were applied, as shown by the specific 
detection of HSV1-sr39TK (figure 4.4 B).  
 
A 
 
 
 
       
B 
 
 
 
 
 
 
 
 
 
Figure 4.4: Analysis of adenoviral replication in glioma cells. U87-MG cells (5 x 105) were infected with the 
indicated adenoviruses at MOI of 100 ifu/cell. A: DNA was isolated from cells 6 h, 24 h, 48 h and 96 h after 
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infection using phenol-chloroform extraction. Southern blot analysis was performed with 1 µg DNA, digested 
with PvuI. A 1669 bp fragment of the adenoviral E2 region and, after stripping and re-probing, a 1146 bp 
fragment of HSV1-sr39TK were detected by hybridisation with complementary DIG-dUTP-labelled DNA probes. 
B: GCV [50 µg/ml] was added to U87-MG cells immediately after infection. DNA was isolated 72 h after 
infection and subjected to Southern blot analysis and specific detection of HSV1-sr39TK as described in A.    
 
 
Consistent with the detection of viral DNA by Southern blot analysis, but more accurately, the 
replication of the oncolytic adenoviruses was demonstrated by real-time qPCR analysis of adenoviral 
Fiber 5 gene copy number in U87-MG glioma cells and in the multidrug-resistant cell line EPP85-
181RDB (figure 4.5). A significant replication burst of Ad-delo-sr39TK-RGD was observed in U87-MG 
cells from 24 h to 48 h (150-fold) and in EPP85-181RDB cells from 12 h to 24 h (260-fold) after 
infection. The overall DNA accumulation from 6 h to 72 h post infection was about 180,000-fold in 
U87-MG cells and only about 1700-fold in EPP85-181RDB cells. In contrast, the DNA copy number of 
Ad-sr39TK remained constant over time in both cell lines, which confirmed the replication-deficient 
character of the virus. In comparison to Ad-delo-sr39TK-RGD, the replication of Ad-delo3-RGD 
increased only 8300-fold from 6 h to 72 h in U87-MG cells, despite identical E1A genetic backbone. 
The lower replication level obtained by Ad-delo3-RGD reflected the 24 h-delayed induction of c.p.e. 
by Ad-delo3-RGD compared to Ad-delo-sr39TK-RGD, as described in chapter 4.2. In EPP85-181RDB 
cells, the DNA accumulation of Ad-delo3-RGD reached a similar level as Ad-delo-sr39TK-RGD 
replication 48 h and 72 h post infection. Hence, Ad-delo-sr39TK-RGD not only replicates effectively, 
but has an improved replication competence over Ad-delo3-RGD in glioma cells.  
The gene copy number of HSV1-sr39TK paralleled the increase in Ad-delo-sr39TK-RGD replication and 
accumulated about 5000-fold in U87-MG cells and only about 500-fold in EPP85-181RDB cells from   
6 h to 72 h post infection. The transgene copy number remained constant in Ad-sr39TK and was not 
detectable in Ad-delo3-RGD. The difference between the accumulated DNA copy number of Fiber 5 
and that of HSV1-sr39TK resulted most probably from the different efficiency of the detection 
chemistries (SYBR green dye for Fiber 5 and TaqMan® probe for HSV1-sr39TK) used for quantification 
of the genes.   
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Figure 4.5: Accumulation of adenoviral DNA in glioma and pancreatic carcinoma cells. U87-MG and EPP85-
181RDB cells (1 x 106) were infected with the indicated adenoviruses at MOI of 10 ifu/cell. DNA was isolated 
from infected cells 6-72 h after infection by phenol-chloroform extraction. The copy number of adenoviral Fiber 
5 gene and HSV1-sr39TK transgene was quantified by means of absolute real-time qPCR of 2.5 ng (Fiber 5) and 
5 ng (HSV1-sr39TK) DNA per reaction (mean±SD); n=3.   
 
4.3.2. Release of newly synthesised adenoviral particles  
In order to spread to, infect and lyse neighbouring cells, an oncolytic adenovirus should be able to 
produce functional viral progeny. Therefore, the release of newly synthesised viral particles by U87-
MG and EPP85-181RDB cells infected with oncolytic adenoviruses was analysed by absolute real-time 
qPCR of Fiber 5 DNA copy number. Release of newly synthesised Ad-delo-sr39TK-RGD oncolytic 
adenoviral particles from both tumour cell lines was first detected 48 h after infection (figure 4.6). 
The values measured 6 h, 12 h and 24 h after infection indicate most probably not internalised 
adenoviruses, as viral release usually starts about 48 h to 72 h post infection [165]. After 96 h, viral 
release from U87-MG and EPP85-181RDB cells reached a 9020-fold and an about 25-fold higher level 
than the initial value, respectively. This finding correlated with the enhanced intracellular replication 
of viral DNA up to 72 h after infection (figure 4.5). In comparison, the cumulative release of Ad-delo3-
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RGD and Ad-delo-shMGMT-RGD particles from U87-MG and EPP85-181RDB cells started 72 h or 96 h 
post infection (figure 4.6).  
In addition to its delayed release, Ad-delo3-RGD yielded 16,000-times and 70-times less viral particles 
than Ad-delo-sr39TK-RGD from U87-MG and EPP85-181RDB cells, respectively, 96 h post infection. 
This finding was in accordance with the attenuated intracellular DNA replication efficacy of Ad-delo3-
RGD compared to the armed oncolytic adenovirus. Ad-delo-shMGMT-RGD was characterised by a 
400-fold and 6-fold lower particle release than Ad-delo-sr39TK-RGD from U87-MG and EPP85-
181RDB cells, respectively, 96 h post infection.  
 
 
 
 
 
 
 
 
 
 
                                                                 
 
 
Figure 4.6: Release of newly synthesised adenoviral particles from glioma and pancreatic carcinoma cells. 
U87-MG and EPP85-181RDB cells (2 x 105) were infected with the indicated oncolytic adenoviruses at MOI of 
10 ifu/cell. DNA was isolated from supernatants of infected cells 6-96 h after infection using DNeasy Blood and 
Tissue Kit (Qiagen). Cumulative release of newly synthesised adenoviral particles was analysed by detection of 
Fiber 5 gene copy number by absolute real-time qPCR of 2.5 ng DNA per reaction (mean±SD); n=3.  
 
4.3.3. Oncolytic adenoviruses produce infectious progeny  
The infectivity of released oncolytic viral progeny from U87-MG glioma cells was examined by End-
point dilution assay on HEK293 cells and the infectious titre was determined accordingly (figure 4.7). 
The infectious titre of released Ad-delo-sr39TK-RGD particles was 7.94 x 106 pfu/ml 5 days after 
infection of U87-MG cells. Ad-delo3-RGD and Ad-delo-shMGMT-RGD particles yielded 25-fold and 3-
fold lower titres than Ad-delo-sr39TK-RGD, respectively. The low amount of infectious particles of 
Ad-delo3-RGD was associated with the attenuated replication efficiency and progeny release of the 
virus, as shown in figures 4.5 and 4.6. No infectious particles were produced by Ad-sr39TK-infected 
glioma cells. 
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Figure 4.7: Infectivity of newly synthesised 
adenoviral particles. U87-MG cells (2 x 105) 
were infected with the indicated adenoviruses 
at MOI of 10 ifu/cell and supernatants 
containing released viral particles were collected 
5 days post infection. The titres of released viral 
particles, defined as plaque forming units per ml 
(pfu/ml), were determined by End-point dilution 
assay in HEK293 cells.                                                                                                       
 
 
 
 
 
 
 
The results described in chapter 4.3. demonstrate the strong replication competence of Ad-delo-
sr39TK-RGD, as well as the efficient production and release of viral progeny, which was in accordance 
with the successful induction of c.p.e in infected tumour cells and proved the oncolytic potential of 
the virus. Moreover, Ad-delo-sr39TK-RGD displayed improved replication capacity and viral release 
as compared to the E3-deleted vector Ad-delo3-RGD. The accumulation of HSV1-sr39TK copy number 
over time correlated with adenoviral replication. The replication competence of Ad-delo-sr39TK-RGD 
in glioma cells was 100-times higher than in multidrug-resistant pancreatic carcinoma cells at late 
time points of viral infection. In addition, Ad-delo-sr39TK-RGD was able to produce high amount of 
viral progeny to re-infect tumour cells.  
 
4.4. Expression of adenovirus-delivered HSV1-sr39TK in tumour cells 
In order to investigate the expression kinetics of the transgene HSV1-sr39TK, U87-MG and EPP85-
181RDB cells infected with armed oncolytic and replication-deficient vectors were subjected to 
specific mRNA real-time quantification and immunodetection of the protein by SDS-PAGE and 
Western blot. 
The relative mRNA levels of HSV1-sr39TK synthesised by Ad-delo-sr39TK-RGD-infected U87-MG and 
EPP85-181RDB cells increased 52-fold and 87-fold, respectively, from 6 h to 72 h post infection, 
whereas mRNA delivered by Ad-sr39TK did not accumulate over time in both cell lines (figure 4.8). 
The highest HSV1-sr39TK mRNA level in Ad-delo-sr39TK-RGD-infected EPP85-181RDB cells was 
detected 48 h post infection. However, the mRNA levels in infected U87-MG cells were about 10-
times higher than the mRNA levels derived from infected EPP85-181RDB cells at each time point 
analysed.   
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Figure 4.8: Relative quantification of adenovirus-delivered HSV1-sr39TK mRNA transcripts. U87-MG and 
EPP85-181RDB cells (1 x 106) were infected with the indicated adenoviruses at MOI of 10 ifu/cell. Total RNA 
was isolated 6-72 h post infection using Trizol reagent (Invitrogen) and reverse transcription into cDNA was 
performed. HSV1-sr39TK mRNA transcripts were deduced from cDNA amount (5 ng per reaction) in a relative 
real-time qPCR and normalised to 18S rRNA endogenous control (mean±SD); n=3.  
 
 
The results of the mRNA quantification were supported by analysis of protein expression (figure 4.9). 
The HSV1-sr39TK protein of 40.97 kDa (UniProtKB) delivered by Ad-delo-sr39TK-RGD and Ad-sr39TK 
was successfully detected 48 h after infection of U87-MG cells and 72 h after infection of EPP85-
181RDB cells (figure 4.9 A left), when first signs of c.p.e. were visible (figure 4.3). As shown by the 
analysis of signal intensity (figure 4.9 A right), the protein expression level of the transgene in Ad-
delo-sr39TK-RGD (second lane) was comparable to that of the transgene in Ad-sr39TK (third lane) in 
both cell lines. The expression levels of the HSV1-sr39TK protein in the EPP85-181RDB cell line were 
lower than those in U87-MG cells, regardless of delivery vector. 
It was further investigated if GCV had an impact on HSV1-sr39TK expression in infected U87-MG cells 
(figure 4.9 B). Ad-delo-sr39TK-RGD- as well as Ad-sr39TK-delivered HSV1-sr39TK was weakly 
expressed when GCV was applied 24 h or 48 h after infection. After GCV addition 72 h post infection, 
a significant level of HSV1-sr39TK expressed by Ad-sr39TK (lane 6) was detected, compared to a 
lower expression by Ad-delo-sr39TK-RGD (lane 5). This finding could result from an enhanced cell 
killing by Ad-delo-sr39TK-RGD 72 h after infection. The lack of a HSV1-sr39TK protein signal, when 
the primary antibody was neutralised by a blocking peptide against HSV1-TK and applied to lysates of 
Ad-delo-sr39TK-RGD-infected cells, proved the specificity of the anti-HSV1-TK antibody (figure 4.9 C).  
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Figure 4.9: Expression of adenovirus-delivered HSV1-sr39TK in tumour cells. U87-MG and EPP85-181RDB cells 
(1 x 106) were infected with the indicated adenoviruses at MOI of 100 ifu/cell. Protein extractions were derived 
at indicated time points using RIPA buffer, concentrated by TCA precipitation and subjected to Western blot 
analysis. HSV1-sr39TK protein expression was analysed in 150 µg protein lysates by immunodetection. A: HSV1-
sr39TK protein was detected 48 h (U87-MG) and 72 h (EPP85-181RDB) after infection (left) and the protein 
signal intensity was determined by densitometry (right). B: U87-MG cells were treated with GCV [50 µg/ml] 24 
h, 48 h and 72 h after infection. Protein expression was analysed 48 h after GCV addition. C: The specificity of 
the primary antibody against HSV1-sr39TK was verified in protein extractions of Ad-delo-sr39TK-RGD-infected 
cells by the incubation of the antibody with a blocking peptide [1 µg/ml].   
 
 
To sum up, the increasing HSV1-sr39TK expression from Ad-delo-sr39TK-RGD 6 h to 72 h after 
infection was due to the replication competence of the oncolytic virus and thus due to accumulation 
of transgene DNA copies, as shown by the replication analysis. Moreover, it could be shown that GCV 
had a negative impact on protein expression at early time points of infection, probably due to HSV1-
sr39TK/GCV-mediated cytotoxicity.   
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4.5. Analysis of growth, cellular migration and infectivity of glioma spheroids 
Spheroids are convenient models to mimic tumour behaviour in vitro and to study anti-tumour 
treatment effects. Therefore, spheroids were first analysed in respect of various parameters 
concerning their growth, migration ability of cells out of the spheroidal structure and infectivity with 
adenoviruses. 
4.5.1. Spheroids exhibit tumour-like growth pattern 
In order to examine U87-MG spheroid growth, spheroids were cultivated for 28 days after formation. 
During that time-course the surface areas and the volumes of the spheroids were calculated, as 
depicted in figure 4.10. The increase of the spheroid surface areas corresponded to the increase of 
their volumes. All of the 12 spheroids analysed displayed similar growth pattern with some 
fluctuations of their volumes from day 17 to day 28 of monitoring, characteristic of tumour-like 
growth. The spheroids grew exponentially until reaching a plateau phase of growth after 14 days. At 
day 14 they had increased up to 6-fold of their initial volumes. After 28 days the spheroids reached 
mean volumes of 0.4 ± 0.11 mm³ that corresponded to an 8-fold increase relative to the initial 
values. All spheroids had mostly uniform morphology at each time point analysed, as depicted in 
figure 4.10, below. 
 
 
 
 
 
 
Figure 4.10: Growth analysis of U87-MG-derived multicellular spheroids. The growth of glioma spheroids, 
consisting of an initial number of about 1 x 105 cells, was monitored in a time-course of 28 days after 
formation. Spheroid diameter was measured in an inverted microscope. The surface areas and volumes were 
calculated accordingly at the indicated time points (mean±SD); n=12. Representative spheroids are shown 
below (magnification: days 1-4: x 100, days 7-28: x 40).         
 
 
 
time [days]
sp
he
rio
d 
su
rfa
ce
 
ar
e
a 
[m
m
²]
1 4 7 14 17 21 28
0.0
0.2
0.4
0.6
0.8
1.0
time [days]
sp
he
ro
id
 
v
o
lu
m
e
 
[m
m
³]
1 4 7 14 17 21 28
0.0
0.2
0.4
0.6
RESULTS 61
 
4.5.2. Migration potential of cells from spheroids 
The migration behaviour of U87-MG cells, detached from spheroids, was explored in the following 
one to seven days after adherence of spheroids to solid substrate. Representative images of 
migrating glioma cells from attached spheroids are displayed in figure 4.11. It could be shown that 
only one day after adherence cells started to migrate from the spheroids and reached migration 
distances in a range of 175-300 µm. Migration continued after two and three days with increasing 
migration behaviour of the cells, spreading at distances of up to 700 µm. Cell filaments outgrowing 
from the spheroids were formed during the migration process. After seven days a significant number 
of cells had detached from the spheroids and migrated at distances of up to 1000 µm, forming 
specific clusters and cell networks.     
 
              
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Cellular migration from U87-MG-derived spheroids. Glioma spheroids consisting of about 1 x 105 
cells were attached after formation to uncoated wells of a 24-well plate. The migration behaviour of cells from 
spheroids (n=2) was monitored 1-7 days after spheroid attachment to the surface. Scale bar: 500 µm.     
 
4.5.3. Spheroids allow for adenoviral infections 
Prior to infection with oncolytic and armed replication-deficient adenoviruses, the infectivity of 
spheroid culture was investigated by infection of spheroids with the eGFP-expressing adenovirus Ad-
mCMVeGFP (chapter 2.14). Fluorescent microscopic analysis of infected spheroids revealed that 
eGFP expression was visible already one to two days post infection, especially at MOI of 20, 50 and 
100 pfu/cell, and was stable up to seven days (figure 4.12 A). However, as Ad-mCMVeGFP is a 
replication-deficient adenovirus, the infection takes place in the outer spheroid layers, giving no 
information about the infectivity of the inner layers. The microscopic observations were confirmed 
by fluorimetric quantification of eGFP expression in spheroid lysates (figure 4.12 B). Both microscopic 
and fluorimetric evaluation methods revealed that the signal intensity of eGFP was directly 
proportional to the viral MOI applied. According to these results and considering that replication-
competent adenoviruses yield better infectivity than replication-deficient viruses, MOI of 50 was 
chosen for further infections.  
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Figure 4.12: Infectivity of U87-MG-derived spheroids. Glioma spheroids with volumes of 0.1-0.18 mm³, 
consisting of an initial number of about 1 x 105 cells, were infected with MOI of 5 to 100 pfu/cell of the 
replication-deficient adenovirus Ad-mCMVeGFP. A: Merged transmitted light and fluorescent images 
demonstrate expression of the reporter gene eGFP as an indicator of spheroid infectivity at indicated time 
points post infection. Scale bar: 500 µm. B: The expression of eGFP at each MOI was quantified at 485/535 nm 
wavelength in lysates of spheroids 7 days after infection according to a standard curve. Quantity of eGFP [ng] 
was normalised to total protein amount [µg]; n=1.   
 
0
1
2
3
4
5
6
7
8
- 5 10 20 50 100
n
g 
e
G
FP
/µ
g 
pr
o
te
in
Ad-mCMVeGFP [MOI]
RESULTS 63
 
Regarding the characterisation of glioma spheroids with respect to their growth, cellular migration 
and infectivity, the spheroids displayed tumour-like growth pattern and characteristics, and were 
susceptible to adenoviral infections. These properties classified them as a suitable in vitro model to 
explore the effects of viral oncolysis and of the HSV1-sr39TK/GCV system against tumours. 
 
4.6. Overlapping time- and dose-dependent HSV1-sr39TK/GCV-mediated 
cytotoxicity and oncolytic effect 
Initially, the influence of overlapping oncolytic potential and HSV1-sr39TK/GCV-mediated cytotoxicity 
on tumour cells was investigated. Bearing in mind that both effects are exerted by Ad-delo-sr39TK-
RGD, it was expected that they should mutually potentiate their action. In this context, it was 
analysed whether the time point of GCV addition and the prodrug dose were crucial for the strength 
of the HSV1-sr39TK/GCV-mediated cytotoxicity and/or oncolytic effect. The highest concentration of 
GCV corresponded to therapeutically relevant GCV concentrations used in preclinical and clinical 
studies [96, 98, 101, 317]. The experiment was performed by means of SRB quantification of cell 
survival and XTT assay for analysis of metabolic activity, using the drug-sensitive cell line U87-MG and 
the multidrug-resistant cell line EPP85-181RDB as a reference. 
As shown in figure 4.13 A, when GCV was added to glioma cells immediately after infection (0 h), the 
GCV dose mediating the strongest cytotoxicity was 100 µg/ml, leading to cell survival of 16.1 ± 5 % 
with Ad-delo-sr39TK-RGD, compared to 7.1 ± 0.11 % cell survival with Ad-sr39TK (figure 4.13 A). The 
XTT cytotoxicity assay displayed the percentage of metabolically active cells. After GCV addition 
directly post infection, the metabolic activity of Ad-delo-sr39TK-RGD-infected cells decreased in a 
dose-dependent way, paralleling SRB quantification (figure 4.13 B). The amount of metabolically 
active cells was 44 ± 8.55 % at 1 µg/ml GCV and only 9 ± 3.19 % at 10 µg/ml GCV. Addition of GCV 24 
h, 48 h or 72 h post infection revealed effective cell killing at the lowest GCV dose of 0.001 µg/ml for 
the oncolytic adenovirus. Glioma cell survival with Ad-delo-sr39TK-RGD and 0.001 µg/ml GCV was 5.6 
± 0.18 %, compared to 106.5 ± 4.6 % survival with Ad-sr39TK, when GCV was added 24 h post 
infection. Cell killing activity was most effective by applying GCV 48 h or 72 h after infection, when 
the least survival of Ad-delo-sr39TK-RGD-infected cells was 4.1 ± 0.02 % (48 h) and 4.1 ± 0.16 % (72 h) 
at 0.001 µg/ml GCV (figure 4.13 A). In contrast, the survival of Ad-sr39TK-infected cells at 0.001 
µg/ml GCV was 99.4 ± 4.98 % (48 h) and 87.6 ± 4.05 % (72 h). These results indicate that addition of 
GCV 48 h or 72 h post infection leads to a significant overlap of viral oncolysis and HSV1-sr39TK/GCV-
mediated cytotoxicity in U87-MG cells regardless of GCV dose, compared to the exclusively prodrug 
dose-dependent cytotoxicity of the replication-deficient Ad-sr39TK at each time point analysed. 
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Supporting the results of the SRB quantification, when GCV was applied 48 h post infection with Ad-
delo-sr39TK-RGD, no metabolically active cells remained, unlike infection with Ad-delo3-RGD plus 
GCV application (figure 4.13 B). Although cell killing was enhanced by rising GCV doses (figure 4.13 
A), Ad-sr39TK-infected cells remained metabolically active (figure 4.13 B). The IC50 values of the Ad-
sr39TK/GCV-mediated cytotoxicity varied from 9.8 µg/ml (72 h) to 0.35 µg/ml (24 h) (figure 4.13 A). 
Although the contribution of suicide system and oncolysis to cell killing could not be clearly 
dissected, the HSV1-sr39TK/GCV-mediated cytotoxicity of Ad-delo-sr39TK-RGD predominated its 
oncolytic activity from GCV concentrations of 1 to 100 µg/ml when applied 0 h and 24 h post 
infection (figure 4.13 A). This finding was confirmed by the strong cytotoxic effects of Ad-sr39TK at 1 
to 100 µg/ml GCV, but less cytotoxicity at lower doses. A peak value of cell survival was observed at 
0.1 µg/ml GCV after infection with Ad-delo-sr39TK-RGD and GCV addition 0 h or 24 h post infection. 
This gave rise to the assumption that viral replication was prevented by the cytotoxicity of the HSV1-
sr39TK/GCV system, acting on the initial number of infected cells. The inhibition of oncolysis was 
overcome when GCV was added 48 h or 72 h post infection, because the oncolytic effect of the virus 
had already been initiated before GCV addition and thus predominated over the HSV1-sr39TK/GCV-
mediated cytotoxicity.  
The oncolytic activity of Ad-delo-sr39TK-RGD (0 µg/ml GCV) promoted strong cell killing. The cell 
survival after oncolysis by Ad-delo-sr39TK-RGD was between 33 ± 2.98 % to 4.2 ± 0.18 % 10 days 
after infection and the cell killing was accordingly 67-96 % (not shown in figure 4.13 A). However, 
without addition of GCV most of the Ad-delo-sr39TK-RGD-infected cells (89 ± 11.7 %) remained 
metabolically active 10 days after infection, despite oncolytic effect (not shown in figure 4.13 B). In 
contrast, progressive cell death mediated by Ad-delo-sr39TK-RGD and GCV could be observed 
microscopically already 3-4 days after infection (data not shown). 
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Figure 4.13: Overlapping time- and dose-dependent HSV1-sr39TK/GCV-mediated cytotoxicity and oncolytic 
effect in glioma cells. U87-MG cells (2 x 103) were infected at MOI of 100 ifu/cell with the indicated 
adenoviruses. GCV was added at increasing concentrations starting 0 h, 24 h, 48 h and 72 h after infection and 
applied again after 72 h. A: Cell killing was detected 10 days after infection using SRB staining and 
quantification of cell survival by measurement of the absorbance at 590 nm. Cell survival was quantified in 
percentage (mean±SD), referring to the survival of uninfected cells (100 %); n=3. B: After GCV addition directly 
(0 h) or 48 h post infection with the indicated adenoviruses, the metabolic activity was quantified by XTT assay 
10 days after infection. The number of metabolically active cells was calculated using a standard curve and 
quantified in percentage (mean±SD) referring to the metabolic activity of uninfected cells (100 %); n=3.  
 
 
Ad-delo-sr39TK-RGD and its HSV1-sr39TK/GCV-mediated cytotoxicity induced an overall weaker cell 
killing in EPP85-181RDB cells compared to U87-MG cells at equal viral MOI and when GCV was 
applied 24 h post infection (figure 4.14). The lowest cell survival amounted to 51 ± 6.31 % at a GCV 
concentration of 10 µg/ml. The IC50 value for the Ad-sr39TK/GCV-mediated cytotoxicity was about 5-
times higher than that for Ad-delo-sr39TK-RGD/GCV. In addition, the IC50 for the Ad-sr39TK/GCV-
mediated cytotoxicity in EPP85-181RDB cells was about 140-times higher than that in U87-MG cells 
(figure 4.13 A) at the same time point of GCV application. In comparison, the oncolytic effect of Ad-
delo-sr39TK-RGD alone led to a cell survival of 61 ± 7.74 % (not shown in figure 4.14). As in Ad-delo-
sr39TK-RGD-infected U87-MG cells, the replication and oncolytic potential of Ad-delo-sr39TK-RGD in 
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EPP85-181RDB cells was inhibited by GCV at a concentration of 0.01 µg/ml. Ad-sr39TK was not 
successful in inducing HSV1-sr39TK/GCV-mediated cytotoxicity, as cell survival was not below 79 ± 
2.34 % at 10 µg/ml GCV. In this context, the HSV1-sr39TK/GCV-mediated effect might be attenuated 
through hampering the activity of GCV by the multidrug-resistant phenotype of the pancreatic 
carcinoma cells.  
Ad-delo3-RGD and Ad-delo-shMGMT-RGD were limited in their oncolytic potential. EPP85-181RDB 
cells infected with Ad-delo3-RGD and Ad-delo-shMGMT-RGD displayed an average cell survival of 90 
% and 50 %, respectively, independent of GCV dose. The application of GCV immediately after 
infection with oncolytic and replication-deficient adenoviruses or two to three days after infection 
did not potentiate the killing of EPP85-181RDB cells (data not shown). A GCV concentration of 100 
µg/ml exerted unspecific toxicity. 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Overlapping dose-dependent HSV1sr39TK/GCV-mediated cytotoxicity and oncolytic effect in 
multidrug-resistant pancreatic carcinoma cells. EPP85-181RDB cells (2 x 103) were infected at MOI of 100 
ifu/cell with indicated adenoviruses. GCV was added at increasing concentrations 24 h after infection and again 
after 72 h. Cell killing was detected 10 days after infection using SRB staining and quantification of cell survival 
by measurement of the absorbance at 590 nm. Cell survival was quantified in percentage (mean±SD), referring 
to the survival of uninfected cells (100 %); n=3.  
 
 
These results show that the oncolytic effect of Ad-delo-sr39TK-RGD in glioma cells was enhanced by 
the HSV1-sr39TK/GCV-mediated cytotoxicity in a prodrug dose-dependent way, although virus-
mediated cell killing was inhibited at critical GCV concentrations applied immediately after infection, 
even at a high viral dose. However, by applying GCV at later time points following infection, the 
combined action of oncolytic effect and the suicide system induced an equally strong cell killing, so 
that the oncolytic effect of the virus could not be further augmented. Due to their multidrug-
resistant phenotype, over 50 % of the EPP85-181RDB cells survived the combined treatment with Ad-
delo-sr39TK-RGD and the HSV1-sr39TK/GCV suicide system.   
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4.7. Bystander effect of viral oncolysis and HSV1-sr39TK/GCV-mediated 
cytotoxicity 
The aim of the following experiment was to prove if the bystander effect, described for the HSV1-
TK/GCV system [55], can be translated into glioma cells infected with oncolytic HSV1-sr39TK-armed 
adenoviruses. The potential of bystander cell killing in glioma cells was compared to the respective 
effect in multidrug-resistant pancreatic carcinoma cells. The major challenge was to distinguish 
between HSV1-sr39TK/GCV-mediated bystander effect and bystander effect by viral replication. A 
GCV concentration of 10 µg/ml was chosen for the analysis of bystander effect in order to circumvent 
inhibition of oncolytic cell killing by GCV at lower doses (figure 4.13, Ad-delo-sr39TK-RGD). To ensure 
that the oncolytic effect did not dominate the HSV1-sr39TK/GCV-mediated cytotoxicity (figure 4.13, 
Ad-delo-sr39TK-RGD), the prodrug was applied shortly after infection to co-cultured infected and 
uninfected cells. Cell survival was analysed by SRB staining and subsequent quantification. 
As shown in figure 4.15, it was demonstrated that the survival of U87-MG glioma cells, treated with 
GCV, decreased exponentially with increasing ratio of Ad-sr39TK-infected to uninfected cells. Cell 
survival was 18 ± 0.01 % even if only 17 % of the whole cell population was infected with Ad-sr39TK, 
compared to the same approach without addition of GCV. This data indicates the action of an Ad-
sr39TK-induced, HSV1-sr39TK/GCV-mediated bystander effect. No bystander effect was observed 
without GCV addition. Ad-delo-sr39TK-RGD also induced a bystander effect after addition of GCV, 
indicated by an inversely proportional decrease in cell survival with increasing ratio of infected to 
uninfected cells. When only 17 % of the cell population were infected, the cell survival was 45.9 ± 9.7 
%. The larger amount of eradicated cells compared to the fraction of virus-infected cells indicated a 
bystander effect of the HSV1-sr39TK/GCV system. Ad-delo-sr39TK-RGD and Ad-sr39TK induced a 
similar bystander effect with GCV. The oncolytic activity of Ad-delo-sr39TK-RGD, shown in the setting 
without GCV, was directly proportional to the fraction of infected cells. The bystander effect, induced 
by GCV, led to enhanced cell killing compared to the oncolytic effect alone.  
In EPP85-181RDB cells, there was a decrease of survival mediated by the HSV1-sr39TK/GCV-effect to 
61 ± 0.04 %, when 50 % of the cell population were infected with Ad-sr39TK (figure 4.15). Survival 
reached 34 ± 0.002 % when 100 % of the cells were infected with Ad-sr39TK and subjected to GCV. 
As expected, there was no influence of Ad-sr39TK-infected cells without GCV on cell survival. In Ad-
delo-sr39TK-RGD-infected cells with GCV, survival decreased with increasing ratio of infected to 
uninfected cells. Survival reached 65 ± 0.02 % even with 50 % infected cells. As observed with Ad-
sr39TK and GCV, the fraction of infected cells corresponded to the fraction of dead cells (cell 
survival), indicating no additional bystander killing. Moreover, the oncolytic effect of Ad-delo-sr39TK-
RGD alone resulted in stronger cell killing of the multidrug-resistant cell line than the combination of 
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virus and HSV1-sr39TK/GCV-mediated cytotoxicity, as only 30 % infected cells led to survival of 8 ± 
0.001 %. A GCV concentration of 50 µg/ml was needed for Ad-delo-sr39TK-RGD- and Ad-sr39TK-
infected EPP85-181RDB cells in order to cause a bystander cell killing with GCV similar to that in U87-
MG cells (data not shown).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Bystander effect of oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity. U87-MG and EPP85-
181RDB cells were infected with Ad-delo-sr39TK-RGD and Ad-sr39TK at MOI of 10 ifu/cell. Infected and 
uninfected cells were co-cultured at ratios 1:0 (100 % infected cells) to 1:5 (17 % infected cells) in a total 
population of 5 x 104 cells. GCV [10 µg/ml] was added 3 h after co-culturing and re-added 72 h after the first 
treatment. The potential bystander effect conducted by the adenoviruses in combination with GCV was 
evaluated by SRB-staining (above) and photometric quantification (below) 10 days after co-culture. Cell survival 
was quantified in percentage (mean±SD), referring to the survival of uninfected cells (100 %); n=2.  
 
 
These results show that Ad-delo-sr39TK-RGD in cooperation with the HSV1-sr39TK/GCV-system 
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with a low fraction of infected cells. In multidrug-resistant pancreatic carcinoma cells, however, no 
significant enhancement of cell killing by a bystander effect with GCV was observed, as the fraction 
of infected cells corresponded to the amount of eradicated cells. This finding indicates a low 
susceptibility of the multidrug-resistant cells to GCV. Taking the results described in chapters 4.6. and 
4.7. into account, EPP85-181RDB cells were not as successfully eradicated through the HSV1-
sr39TK/GCV-mediated cytotoxicity as U87-MG cells and were not further investigated in this context. 
  
4.8. Enhancement of the oncolytic potential of YB-1 dependent adenoviruses 
by TMZ  
It is known that cytostatic drugs are able to enhance the translocation of YB-1 to the nucleus of 
tumour cells. Enhanced nuclear YB-1 accumulation results in augmented replication of YB-1 
dependent oncolytic adenoviruses that consequently leads to an enhanced oncolytic effect [291, 
292]. In order to prove whether treatment with TMZ leads to potentiated oncolytic effect of the 
adenoviruses in tumour cells, different experimental approaches were investigated by varying TMZ 
and viral doses. TMZ concentrations, similar to those used in clinical trials for the study of TMZ 
pharmacokinetics in human plasma [318, 319], were used in this experiment. Cell survival after 
treatment was analysed by SRB staining and quantification. The IC50 value of TMZ was higher than 
500 µM in uninfected U87-MG and EPP85-181RDB cells. It was expected that a combined treatment 
of TMZ and oncolytic adenoviruses should decrease cell survival substantially.    
Ad-delo-sr39TK-RGD led to cell eradication even at a MOI of 5 with rising TMZ concentrations (figure 
4.16). MOI of 5 and 25 µM TMZ led to 49 ± 19.39 % survival of glioma cells. 25 µM TMZ was needed 
to decrease the survival to 10 ± 2.66 % at MOI of 10, and at MOI of 20 and 10 µM TMZ it was reduced 
to 12 ± 2.55 %. A potent oncolytic effect was observed at MOI of 50 and 100 regardless of TMZ 
concentration, resulting in reduction of survival to 6 %. 
Ad-delo3-RGD did not result in enhanced oncolytic cell killing in combination with TMZ pre-treatment 
at the same level as Ad-delo-sr39TK-RGD at MOI of 5, 10 and 20 (figure 4.16). The cell survival at MOI 
of 5 and 10 with 250 µM TMZ was 61 ± 3.57 % and 55 ± 0.88 %, respectively. MOI of 20 of Ad-delo-3-
RGD caused a more prominent decrease in cell survival than MOI of 5 and 10. At MOI of 20 and 50 
µM TMZ, the fraction of surviving cells was 33 ± 4.75 %. A significant cell killing potential, similar to 
that of Ad-delo-sr39TK-RGD, was observed at MOI of 50 and 100, regardless of TMZ dose.  
Ad-delo-shMGMT-RGD carries a shRNA sequence for silencing the expression of the cellular MGMT 
gene (figure 2.1). Silenced MGMT is no longer able to remove the cytotoxic adducts caused by TMZ 
and consequently the lack of MGMT-mediated repair mechanism leads to improved outcome of TMZ 
therapy [320]. Ad-delo-shMGMT-RGD is therefore expected to enhance tumour cell killing on the one 
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hand through TMZ-mediated and YB-1 dependent replication and on the other hand, by stimulation 
of the cytotoxic activity of TMZ. As shown in figure 4.16, Ad-delo-shMGMT-RGD displayed an MOI- 
and TMZ dose-dependent oncolytic potential, similar to that of Ad-delo-sr39TK-RGD. The cell survival 
at MOI of 5 and 50 µM TMZ was 46 ± 4.4 %. MOI of 10 and 50 µM TMZ resulted in 19 ± 11.9 % 
survival. At MOI of 20, 2.5 µM TMZ was necessary to reduce the cell survival to 19 ± 13.6 %. Similar 
to Ad-delo-sr39TK-RGD and Ad-delo3-RGD, MOI of 50 and 100 of Ad-delo-shMGMT-RGD caused 
almost complete eradication of glioma cells, regardless of TMZ dose.  
Infection with Ad-sr39TK did not cause oncolytic activity in TMZ pre-treated cells (figure 4.16). The 
decrease of cell survival after infection with Ad-sr39TK was rather due to non-virally induced 
cytotoxicity by rising TMZ doses, as also observed in uninfected cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Enhancement of oncolytic effect by TMZ in glioma cells. U87-MG cells (2 x 103) were pre-treated 
for 24 h with varying doses of TMZ and infected at MOI of 5-100 ifu/cell with the indicated adenoviruses. Cell 
survival was determined 7 days post infection by photometric quantification of SRB-staining and displayed in 
percentage (mean±SD), referring to the survival of uninfected and untreated cells (100 %); n=3.  
 
 
In EPP85-181RDB cells, TMZ post-treatment (figure 4.17) was more efficient for potentiation of 
oncolysis than TMZ pre-treatment (data not shown). 250 µM TMZ was necessary to be applied after 
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0.09 %, whereas 500 µM TMZ and MOI of 100 resulted in a decrease to only 4 ± 0.01 % survival 
(figure 4.17). Ad-delo3-RGD and Ad-delo-shMGMT-RGD mediated significant oncolysis and decrease 
in survival to 44 ± 0.05 % and 17 ± 0.1 %, respectively, with 500 µM TMZ. Ad-sr39TK-infected and 
uninfected cells were not affected by TMZ, except at a cytotoxic dose of 500 µM. Considering the low 
efficiency of TMZ-enhanced oncolysis in EPP85-181RDB cells, the cell line was not taken into account 
for further analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Enhancement of oncolytic effect by TMZ in multidrug resistant pancreatic carcinoma cells. 
EPP85-181RDB cells (2 x 103) were infected at MOI of 100 ifu/cell with the indicated adenoviruses and treated 
with varying doses of TMZ after infection. Cell survival after treatment was determined 7 days post infection by 
photometric quantification of SRB-staining. Cell survival is displayed in percentage (mean±SD), referring to the 
survival of uninfected and untreated cells (100 %); n=3.  
 
 
The above described results show efficient TMZ-mediated augmentation of the oncolytic activity of 
YB-1 dependent adenoviruses in glioma cells. The oncolytic activity correlated with viral MOI and 
cytostatic drug dose, and was potentiated by TMZ even at low virus and TMZ doses. The oncolytic 
potential of Ad-delo-sr39TK-RGD was similar to that of Ad-delo-shMGMT-RGD, which has a dual 
function of mediating YB-1 dependent oncolysis and potentiation of TMZ cytotoxicity by silencing of 
MGMT. The enhancement of the oncolytic effect by TMZ in the multidrug-resistant EPP85-181RDB 
cell line was successful only after infection of cells at a high viral MOI and treatment with high TMZ 
doses post infection.  
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4.9. Improved cell killing by the combination of oncolytic potential, TMZ and 
HSV1-sr39TK/GCV-mediated cytotoxicity 
4.9.1. Combined cell killing in 2D glioma culture 
It was further analysed if TMZ and GCV enhance the killing of infected glioma cells through the 
combined activity of TMZ-mediated potentiation of oncolysis and HSV1-sr39TK/GCV-mediated 
cytotoxicity. Cell survival after virus infection and treatment with TMZ, GCV or TMZ plus GCV was 
analysed by SRB staining and quantification. In addition, the metabolic activity was investigated by 
XTT assay. As described in chapter 3.13.2, the XTT assay quantifies living and metabolically active 
cells, whereas SRB staining detects detached but intact cells, regardless of their viability and 
functional metabolism. A low concentration of GCV [0.5 µg/ml] and variable concentrations of TMZ, 
as well as a viral dose of 10 ifu/cell were chosen in order to be able to detect subtle effects. 
In 2D glioma culture, GCV addition to Ad-delo-sr39TK-RGD-infected TMZ-untreated cells resulted in 
cell survival of 24 ± 10.66 % (cell killing of 80 %), compared to survival of 36 ± 13.41 % (cell killing of 
60 %, not shown) after infection with Ad-delo-sr39TK-RGD and without treatment (figure 4.18 A). 
TMZ pre-treatment of Ad-delo-sr39TK-RGD-infected cells in combination with GCV led to a 
potentiated GCV-enhanced cytotoxic effect, even with only 2.5 µM TMZ (survival 13 ± 0.58 %). This 
effect caused a 2.7-fold reduction in survival compared to infected and untreated cells. Therefore, 
2.5 µM TMZ in combination with 0.5 µg/ml GCV was sufficient to induce an oncolytic effect, which 
was able to eradicate about 90 % of the cell population. In addition, the reduction of cell survival by 
Ad-delo-sr39TK-RGD in combination with TMZ and GCV was stronger than TMZ-enhanced oncolysis 
elicited by Ad-delo3-RGD and Ad-delo-shMGMT-RGD at all TMZ concentrations analysed. The 
combination of TMZ pre-treatment and GCV reduced the cell survival of uninfected and Ad-sr39TK-
infected glioma cells, probably due to toxicity of TMZ.  
The results of the survival analysis by SRB quantification were confirmed by measurement of the 
metabolic activity of infected and treated cells. As shown in figure 4.18 B, the amount of 
metabolically active Ad-delo-sr39TK-RGD-infected cells was decreased from about 50 % to < 30 % 
when treated with TMZ plus GCV and correlated with cell survival, as demonstrated by SRB 
quantification. The reduction of the metabolic activity of Ad-delo3-RGD- and Ad-delo-shMGMT-RGD-
infected cells upon combined treatment paralleled cell survival, as shown in figure 4.18 A. However, 
the oncolytic effect of Ad-delo-shMGMT-RGD (0 µM TMZ) resulted in a lower amount of living cells 
than detected by the analysis of cell survival in figure 4.18 A. Despite of the toxicity exerted by TMZ 
and GCV upon uninfected and Ad-sr39TK-infected cells (figure 4.18 A), over 60 % of these cells 
remained metabolically active after double treatment.      
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As demonstrated by some representative images of cell survival (figure 4.18 C), GCV addition to TMZ-
pre-treated and Ad-delo-sr39TK-RGD-infected cells altered the morphology and induced lysis of the 
affected cells. While untreated oncolytic adenovirus-infected cells, or either TMZ- or GCV-treated Ad-
delo-sr39TK-RGD-infected cells showed only signs of c.p.e. and appeared rounded, but without 
disrupted membranes (no necrosis), simultaneous TMZ and GCV treatment of cells infected with Ad-
delo-sr39TK-RGD resulted in massive cell death (arrows). Cell death was also observed when TMZ 
concentrations lower than 10 µM were applied (data not shown). Cells, subjected to the combined 
effect of oncolysis, HSV1-sr39TK/GCV-mediated cytotoxicity and TMZ treatment, showed indications 
of a mixed type of cell death. On the one hand, some cells probably displayed apoptotic 
characteristics, indicated by formation and lysis of apoptotic bodies. On the other hand, few cells had 
a necrotic appearance, indicated by swelling and an enlarged nucleus. In contrast, Ad-delo3-RGD- 
and Ad-delo-shMGMT-RGD-infected cells displayed c.p.e. that was potentiated by TMZ, but not 
further enhanced by GCV. Thus, the mode of cell death, induced by HSV1-sr39TK/GCV, contributed to 
the combined TMZ-mediated- and oncolytic effect of the virus and was responsible for the low 
metabolic activity of Ad-delo-sr39TK-RGD-infected cells, as shown in figure 4.18 B. No major 
alteration in cellular morphology was observed in uninfected cells and cells infected with Ad-sr39TK 
and treated with TMZ and GCV, their number was however slightly reduced upon treatment.  
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Figure 4.18: Improved cell killing by the combination of oncolytic effect, TMZ and HSV1-sr39TK/GCV-
mediated cytotoxicity in glioma cells. U87-MG cells (2 x 103) were pre-treated for 24 h with varying doses of 
TMZ and infected at MOI of 10 ifu/cell with the indicated adenoviruses. GCV [0.5 µg/ml] was applied 24 h post 
infection. Cell survival after combined treatment was assessed 5 days post infection by photometric 
quantification of SRB-staining (A) and metabolic activity was analysed by XTT assay (B). Cell survival or 
metabolic activity are displayed in percentage (mean±SD), referring to the survival or metabolic activity of 
uninfected and untreated cells (100 %); n=3. C: Representative images of U87-MG cells pre-treated with 0, 10 
and 100 µM TMZ and infected as described above with or without GCV addition were taken in an inverted 
microscope 5 days post infection. Arrows indicate morphologic changes due to apoptotic (black) or necrosis-
like (red) cell death. Scale bar: 100 µm.  
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4.9.2. Combined cell killing in 3D glioma spheroids 
It was further investigated whether the HSV1-sr39TK/GCV-mediated cytotoxicity and TMZ-enhanced 
oncolysis can be translated from U87-MG monolayer culture into 3D spheroids of glioma cells. To 
increase the accessibility of cells in the inner spheroid layers and because of low cell killing at MOI of 
10 ifu/cell (data not shown), spheroids were transduced with MOI of 50 ifu/cell. Moreover, 100 µM 
TMZ was applied in order to increase penetration of the drug into the 3D cell structure. The effect of 
viral oncolysis and single or combined TMZ and GCV treatment on spheroids was assessed by 
monitoring the spheroid growth and metabolic activity.  
As indicated in figure 4.19 A, a combined application of TMZ [100 µM] and GCV [0.5 µg/ml] induced 
the strongest decrease of spheroid volume in Ad-delo-sr39TK-RGD-infected spheroids and resulted in 
growth retardation from day 4 till day 10 after infection, when spheroids were markedly reduced to 
their initial volume of 0.06 ± 0.003 mm³. The combination between TMZ and GCV seemed to have a 
more pronounced effect than TMZ and GCV treatment alone. The volume of TMZ-treated or 
untreated Ad-delo-sr39TK-RGD-infected spheroids started to reduce 7 days post infection. At that 
time point the combined treatment was 3-times more effective than Ad-delo-sr39TK-RGD alone and 
2-times more effective than Ad-delo-sr39TK-RGD in combination with TMZ.  Ad-delo3-RGD- and Ad-
delo-shMGMT-RGD-infected spheroids also displayed stronger growth retardation from day 2 to 4 
due to the TMZ treatment, compared to virus alone. Their growth was not further affected by GCV. 
The oncolytic effect of Ad-delo-shMGMT-RGD alone was able to reduce spheroid growth 10 days 
after infection, whereas the oncolytic effect of Ad-delo3-RGD only prevented further spheroid 
growth 7 to 10 days post infection. However, TMZ elicited cellular toxicity also without oncolytic virus 
activity, as shown in untreated and in Ad-sr39TK-infected spheroids. Compared to Ad-delo-sr39TK-
RGD, Ad-sr39TK did not induce a pronounced reduction in spheroid volume in combination with 
simultaneous TMZ and GCV treatment. 
According to the results observed in Ad-delo-sr39TK-RGD-infected spheroids (figure 4.19 B), TMZ and 
GCV treatment alone as well as combined TMZ plus GCV treatment resulted in significant reduction 
of the cellular metabolic activity to 14 ± 0.4 %, 19 ± 1 % and 16 ± 1 %, respectively, compared to 26 ± 
3 % metabolic activity of infected and untreated spheroids. TMZ induced a 2- to 4-fold reduction in 
the metabolic activity of Ad-delo3-RGD- and Ad-delo-shMGMT-RGD-infected spheroids, in relation to 
virus infection alone and virus with GCV treatment. In comparison, TMZ attenuated the metabolic 
activity of uninfected and Ad-sr39TK-infected spheroids only about 1.5-fold, as also demonstrated in 
figure 4.19 A. Moreover, the oncolytic activity of Ad-delo-sr39TK-RGD as single treatment induced 
the strongest reduction of spheroid metabolic activity amongst all oncolytic adenoviruses. Taken 
together, the analysis of the metabolic activity of spheroids confirmed the data of the spheroid 
growth monitoring.  
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Furthermore, detachment of cells from the rim of spheroids, infected with Ad-delo-sr39TK-RGD, Ad-
delo3-RGD and Ad-delo-shMGMT-RGD, revealed an enhanced c.p.e. due to the oncolytic effect 10 
days post infection (figure 4.19 C). The c.p.e. in additionally TMZ- or GCV-treated spheroids was not 
as prominent as the c.p.e. elicited in untreated spheroids, probably due to the fact that most of the 
infected cells had been already lysed or that their growth had been suppressed by the combination 
of oncolysis and drug treatment. No c.p.e. was induced in Ad-sr39TK-infected spheroids, but their 
growth was retarded by TMZ, similar to uninfected spheroids. The combination of oncolytic cell 
killing, TMZ and HSV1-sr39TK/GCV-mediated cytotoxicity (Ad-delo-sr39TK-RGD + GCV/TMZ + GCV) 
was superior to HSV1-sr39TK/GCV-mediated cytotoxicity alone (Ad-sr39TK + GCV) (figure 4.19 A-C).   
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Figure 4.19: Improved cell killing by the combination of oncolytic effect, TMZ and HSV1-sr39TK/GCV-
mediated cytotoxicity in 3D glioma spheroids. U87-MG-derived spheroids, consisting of about 1 x 105 cells, 
were treated with 100 µM TMZ 24 h before and immediately after infection with the indicated adenoviruses at 
MOI of 50 ifu/cell, and/or treated every three days with GCV [0.5 µg/ml] starting 24 h after infection. A: 
Spheroid growth was monitored on an inverted microscope by diameter measurement and volume calculation 
(mean±SD) 0, 2, 4, 7 and 10 days after infection; n=3. Asterisks indicate significant differences of Ad-delo-
sr39TK-RGD, TMZ+GCV vs. untreated: **p=0.001-0.01 (day 2), ****p < 0.0001 (days 4-10), as calculated using 
two-way ANOVA with Tukey’s multiple comparison test. B: XTT assay was performed with spheroids, which 
were infected and treated as described above, 10 days after infection. Asterisks indicate significant differences 
of Ad-delo-sr39TK-RGD, TMZ and TMZ+GCV vs. untreated: ***p=0.0001-0.001; Ad-delo-sr39TK-RGD, GCV vs. 
untreated: **p=0.001-0.01, as calculated using one-way ANOVA with Tukey’s multiple comparison test. C: 
Representative images of infected and treated spheroids at day 10 after infection reveal c.p.e. caused by the 
oncolytic viruses. Significant differences between treatment combinations are marked (squares; Ad-delo-
sr39TK-RGD, GCV and TMZ+GCV vs. Ad-sr39TK, GCV: ****p<0.0001). Scale bar: 500 µm.  
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treatments. The combined approach was efficient for eradication of glioma cells and 3D spheroids. 
Furthermore, it is suggested that glioma cells, subjected to the combined action of HSV1-
sr39TK/GCV-mediated cytotoxicity and enhancement of oncolysis by TMZ, underwent probably a 
mixed type of cell death. 
 
4.10. Enhancement of replication of YB-1 dependent adenoviruses by TMZ 
As described previously, YB-1, which is accumulated into the nucleus as a result of treatment with 
cytostatic drugs, augments the replication of YB-1 dependent oncolytic adenoviruses [291, 292]. It 
was therefore investigated if TMZ was able to boost the replication of YB-1 dependent oncolytic 
adenoviruses in glioma cells and whether the augmented viral replication was responsible for the 
enhanced oncolytic activity of these viruses. Moreover, the influence of GCV and combined TMZ and 
GCV treatment upon adenoviral replication was analysed. Similar to the analyses of cell and spheroid 
survival after different treatment combinations (figures 4.18 and 4.19), a low concentration of GCV 
[0.5 µg/ml] was chosen in order to be able to detect subtle effects. A TMZ concentration of 50 µM, 
which enhanced adenoviral oncolysis of glioma cells substantially (figure 4.16), was applied to 2D cell 
culture. As for the analysis of spheroid growth (figure 4.19), 100 µM TMZ was applied to spheroids 
also in this experiment. Adenoviral replication analyses were performed by absolute real-time qPCR 
with DNA isolated from infected 2D glioma culture and 3D glioma spheroids. 
4.10.1. Enhancement of replication in 2D glioma culture 
In 2D glioma culture, continuous TMZ treatment induced a highly significant 8-fold increase of Ad-
delo-sr39TK-RGD DNA copy number 72 h post infection, compared to a 5-fold and 2-fold replication 
enhancement of Ad-delo3-RGD and Ad-delo-shMGMT-RGD, respectively, related to untreated 
infected samples (figure 4.20). Because of its replication-deficient character, no increase in DNA 
amount of Ad-sr39TK was induced by TMZ. Simultaneous TMZ and GCV treatment resulted in an only 
1.7-fold replication augmentation of Ad-delo-sr39TK-RGD, related to Ad-delo-sr39TK-RGD and GCV 
treatment only. Moreover, GCV reduced the DNA amount of Ad-delo-sr39TK-RGD 3000-fold, as 
compared to virus infection alone, and 13,700-fold in combination with TMZ, as compared to virus 
plus TMZ treatment. There is strong evidence that the reduction of the DNA copy number of Ad-delo-
sr39TK-RGD by GCV and TMZ plus GCV was caused by attenuation of viral DNA replication by the 
HSV1-sr39TK/GCV-mediated cytotoxicity (figures 4.18 A and 4.18 B), acting on the DNA of replicating 
HSV1-TK-bearing adenoviruses. GCV addition did not alter the replication kinetics of the GCV-
insensitive adenoviruses Ad-delo3-RGD and Ad-delo-shMGMT-RGD, consequently TMZ and 
combined TMZ plus GCV treatment caused a similar increase in DNA replication. Single or double 
treatment did not influence the replication of Ad-sr39TK.  
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Figure 4.20: Enhancement of oncolytic adenoviral replication by TMZ in 2D culture of glioma cells. U87-MG 
cells (5 x 104) were treated with 50 µM TMZ 24 h before and immediately after infection with the indicated 
adenoviruses. Infections were performed at MOI of 10 ifu/cell. GCV [0.5 µg/ml] was added 24 h post infection 
and incubated for 48 h. DNA was isolated from infected cells by phenol-chloroform extraction. Fiber 5 gene 
copy number was detected by absolute real-time qPCR of 2 ng DNA (mean±SD); n=3. Asterisks indicate 
significant differences between treatment approaches (only shown for Ad-delo-sr39TK-RGD in terms of 
simplification): ****p < 0.0001, as calculated using one-way ANOVA with Tukey’s multiple comparison test.   
 
4.10.2. Enhancement of replication in 3D glioma spheroids 
The enhancement of replication of the oncolytic adenoviruses by TMZ was further investigated in 
infected 3D glioma spheroids 48 h after infection (figure 4.21). Continuous TMZ application induced a 
27-fold replication increase of Ad-delo-sr39TK-RGD DNA, compared to an 11.4-fold and 18.9-fold 
increase of Ad-delo3-RGD and Ad-delo-shMGMT-RGD DNA, respectively, related to untreated 
spheroids (figure 4.21 A). As expected, TMZ did not enhance the replication of Ad-sr39TK. Similar to 
2D culture, but to a lesser extent, GCV addition to TMZ-untreated or TMZ-treated spheroids 24 h 
after infection attenuated the replication of Ad-delo-sr39TK-RGD significantly, compared to infected 
TMZ-/GCV-untreated spheroids. As observed in 2D culture, GCV did not affect Ad-delo3-RGD and Ad-
delo-shMGMT-RGD replication negatively.  
In parallel with Fiber 5 replication, the replication of the HSV1-sr39TK transgene in Ad-delo-sr39TK-
RGD-infected spheroids was enhanced 1.7-fold by TMZ (figure 4.21 B). As for Fiber 5, the replication 
of HSV1-sr39TK was attenuated 10- to 25-fold by GCV and combined TMZ plus GCV treatment, as 
compared to untreated or TMZ-treated Ad-delo-sr39TK-RGD-infected spheroids. The lower level of 
replication enhancement of HSV1-sr39TK than that of Fiber 5 by TMZ could be due to the different 
efficiency of the detection chemistries used for detecting HSV1-sr39TK and Fiber 5, as also described 
in chapter 4.3. The replication of the transgene in Ad-sr39TK was not augmented by TMZ.  
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A                                                                                         B    
 
 
 
 
 
 
 
 
Figure 4.21: Enhancement of oncolytic adenoviral replication by TMZ in 3D glioma spheroids. U87-MG 
spheroids with volumes of 0.1-0.18 mm³ and consisting of about 1 x 105 cells were treated with 100 µM TMZ 
24 h before and immediately after infection with the indicated adenoviruses. Infections were performed at 
MOI of 50 ifu/cell. GCV [0.5 µg/ml] was added 24 h post infection and incubated for additional 24 h. DNA was 
isolated from infected spheroids by phenol-chloroform extraction. Fiber 5 (A) and HSV1-sr39TK (B) gene copy 
number was detected by absolute real-time qPCR of 2 ng DNA (mean±SD); n=3. Asterisks indicate significant 
differences between treatment approaches (only shown for Ad-delo-sr39TK-RGD in terms of simplification): 
**p=0.001-0.01, as calculated using one-way ANOVA with Tukey’s multiple comparison test. 
 
 
TMZ caused an efficient augmentation of oncolytic adenoviral replication and transgene DNA 
accumulation in 2D glioma culture and in 3D glioma spheroids. The enhancement of viral replication 
by TMZ verified the concept of YB-1 dependent oncolysis in the presence of cytotoxic stress. The 
augmented replication of the oncolytic adenoviruses resulted in enhancement of both oncolysis and 
combined oncolytic and HSV1-sr39TK/GCV-mediated cytotoxicity in 2D culture and 3D spheroids, as 
described in chapter 4.8. and chapter 4.9. However, the HSV1-sr39TK/GCV-mediated cytotoxicity 
inhibited the DNA replication of Ad-delo-sr39TK-RGD. 
 
4.11. Release and infectivity of newly synthesised viral particles from 
infected and drug-treated 3D glioma spheroids   
The infectivity of newly synthesised and released oncolytic adenoviral particles from infected 
spheroids was determined by titration of the viral particles using End-point dilution assay. It was also 
analysed whether the viral titre changed upon TMZ, GCV or combined TMZ plus GCV treatment. Ad-
delo-sr39TK-RGD was compared to an oncolytic (Ad-delo3-RGD) and replication-deficient (Ad-sr39TK) 
adenovirus in respect of infectivity of released particles.  
The infectious titre of newly synthesised and released adenoviral particles from infected non-treated 
spheroids was 1.42 x 106 pfu/ml for Ad-delo-sr39TK-RGD and 7.04 x 105 pfu/ml for Ad-delo3-RGD two 
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days post infection, and was not further enhanced by TMZ treatment at that time point (figure 4.22). 
GCV and combined TMZ plus GCV addition did not result in markedly reduced viral release. The 
infectious progeny increased to 2.94 x 1011 pfu/ml for Ad-delo-sr39TK-RGD and 3.01 x 107 pfu/ml for 
Ad-delo3-RGD 4 days post infection. TMZ treatment augmented the release of Ad-delo-sr39TK-RGD 
particles 68-fold, compared to only 1.4-fold for Ad-delo3-RGD. Therefore, the enhancement of viral 
replication by TMZ (figure 4.21) correlated with an increase of the release of new infectious viral 
particles. Following GCV addition and combined TMZ and GCV treatment, the amount of released Ad-
delo-sr39TK-RGD particles was decreased over 1000-fold in relation to untreated spheroids. GCV 
treatment did not alter Ad-delo3-RGD viral release. 10 days after infection, TMZ enhanced the viral 
release of Ad-delo-sr39TK-RGD 36-fold compared to virus infection alone, although the overall viral 
titre decreased significantly, probably because of pronounced cell killing. A decrease was also 
observed for the titre of released Ad-delo3-RGD particles upon single and combined treatment. 
According to its replication-deficiency, Ad-sr39TK did not show increase of the titre of its progeny 
over time.    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Release and infectivity of newly synthesised viral particles from infected 3D glioma spheroids. 
U87-MG spheroids with volumes of 0.1-0.18 mm³, consisting of about 1 x 105 cells, were infected with MOI of 
50 ifu/cell of the indicated adenoviruses after pre-treatment with 100 µM TMZ for 24 h. Following an anew 
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treatment with 100 µM TMZ directly after infection, GCV [0.5 µg/ml] was added 24 h post infection. 
Supernatants containing released viral particles were collected 2, 4 and 10 days after infection. Titres of 
released viral particles, defined as plaque forming units per ml (pfu/ml), were determined in supernatants by 
End-point dilution assay in HEK293 cells (mean±SD); n=2.  
 
 
As in 2D culture, YB-1 dependent oncolytic adenoviruses showed successful viral release and 
infectivity of newly synthesised viral particles in 3D glioma spheroids. The release of Ad-delo-sr39TK-
RGD particles was enhanced by TMZ as predicted by viral replication. Moreover, the combined 
oncolytic effect and HSV1-sr39TK/GCV-mediated cytotoxicity diminished the production of infectious 
progeny in spheroids, infected with the armed oncolytic adenovirus. 
 
4.12. Adenovirus dissemination and HSV1-sr39TK expression in 3D glioma 
spheroids   
In the following, viral dissemination and transgene expression in spheroids, transduced with 
oncolytic adenoviruses and treated with TMZ, GCV or a combination of TMZ and GCV, was explored. 
For this purpose, viral hexon protein and HSV1-sr39TK expression was analysed by simultaneous 
immunodetection on cryosections of spheroids.  
The spread of Ad-delo-sr39TK-RGD, Ad-delo3-RGD and Ad-delo-shMGMT-RGD, as visualised by hexon 
staining, was mainly restricted to several outer layers of non-drug treated and TMZ-treated spheroids 
48 h after infection, but progression to the inner layers was also observed (figure 4.23). The oncolytic 
adenoviruses were evenly distributed throughout the spheroid layers. A co-localisation of hexon and 
HSV1-sr39TK expression was observed in Ad-delo-sr39TK-RGD-infected spheroids. Upon GCV and 
combined TMZ and GCV treatment, adenoviral localisation and transgene expression were focused to 
only few cells of the outer spheroid layer. Regardless of treatment approach, the oncolytic 
adenoviruses displayed a prominent lateral spread within a single cell layer of some spheroids, rather 
than a medial spread, as indicated most distinctively for Ad-delo-sr39TK-RGD (untreated), Ad-delo3-
RGD (TMZ + GCV) and Ad-delo-shMGMT-RGD (GCV). This phenomenon was not observed in Ad-
sr39TK-infected spheroids, where the overall adenoviral distribution was hampered by the 
replication-deficient character of the virus. HSV1-sr39TK expression was restricted only to the outer 
layers of Ad-delo-sr39TK-RGD- and Ad-sr39TK-infected spheroids, regardless of treatment approach. 
Considering the replication of oncolytic adenoviruses, an enhanced viral spread was observed both in 
untreated and TMZ-treated spheroids. In contrast, GCV or combined TMZ and GCV treatment 
impaired intercellular viral dissemination, but not viral replication within spheroid cells, as indicated 
by the strong localised hexon expression, which resulted in decrease of overall particle amount. 
These data are consistent with the adenoviral DNA replication pattern as described in chapter 4.10.2.  
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Figure 4.23: Adenovirus dissemination and HSV1-sr39TK expression in 3D spheroid culture model. U87-MG 
spheroids with volumes of 0.1-0.18 mm³ and consisting of about 1 x 105 cells were infected with MOI of 50 
ifu/cell of the indicated adenoviruses after pre-treatment with 100 µM TMZ for 24 h. TMZ treatment was 
repeated again directly after infection and GCV [0.5 µg/ml] was added once 24 h post infection. 
Immunodetection of adenoviral hexon protein and HSV1-sr39TK was performed on cryosections of infected 
and treated spheroids 48 h post infection. Cell nuclei were visualized using DAPI staining. Representative 
sections show the widest diameter of spheroids. Scale bar: 100 µm.  
 
 
Thus, as a prerequisite for cell killing, the YB-1 dependent oncolytic adenoviruses displayed 
successful infectivity and spread within glioma spheroids due to their replication competence. In 
addition, Ad-delo-sr39TK-RGD was able to trigger HSV1-sr39TK expression in parallel with adenoviral 
replication. However, adenoviral spread was attenuated by the inhibition of viral replication by the 
HSV1-sr39TK/GCV-mediated suicide system. 
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4.13. Uptake of [18F]-FHBG by HSV1-sr39TK-expressing glioma cells 
In order to evaluate the potential of the armed oncolytic adenovirus for non-invasive imaging using 
HSV1-sr39TK as a reporter gene, in vitro uptake studies using the enzymatic activity of HSV1-sr39TK 
for metabolising the radiotracer [18F]-FHBG were performed by gamma-counting and PET imaging.  
4.13.1. [18F]-FHBG accumulation in 2D glioma culture 
Regarding the radiotracer uptake in 2D glioma culture, a 2.8-fold lower radiotracer accumulation was 
mediated by HSV1-sr39TK, when expressed by Ad-delo-sr39TK-RGD, than when delivered by Ad-
sr39TK, two days post infection (figure 4.24 A). Thus, these data suggest that the enzyme level of 
HSV1-sr39TK was attenuated by the progressive oncolytic potential of Ad-delo-sr39TK-RGD. As 
expected, only background radiotracer accumulation was detected in uninfected and Ad-delo3-RGD-
infected glioma cells. The replication-competent adenovirus Ad-delo-sr39TK-RGD was analysed for 
alteration of its ability to induce radiotracer accumulation over time due to an influence of the viral 
oncolytic potential and HSV1-sr39TK/GCV-mediated cytotoxicity on transgene expression (figure 4.24 
B). The highest uptake was detected three days after infection, when HSV1-sr39TK gave rise to a 
significant 5.4-fold increase of accumulated radiotracer, compared to the uptake on day 1. GCV 
addition 24 h prior to the uptake study led to a 2-fold decrease in radiotracer accumulation, 
compared to the respective approach without GCV, indicating HSV1-sr39TK/GCV-mediated 
cytotoxicity. Thus, the uptake of radiotracer was positively influenced by the adenoviral replication 
competence, but was attenuated by HSV1-sr39TK/GCV-mediated cell killing, as demonstrated 
previously. However, cytotoxicity was not as excessive as to abolish radiotracer accumulation 
completely. Background levels of radiotracer accumulation were detected in uninfected cells.    
 
A                                                                                         B                                                                                                                
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: Accumulation of [18F]-FHBG in HSV1-sr39TK-expressing glioma cells. 2D culture of U87-MG cells (1 
x 105) were infected with the indicated adenoviruses at MOI of 10 ifu/cell. [18F]-FHBG uptake was performed 
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using 1 x 105 cells 2 days post infection (A) or 1-3 days post infection with GCV [0.5 µg/ml] addition 24 h prior 
to performing the uptake study on day 3 (B). After labelling with 0.1 MBq [18F]-FHBG per 1 x 105 cells, the 
accumulated radiotracer due to HSV1-sr39TK activity was released from the cells using 1M NaOH and 
measured by gamma-counting. Accumulated radiotracer dose was calculated as % of total applied (100 %) [18F]-
FHBG dose (mean±SD); n=3. Asterisks indicate significant differences between treatment approaches. 
***p=0.0001-0.001, as calculated using one-way ANOVA with Tukey’s multiple comparison test.  
 
4.13.2. [18F]-FHBG accumulation in 3D glioma spheroids 
Measurement of the uptake activity of the enzyme HSV1-sr39TK in 3D spheroids by gamma-counting 
revealed a slight decrease in radiotracer accumulation upon TMZ treatment of Ad-delo-sr39TK-RGD-
infected spheroids, compared to untreated Ad-delo-sr39TK-RGD-infected spheroids (figure 4.25). 
Radiotracer accumulation was further reduced by GCV treatment and combined TMZ plus GCV 
application in Ad-delo-sr39TK-RGD-infected spheroids, compared to untreated virus-infected 
spheroids, indicating an effect of the HSV1-sr39TK/GCV-mediated cytotoxicity in combination with 
the oncolytic activity of the virus. However, the overall radiotracer accumulation levels in Ad-delo-
sr39TK-RGD-infected spheroids were about 10-fold lower than the respective accumulation levels in 
2D cell culture three days post infection (figure 4.24), suggesting an influence of the spheroidal 
geometry on the uptake capacity. Accumulation of metabolised [18F]-FHBG in untreated Ad-sr39TK-
infected spheroids was lower than in untreated Ad-delo-sr39TK-RGD-infected spheroids and was not 
markedly influenced by treatment with TMZ, GCV or by combined TMZ and GCV treatment.  
 
 
 
 
 
 
 
 
 
Figure 4.25: Accumulation of [18F]-FHBG in HSV1-sr39TK-expressing 3D glioma spheroids. U87-MG-derived 
spheroids, containing about 1 x 105 cells, were infected at MOI of 50 ifu/cell with the indicated adenoviruses. 
Spheroids were treated with 100 µM TMZ 24 h before and directly after infection and/or treated with 0.5 
µg/ml GCV 24 h after infection. Uptake was performed with 0.1 MBq [18F]-FHBG per spheroid 4 days after 
infection. Accumulated radiotracer was released from spheroids using 1M NaOH measured by gamma-
counting. Radiotracer dose was calculated as % of total applied (100 %) [18F]-FHBG dose (mean±SD); n=3. 
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Asterisks indicate significant differences between treatment approaches. **p=0.001-0.01, ***p=0.0001-0.001, 
as calculated using one-way ANOVA with Tukey’s multiple comparison test. 
 
 
The feasibility of HSV1-sr39TK for nuclear non-invasive imaging as well as the spatial distribution of 
Ad-delo-sr39TK-RGD and Ad-sr39TK were additionally examined by PET measurement of [18F]-FHBG 
accumulation in virus-infected spheroids (figure 4.26). The accumulated radiotracer activity into 
representative infected and/or drug-treated spheroids is displayed in figure 4.26 A, showing a single 
spheroid per well and no overlap between the signals in the wells. Each region of interest (ROI) 
analysed (circle) had an average volume of 7 mm3, which corresponded to the actual mean spheroid 
volume (data not shown). ROI analysis of the single spheroids allowed the calculation of the mean 
signal intensity of the samples (figure 4.26 B). In addition, the accumulated radiotracer dose [% 
applied dose] (figure 4.26 C) was determined by means of a standard, consisting of serial dilutions of 
[18F]-FHBG with indicated absolute intensities (figure 4.26 D).  
Accordingly, the spheroids had incorporated 2 to 3 % of the applied radiotracer dose, depending on 
virus and treatment approach (figure 4.26 C). PET imaging detected about 3- to 5-fold higher levels of 
accumulated [18F]-FHBG than detected by gamma-counting (figure 4.25). This fact was due to the 4-
fold higher cell number in spheroids applied for PET analysis than for gamma-counting, resulting in 
an enhanced uptake. The data derived by PET imaging revealed no large variations in HSV1-sr39TK-
mediated radiotracer incorporation amongst untreated and TMZ-treated Ad-delo-sr39TK-RGD-
infected spheroids. As also shown by gamma-counting (figure 4.25), radiotracer incorporation was 
reduced in GCV-treated and especially in combined TMZ- and GCV-treated Ad-delo-sr39TK-RGD-
infected spheroids, indicating activity of the HSV1-sr39TK/GCV-mediated system in cooperation with 
TMZ-enhanced viral oncolysis. No significant variations in radiotracer accumulation amongst Ad-
sr39TK-infected spheroids were detected in respect of treatment approach. The overall [18F]-FHBG 
accumulation in spheroids, resulting from the use of Ad-sr39TK, was comparable to that in Ad-delo-
sr39TK-RGD-infected and combined virus-infected and TMZ-treated spheroids, which was in 
accordance with the results shown in figure 4.25. 
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Figure 4.26: Accumulation of [18F]-FHBG in HSV1-sr39TK-expressing 3D glioma spheroids. U87-MG-derived 
spheroids were infected at MOI of 50 ifu/cell with the indicated adenoviruses. Spheroids containing about 4 x 
105 cells were treated with 100 µM TMZ 24 h before and directly after infection and/or treated with 0.5 µg/ml 
GCV 24 h after infection. Uptake was performed with 0.1 MBq [18F]-FHBG per spheroid 4 days after infection. 
Radiotracer accumulation was measured by PET/CT imaging and mean intensity of ROIs was analysed using 
OSEM 3D reconstruction algorithm with attenuation correction. One representative ROI is displayed for each 
data set (A). The average of n=3 ROIs per data set was calculated as mean intensity after decay and volume 
correction (B) and [18F]-FHBG accumulation was calculated as % of total applied [18F]-FHBG dose (mean±SD) (C) 
according to a [18F]-FHBG standard (D). Asterisks indicate significant differences between treatment 
approaches. *p=0.01-0.05, ***p=0.0001-0.001, as calculated using one-way ANOVA with Tukey’s multiple 
comparison test. 
 
 
The data above demonstrate the successful radiotracer accumulation in both 2D and 3D glioma cell 
models infected with HSV1-sr39TK-expressing oncolytic adenovirus, using HSV1-sr39TK as a reporter 
 Mean intensity of ROI [Bq] 
Sample untreated TMZ GCV TMZ+GCV 
uninfected 0 0 0 0 
Ad-delo-sr39TK-RGD 2774 ± 14 3015 ± 250 2312 ± 116 1913 ± 88 
Ad-sr39TK 3269 ± 260 3379 ± 102 3186 ± 121 3278 ± 115 
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gene. The radiotracer uptake rate was facilitated by the replication competence of the virus. 
However, the radiotracer accumulation was not augmented by enhancement of viral replication 
through TMZ, presuming that the potentiated oncolytic effect of Ad-delo-sr39TK-RGD by TMZ or the 
combination of TMZ-mediated enhancement of replication and HSV1-sr39TK/GCV-mediated 
cytotoxicity resulted in decrease of uptake, compared to Ad-sr39TK-infected glioma cells.  
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5. DISCUSSION  
 
5.1. Application of YB-1 dependent oncolytic adenoviruses to address 
limitations of GBM therapy 
Despite promising advances in GBM therapy [16, 17], the search for a treatment with sustained 
efficacy is still a challenge. Major limitations for the success of anti-GBM therapy are the highly 
aggressive character of the tumour, leading to heterogeneous response to therapy from one GBM 
case to the other [321], and an acquired drug resistance. Gene therapy with single gene-replacement 
approaches is often insufficient, because of the accumulation of mutations during cancer progression 
[37]. Hence, novel targeted experimental approaches are urgently needed. Since conditionally 
replicating adenoviruses have limited success in clinical trials, combined experimental approaches 
like YB-1 dependent virotherapy plus chemotherapy [292] or a three-pronged strategy [289] are 
gaining more interest. Suicide gene therapy is also a potent approach to eradicate tumour cells. 
However, cell killing is often hampered by impaired diffusion of the prodrug GCV into the cells, by 
insufficient gene transfer and limited distribution within the tumour mass [54]. The issue of 
inefficient biodistribution of therapeutic vectors and limited treatment success can be circumvented 
by introducing a suicide gene into replication-competent adenoviruses. Hence, the objective of this 
study was to investigate whether the oncolytic effect could be augmented by HSV1-sr39TK/GCV-
mediated cytotoxicity and classical TMZ therapy, using the background of YB-1 dependent oncolysis 
and the finding that YB-1 is upregulated in recurrent glioma [284]. To the author’s knowledge, YB-1 
dependent oncolytic adenoviruses have so far not been combined with suicide genes. In addition, the 
suitability of the HSV1-sr39TK-armed oncolytic adenovirus for non-invasive imaging was explored, in 
order to provide an insight into the viral biodistribution in future preclinical trials.  
5.2. Genetic stability and quality of adenoviruses is crucial for their 
application as anti-tumour agents 
The YB-1 dependency of oncolytic adenoviruses is ensured by a deletion in the CR3 of E1A, resulting 
in lack of the transactivating E1A13S splice variant [259, 288]. In addition, the YB-1 dependent 
oncolytic adenoviruses Ad-delo-sr39TK-RGD and Ad-delo3-RGD contain a deletion of E1B19K, which 
increases the cell killing potential of the viruses [201]. The presence of the crucial mutations in the 
E1A and E3 regions of the adenoviral vectors applied in this thesis, as well as the insertion of the 
transgene HSV1-sr39TK in Ad-delo-sr39TK-RGD and Ad-sr39TK, was verified (table 4.1, figure 4.1), 
proving the genetic stability of the adenoviruses after CsCl-purification. Thus, the adenoviruses 
contained the desired modifications in order to be applied as virotherapeutic agents. 
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A major obstacle in the production of qualitative adenoviral vectors for gene therapy is the potential 
contamination of adenoviral preparations for clinical application with recombinant RCA. Although 
there is a safety guideline allowing the presence of not more than 1 RCA per 3 x 1010 viral particles in 
replication-deficient adenovirus preparations for human use, no corresponding guideline for the 
permissive amount of wild-type-like or non-selective recombinants for oncolytic adenovirus 
preparations exists [322, 323]. As recombination between residual E1 sequences in E1A-mutated 
conditionally replicating oncolytic adenoviruses and the E1 region in HEK293 cells can result in loss of 
the tumour specificity of oncolytic adenoviruses, RCA generation in large-scale oncolytic adenovirus 
preparations should be avoided. The lack of contamination of the adenoviruses applied in this thesis 
with wild-type RCA could not be definitely verified by the applied PCR analysis. Due to the E1A 
deletion of only 11 bp in the oncolytic vectors, the E1A PCR products of the oncolytic vectors and of 
the Ad5-wt-derived reference vector pXC1 were not clearly distinguishable from each other by this 
standard method for RCA detection (table 4.2, figure 4.2). The E1A PCR signals derived from the 
oncolytic vectors may therefore indicate a false-positive RCA contamination. However, the PCR 
products derived by E1- and E3-specific amplification of the oncolytic vectors (table 4.1, figure 4.1), 
confirmed the lack of wild-type RCA contamination. 
In order to discriminate between E1A-mutated oncolytic vectors and wild-type RCA contaminations 
more accurately, PCR analysis can be performed by using primers that amplify only wild-type 
adenovirus E1 sequences or DNA fragments of a size of less than 1 kb, which allow the detection of 
the 11 bp E1A-deletion in YB-1 dependent oncolytic vectors [291].    
An alternative method for the detection of RCA in preparations of oncolytic adenoviruses represents 
a bioamplification assay, which amplifies non-selective adenoviruses through multiple passages in 
order to assess the biological activity of wild-type and non-selective recombinants by a panel of 
analytical methods [323]. This assay is based on the use of cell lines, permissive only for non-selective 
RCA and not for conditionally replicating adenoviruses. However, despite of being highly sensitive, 
this bioamplification assay does not eliminate the need of a specific PCR for detection of potential 
RCA contaminations, but moreover supports the design of appropriate qPCR assays for detecting 
RCA. Furthermore, the generation of wild-type RCA can be avoided by the use of alternative virus 
packaging cell lines for large-scale and clinical applications, such as Per.C6 cells, which contain a 
truncated E1 sequence with limited homology to many E1-deficient adenoviral vectors [324]. 
Alternative packaging cell lines with improved safety compared to Per.C6 cells could be the E1-
transcomplementing cell lines Ac51 and Ac139, derived by stable retrovirus transfection, which 
contain the E1A and E1B genes located on separate genomic loci and thus minimising the risk of RCA 
production [324].    
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5.3. Efficient replication and oncolytic potential of YB-1 dependent 
adenoviruses 
The localisation of YB-1 in the nucleus of tumour cells is a prerequisite for successful replication of 
YB-1 dependent oncolytic adenoviruses [259, 265]. The nuclear YB-1 status of U87-MG cells and the 
multidrug-resistant EPP85-181RDB cell line has been already verified as sufficient to activate 
adenoviral replication [288, 290, 292]. It is of importance to examine the targeting of multidrug 
resistance by YB-1 dependent oncolytic adenoviruses, as YB-1 is associated with overexpression of 
MDR1 [258]. Moreover, GBM cells often develop multiple resistance against chemotherapy, arising 
from cancer stem cells [40] or from the overexpression of ABC-transporter proteins in some subsets 
of stem cells [325]. 
Indeed, the YB-1 dependent adenoviruses induced c.p.e. and thus oncolytic effect in the YB-1-
positive cell lines U87-MG and EPP85-181RDB, confirming the YB-1-based mechanism of activating 
adenoviral replication (figure 4.3). The strong replication competence of the YB-1 dependent 
adenoviruses in both tumour cell lines was confirmed by Southern blot (figure 4.4 A) and real-time 
qPCR analyses (figure 4.5). The results indicate that a threshold amount of produced viral DNA is 
needed for the virus to be able to induce oncolytic cell killing. The improved replication potency of 
Ad-delo-sr39TK-RGD over the E3-deleted vector Ad-delo3-RGD, despite the identical genetic 
background of the E1 region, may be caused by the function of the HSV1-sr39TK enzyme in Ad-delo-
sr39TK-RGD. The enzyme is part of the thymidine salvage pathway, catalysing the transfer of the γ-
phosphate from ATP to the 5’-hydroxyl of deoxythymidine to form deoxythymidine-5‘-
monophosphate [326]. Furthermore, as an alphaherpesvirus enzyme, HSV1-TK is in fact a 
polynucleoside kinase that can phosphorylate all four nucleosides [327]. Therefore, it can be 
hypothesised that the synthesis of adenoviral DNA can be potentiated by increasing the availability of 
phosphorylated endogenous nucleosides by HSV1-sr39TK. The incorporation of nucleosides into viral 
DNA during replication can be analysed by incubation with radiolabelled nucleosides, e.g. [3H]-
thymidine [328].  
The increasing release of newly synthesised viral particles (figure 4.6) and the high infectivity of the 
viral progeny (figure 4.7, figure 4.22) proved the disseminating character of the oncolytic 
adenoviruses and were especially important for enhancing the oncolytic potential. The higher release 
of newly synthesised Ad-delo-sr39TK-RGD viral particles in comparison to Ad-delo3-RGD release 
might be explained by the expression of the ADP protein by the armed vector. ADP is required for 
efficient lysis of adenovirus-infected cells and for release of adenoviral progeny [165]. The 
attenuated release of Ad-delo-shMGMT-RGD particles compared to Ad-delo-sr39TK-RGD, despite 
functional ADP, could be due to the anti-apoptotic action of the E1B19K protein, which prevents 
sufficient viral release, and is therefore deleted in many oncolytic adenoviruses [201, 329]. With its 
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strong replication capacity, oncolytic potential and successful production of functional progeny, Ad-
delo-sr39TK-RGD meets first requirements of efficient oncolytic virotherapy. The tumour-specific 
replication of the virus, which is comparable in its strength to that of other armed oncolytic 
adenoviruses used in some preclinical [244, 248] or clinical trials [247], could be therefore beneficial 
for achieving potent anti-tumour effects in future preclinical studies with Ad-delo-sr39TK-RGD. The 
viremic threshold of 3 x 107 pfu/kg for yielding efficient delivery of oncolytic viruses to tumours [175, 
330] could be reached by Ad-delo-sr39TK-RGD.      
The correlation between YB-1 and multidrug resistance is controversial [331]. Moreover, it is 
suggested that YB-1 is necessary for the initiation rather than for the maintenance of drug resistance 
[332]. These findings could explain the delayed induction of cytopathic effect and attenuated 
replication of YB-1 dependent oncolytic adenoviruses in the multidrug-resistant cell line EPP85-
181RDB 48 h to 72 h post infection in comparison to the U87-MG cell line, as the abundance of cells 
with nuclear localised YB-1 is probably diminished at late stages of multidrug resistance 
development.   
Malignant glioma cells have been characterised by low to intermediate CAR expression [236, 289, 
290, 333-335]. Therefore, the modification of the oncolytic adenoviruses with a RGD motif is crucial 
for targeting the rather CAR-deficient cell line U87-MG [236, 290, 334]. This cell line exhibits also a 
moderate expression level of receptor CD46, necessary for binding of adenoviruses of the serotype B 
[334, 335]. In contrast, U87-MG cells express high levels of ανβ3/ανβ5 integrins [334], which interact 
with the RGD motif and enhance the CAR-independent infectivity of adenoviruses. In addition to 
their replication competence, the RGD-modified oncolytic adenoviruses have an advantage over the 
non-RGD-modified replication-deficient Ad-sr39TK in their improved tumour transduction. Though 
the cell line EPP85-181RGD is also CAR-deficient [336], there is evidence that low viral replication did 
not result from low infectivity, as the RGD-modified adenoviruses induced c.p.e. in these cells. 
However, the integrin status of the multidrug-resistant cell line has to be verified.     
5.4. Stable expression of HSV1-sr39TK from replication-competent adenoviral 
vectors  
In contrast to the constant transcription of the HSV1-sr39TK transgene into mRNA from the 
replication-deficient vector Ad-sr39TK as an indication of protein expression, the cumulative 
production of HSV1-sr39TK mRNA transcripts from Ad-delo-sr39TK-RGD correlated with the 
replication capacity of the virus in U87-MG and EPP85-181RDB cells (figure 4.8). Consequently, the 
replication of Ad-delo-sr39TK-RGD was not impaired by the constitutive expression of the transgene. 
Contrariwise, the HSV1-sr39TK expression level was not attenuated by the induction of c.p.e. in Ad-
delo-sr39TK-RGD-infected tumour cells (figure 4.3). The difference in HSV1-sr39TK protein expression 
DISCUSSION 96
 
level between Ad-delo-sr39TK-RGD and Ad-sr39TK was marginal (figure 4.9 A), in contrast to mRNA 
transcription. This finding was due to the fact that all configurations of the protein are detected by 
Western blotting, including inactivated or degraded forms, making variations in protein expression 
difficult to recognise. The attenuated expression kinetics of HSV1-sr39TK from Ad-delo-sr39TK-RGD 
in EPP85-181RDB cells compared to U87-MG cells reflects the attenuated YB-1 dependent 
replication, as described above. A hypothesis for the decreased expression is that the 
downregulation of cellular protein biosynthesis in favour of virus replication [161] could be more 
prominent during maintenance of multidrug resistance.  
Taken together, these data prove that propagation of a transgene with viral replication is one of the 
benefits of applying replication-competent adenoviruses in gene therapy. An alternative method for 
arming oncolytic adenoviruses is the insertion of a transgene into the L3 region of the vectors [337]. 
This method links transgene expression to late viral gene expression and leads to high levels of 
tumour-specific expression of the transgene. On the contrary, the regulation of a transgene by 
constitutive promoters or its insertion into E3 locations may exhibit low levels of off-target gene 
expression, a critical issue when arming oncolytic adenoviruses with cytotoxic genes [337].      
5.5. Multicellular 3D glioma spheroids as a feasible model to explore anti-
tumour treatment 
Due to their resemblance to tumour tissue in vivo in respect of multicellular architecture, growth 
kinetics and metabolism [205, 209], 3D glioma spheroids were developed in order to explore the 
efficacy of YB-1 dependent oncolytic adenoviruses in combination with TMZ and the HSV1-
sr39TK/GCV suicide system in vitro. The 3D spheroids displayed classical tumour characteristics, such 
as proliferative growth and migration of cells from the tumour focus [8] (figure 4.10, figure 4.11), the 
latter being a prerequisite for tumour invasion and recurrence [338]. Consistent with this fact, 
formation of clusters of outgrowing cells were observed with progression of cellular migration (figure 
4.11, day 7), giving an indication of the highly invasive character of GBM [8]. These data support the 
use of spheroids as tumour-mimicking models to study the response of tumour growth to therapy in 
vitro [209]. The tumour characteristics of spheroids can be utilised to explore tumour angiogenesis in 
a 3D model [339]. Moreover, neurospheres formed by single CD133+ cancer stem cells in vitro can be 
applied to analyse chemoresistance in GBM [340]. The MOI-dependent transduction efficiency of the 
glioma spheroids indicated their suitability for adenoviral gene transfer (figure 4.12), which was in 
line with previous observations [210]. It was expected that the introduction of a RGD motif and the 
use of replicating adenoviruses would enhance viral transduction [341]. The infectivity of spheroids 
can also predict the transduction efficiency and viral effects in tumours in vivo [211].  
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The dissemination of oncolytic adenoviruses and the combined effect of oncolysis, TMZ and HSV1-
sr39TK/GCV-mediated cytotoxicity were investigated in 3D spheroids, because they are more 
representative than 2D culture as in vitro model for solid tumours, where the penetration of large 
molecules, such as viruses or drugs, is attenuated by the complexity of tumour geometry and the 
presence of extracellular matrix. In tumour spheroids, cells are clustered together by surface 
membrane microprojections and a plethora of intercellular junctions [205, 212]. These properties of 
spheroids reproduce the treatment-related effects in vivo more precisely than 2D culture. 
5.6. Mutual potentiation of adenoviral oncolysis and HSV1-sr39TK/GCV-
mediated effect  
The analysis of the HSV1-sr39TK/GCV-mediated cytotoxicity was first carried out in 2D cell culture to 
optimise the cell killing conditions by variation of dose and timing of pro-drug application. U87-MG 
glioma cells are susceptible to the suicide gene approach, as indicated by the strong HSV1-
sr39TK/GCV-mediated cytotoxicity in Ad-sr39TK-infected cells (figure 4.13 A). Cell killing was induced 
by the combination of overlapping HSV1-sr39TK/GCV-mediated cytotoxicity and oncolytic activity of 
Ad-delo-sr39TK-RGD. The E1A12S protein of Ad-delo-sr39TK-RGD might also contribute to the HSV1-
sr39TK/GCV-killing, for it is known that E1A as an S-phase inducer enhances the HSV1-TK/GCV activity 
[342]. Although the oncolytic effect alone was strong enough to induce cell killing, the cells were still 
metabolically active after c.p.e. (data not shown in figure 4.13 B), in contrast to infected and 
concomitantly GCV-treated cells (figure 4.13 B). This observation indicated that the HSV1-
sr39TK/GCV-mediated cytotoxicity contributes to eradicate tumour cells completely. Important for 
the successful cell killing were the concentration of GCV and the timing of GCV application. The cell 
survival was drastically reduced at GCV concentrations of even less than 0.01 µg/ml, indicating that 
the high sensitivity of HSV1-sr39TK to GCV overlapped with the oncolytic effect of the adenovirus. It 
was previously reported that HSV1-sr39TK displays a 14-fold decrease in the Km value for GCV and an 
80-fold higher kinetics with GCV when compared with wild-type TK, which enables the use of GCV at 
lower, less immunosuppressive doses [343]. A recent study demonstrated a strong therapeutic 
efficacy of the HSV1-sr39TK/GCV system against rat C6 glioma both in vitro and in vivo, by applying 
GCV to HSV1-sr39TK-transduced cells at a lower concentration as compared to wild-type TK-
transduced cells [317]. Thus, the mutant HSV1-sr39TK is a potent suicide gene for inhibition of 
tumour growth and favours the application of low GCV doses for mediating cytotoxic effects, which 
can result in less unspecific toxicity of the prodrug. 
The eradication of tumour cells was more successful when GCV was applied one to three days after 
infection than when applied directly after infection (figure 4.13). This observation was consistent 
with a previously described study of an HSV1-TK armed oncolytic adenovirus with potent anti-tumour 
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effects in glioma [240]. The reduced response of cells infected with replicating adenoviruses to GCV 
when added immediately after infection than when added at later time points could be due to the 
ability of GCV-triphosphate to extenuate adenoviral replication, as it incorporates into the DNA of 
dividing cells as well as into replicating viral DNA [61]. This finding is in accordance with the 
replication analyses shown in this thesis (figure 4.4 B, figure 4.21) and is also supported by the 
observation of HSV1-TK/GCV-triphosphate-mediated inhibition of replication-competent 
adenoviruses in other studies [243, 344, 345]. By adding GCV one day post infection, the progressive 
cytotoxicity mediated by HSV1-sr39TK/GCV exerted a deleterious effect on Ad-delo-sr39TK-RGD 
DNA, as it abolishes the proliferation of virus-infected cells and thus viral replication and spread 
(figure 4.22). The attenuated replication of Ad-delo-sr39TK-RGD by GCV, added immediately after 
infection, was the most probable explanation for the cell survival at 0.1 µg/ml GCV (figure 4.13 A). 
This dose was insufficient to induce HSV1-sr39TK/GCV-mediated cytotoxicity and to counteract the 
repressed oncolysis. The deleterious effect of GCV upon viral replication was not dependent on viral 
dose, as a pronounced cell survival could also be observed with MOI of 10 ifu/cell (data not shown). 
The finding that the level of HSV1-sr39TK/GCV-mediated cell killing of Ad-sr39TK remained constant 
regardless of the time point of GCV addition confirmed the inhibitory action of GCV against HSV-TK1-
armed replicating adenoviruses. When GCV was applied at later time points, the accumulated Ad-
delo-sr39TK-RGD viral particles were able to overcome the initial inhibitory effect of GCV. The 
oncolysis could be promoted successfully, as already small amounts of E1A gene products are 
sufficient to initiate adenoviral replication [346]. However, the predominating oncolytic effect of Ad-
delo-sr39TK-RGD led to decrease in HSV1-sr39TK expression due to cell killing, when GCV was added 
48 h to 72 h post infection (figure 4.9 B). This observation suggests that a strong oncolytic potential 
may lead to an increased risk of uncontrolled viral spread. Inhibition of adenoviral replication by 
HSV1-TK/GCV at early stages of the viral life cycle presents therefore an important safety regard and 
a fail-safe means to control viral dissemination, which is crucial for a safe in vivo application. In order 
to maintain a balance between the strength of the oncolytic effect and the activity of the HSV1-
sr39TK/GCV system, as well as to control viral spread, the optimal time point of GCV application in 
vitro was determined to be one day after infection. 
The weak oncolytic effect of Ad-delo-sr39TK-RGD in EPP85-181RDB cells could not be substantially 
enhanced by the HSV1-sr39TK/GCV-mediated cytotoxicity, even at a high viral dose (figure 4.14). The 
high IC50 value of HSV1-sr39TK/GCV in EPP85-181RDB cells (50 µg/ml as compared to 0.35 µg/ml in 
U87-MG cells) and the thus resulting attenuated HSV1-sr39TK/GCV-mediated cell killing could be 
explained by a low susceptibility of the cell line to GCV as a result of its multidrug-resistant 
phenotype. Considering the broad spectrum of drug substrates transported by P-gp [50], a developed 
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cross-resistance towards the guanosine analogue GCV after long-term exposure could be possible. 
Optimisation of the HSV1-sr39TK/GCV-mediated bystander effect could be considered as a method 
to increase the GCV-sensitivity of multidrug-resistant cells, as described in the following.      
5.7. Potentiation of viral oncolysis by HSV1-sr39TK/GCV-mediated bystander 
effect  
The bystander effect contributed successfully to the HSV1-sr39TK/GCV-mediated cytotoxicity and 
enabled the eradication of tumour cells containing a small fraction of infected cells (figure 4.15). This 
observation was in line with previous findings that the mutant sr39TK could induce a strong 
bystander effect at lower GCV concentrations than the wild-type enzyme in vitro as well as in vivo 
[90, 347]. Through the replication-competence of Ad-delo-sr39TK-RGD and the resulting increase in 
HSV1-sr39TK expression, the oncolytic potential of the virus was enhanced by the bystander effect of 
HSV1-sr39TK/GCV. Although the bystander effect alone, elicited by Ad-sr39TK, was sufficient to 
induce almost complete cell eradication due to the high sensitivity of HSV1-sr39TK for GCV, this 
effect cannot be always translated into an in vivo situation. In this context, U87-MG glioma cells have 
been shown to be susceptible to bystander killing in vitro by GCV-mediated apoptosis, but this effect 
is insufficient in vivo [80]. Therefore, the use of replicating adenoviruses has a benefit over 
replication-deficient adenoviruses in enhancing the bystander effect in vivo. Moreover, the use of 
high viral and prodrug doses, which can compromise the safety of adenovirus-mediated suicide gene 
therapy [348], can be circumvented by a bystander effect. Regarding the mode of action of the 
bystander effect, it was demonstrated that TK from a replication-competent HSV-1 was able to 
enhance connexin 43 subunit (Cx43) expression in the presence of GCV and thus to induce bystander 
effect in a tumour cell line, suggesting augmented intercellular transport of active GCV through gap 
junctions [349]. If the enhancement of Cx43 expression by the HSV1-TK/GCV suicide system as a 
bystander mechanism is also valid in the context of HSV1-TK-armed oncolytic adenoviruses, remains 
to be shown.  
No bystander effect of HSV1-sr39TK/GCV was observed in the multidrug-resistant cell line EPP85-
181RDB under the same conditions as for U87-MG cells (figure 4.15). In contrast, a strong bystander 
cell killing with only 17 % infected cells was induced by applying a 5-fold higher GCV concentration 
that increased the sensitivity of EPP85-181RDB cells for the prodrug (data not shown). However, an 
increase of GCV concentration alone may not be sufficient for preventing resistance against HSV1-
TK/GCV-mediated killing in vivo. Considering the low HSV1-sr39TK expression from Ad-delo-sr39TK-
RGD (figure 4.9 A) and the attenuated viral oncolytic effect plus HSV1-sr39TK/GCV-mediated 
cytotoxicity (figure 4.14, figure 4.15) in EPP85-181RDB cells, it can be assumed that unarmed 
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conditionally replicating adenoviruses could be more efficient in eradication of multidrug-resistant 
tumour cells [265, 288, 291] than armed replicating adenoviruses.  
A promising approach to target multidrug resistance and to enhance the HSV1-TK/GCV suicide 
system in vivo could be the silencing of MDR1 by shRNA-targeting [350]. Another consideration for in 
vivo studies is the finding that overexpression of the proto-oncogene Bcl-2 in GBM is associated with 
resistance against HSV1-TK/GCV suicide gene therapy [351]. This issue could be addressed by an 
inhibitor of Bcl-2 [352].  
In order to increase the safety and efficacy of the HSV1-TK/GCV suicide system, potent bystander 
tumour cell eradication in in vivo glioma models can be induced through gap junction-mediated 
transport of toxic metabolites between HSV1-TK expressing bone marrow-derived cells or normal 
brain cells and glioma cells [353, 354]. These strategies demonstrate that normal brain cells may 
contribute to the HSV1-TK/GCV therapy by long-term delivery of therapeutic genes and through 
induction of a bystander effect.   
5.8. Potentiation of YB-1 dependent viral oncolysis by TMZ and benefit of 
viral dissemination in 3D  
The oncolytic potency of Ad-delo-sr39TK-RGD was augmented by TMZ treatment of glioma cells in 
both 2D and 3D culture, as shown by the decrease in cell survival (figure 4.16) and enhancement of 
viral replication (figure 4.20 and 4.21) and viral release (figure 4.22) by TMZ. Treatment of glioma 
cells and spheroids with TMZ once before and after infection achieved a higher level of replication 
enhancement than pre-treatment only (data not shown). This level was also higher than the 
replication enhancement of Ad-delo3-RGD within an in vivo study [292], indicating that the 
continuous TMZ treatment schedule could be beneficial for improving the oncolytic potential of YB-1 
virotherapy in vivo. In respect of in vivo use, it is noteworthy that the half-life of TMZ in human 
plasma is only 1.8 h [318, 319], corroborating the need of repeated TMZ addition in order to increase 
the virotherapeutic performance. These results indicate that sensitisation of glioma cells to 
adenoviral infection by TMZ could be a promising virotherapeutic approach. As the IC50 of TMZ for 
U87-MG cells was stated to range between < 100 µM [355] and 20.2 mM [103], the IC50 of TMZ of > 
500 µM for this cell line (figure 4.16) lies within the published range. The discrepancy of IC50 of TMZ 
for U87-MG cells in the literature probably arises from the different incubation periods of the drug 
on cells: 72 h [355] and 96 h [103]. Here, TMZ was incubated on cells for 24 h (figure 4.16). Thus, the 
combinatorial approach of virotherapy and TMZ raises the susceptibility of GBM cells to TMZ and 
allows the use of low virus and TMZ doses (e.g. MOI 10 and 25 µM TMZ, or MOI 20 and 10 µM TMZ) 
to reach the same level of cell killing as high doses of single treatment (e.g. MOI 50/100 or > 500 µM 
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TMZ). The combined treatment is therefore beneficial for reducing potential toxic effects in future 
systemic applications in vivo.  
The enhancement of oncolysis is based on the nuclear translocation of the transcription factor YB-1 
as a result of TMZ-mediated cytostatic stress and thus stimulation of adenoviral replication, as shown 
previously for Ad-delo3-RGD [292]. The mechanisms of YB-1 nuclear translocation as a result of stress 
response are not clear yet. There is strong evidence that several concurrent signalling pathways, 
activated as a result of DNA-damaging agents, are involved in this process [262, 356]. 
Phosphorylation of YB-1 at Ser102 by the serine/threonine kinase Akt has been shown to trigger the 
transition of YB-1 to the nucleus [357]. However, the dependence of YB-1 nuclear transport on Akt 
could not be reproduced for some tumour cell lines [358]. Another regulatory mechanism for nuclear 
translocation of YB-1 is associated with the C-terminal cleavage of the protein by the 20S 
proteasome, induced by DNA-damaging agents [359], but the molecular mechanism of YB-1 nuclear 
transport mediated by proteolysis needs to be re-assessed [360].  
The improved oncolytic effect of Ad-delo-sr39TK-RGD over Ad-delo3-RGD in combination with TMZ 
(figure 4.16) was likely to be caused by the improved viral release of the armed oncolytic adenovirus 
due to the expression of ADP, as described previously. Ad-delo-sr39TK-RGD demonstrated a similar 
to slightly stronger oncolytic effect depending on viral MOI and TMZ concentration than Ad-delo-
shMGMT-RGD. It was expected that the double function of Ad-delo-shMGMT-RGD in inducing 
oncolysis and simultaneously potentiating the cytostatic effect of TMZ by silencing of the DNA repair 
gene MGMT [320] could achieve stronger glioma cell killing than YB-1 dependent virotherapy with 
Ad-delo-sr39TK-RGD alone. A synergistic therapeutic efficacy of oncolytic virotherapy, TMZ and 
down-modulation of MGMT expression against GBM has been already demonstrated [361], but not 
in the context of YB-1 dependent oncolysis. However, the use of U87-MG cells to assess the benefit 
of adding MGMT-silencing to YB-1 dependent oncolysis is equivocal, as these cells exhibit MGMT-
promoter hypermethylation and thus low MGMT expression [355]. The use of TMZ-resistant glioma 
cells with an unmethylated MGMT-promoter reflects the clinical scenario more accurately. 
Moreover, the lack of the anti-apoptotic protein E1B19K in Ad-delo-sr39TK-RGD contributed to the 
enhanced TMZ-mediated oncolytic effect of Ad-delo-sr39TK-RGD at low MOIs in comparison to Ad-
delo-shMGMT-RGD. Ad-delo-sr39TK-RGD has therefore the potential for eliminating of GBM cells 
regardless of their MGMT status.  
In contrast to the high oncolytic potential of the YB-1 dependent adenoviruses upon TMZ treatment 
in GBM cells, a 20-fold higher viral MOI and 50- to 200-fold higher TMZ doses than applied in U87-
MG cells were needed for the oncolytic viruses to achieve an almost complete eradication of EPP85-
181RDB cells (figure 4.17). The multidrug-resistant phenotype of the pancreatic carcinoma cells was 
most likely to be responsible for the worse response to TMZ and thus low oncolytic potential, 
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considering also the controversial role of YB-1 in multidrug resistance [331, 332]. Explanations for 
this worse effect could be on the one hand a cross-resistance towards TMZ. On the other hand, no 
additional stress stimuli like TMZ could further enhance the nuclear accumulation of YB-1, due to a 
selection pressure over TMZ, since EPP85-181RDB cells are maintained in the presence of 
daunorubicin [290].  
The role of multidrug resistance-mediating ABC-transporter proteins in GBM is controversial. 
Although expressed in GBM cells, it is still unknown whether TMZ is actually transported by these 
proteins [362]. However, evidence exist that MDR1 is associated with TMZ resistance and the protein 
is therefore an independent predictive factor for the outcome of TMZ therapy [363]. 
The level of DNA replication enhancement of the oncolytic adenoviruses by TMZ was stronger in 
spheroids than in 2D culture (figure 4.20, figure 4.21), indicating that the 3D cell structure facilitated 
the viral spread and confirming the 3D model as the more relevant one for replication analyses. This 
statement was supported by the finding that Ad-delo-sr39TK-RGD invaded not only the outer layers, 
but also several inner layers of the spheroids, in contrast to the replication-deficient Ad-sr39TK 
(figure 4.23). The adenoviral distribution in spheroids shown here was in accordance with the finding 
of Grill et al. that spread of a replication-deficient adenovirus is restricted to the outer layers of 
glioma spheroids, but replication-competent and oncolytic adenoviruses invade also the inner layers 
[210]. The reasons for the restriction of adenoviral replication to the outer replicating layers of 
spheroids may be the increasing proportion of nonproliferating cells during growth and the 
occurrence of necrotic regions in the spheroid core as a result of a hypoxic environment and glucose 
deprivation, similar to cancers in vivo [205]. Hypoxia usually exists in sections within solid tumours 
and can attenuate adenoviral replication by downregulation of viral protein expression [364, 365]. 
Necrotic regions in the core of tumour spheroids with diameters larger than 400-500 µm, as in the 
case of the glioma spheroids generated in this thesis, may occur at a distance of 50-300 µm from the 
spheroid periphery and the thickness of the proliferating layers, surrounding the necrotic centre, may 
range between 100-220 µm [205, 209].  
Spheroids can give also an insight into the mode of viral dissemination within a solid tumour. 
Regarding viral dissemination, it was shown that oncolytic adenoviruses seemed to favour lateral 
rather than medial spread within spheroids (figure 4.23). This could be due to a tight lateral 
clustering of cells or an uneven distribution of the adenovirus-binding integrins αvβ3 and αvβ5 on the 
cell surface, as these integrins are known to be overexpressed in the periphery of high-grade gliomas 
[366].     
 
DISCUSSION 103
 
5.9. Relevance of 3D spheroids for exploring potential in vivo effects of the 
HSV1-sr39TK/GCV suicide system 
Although the spread of Ad-delo-sr39TK-RGD (figure 4.23) and the release of infectious Ad-delo-
sr39TK-RGD-particles (figure 4.22) was impaired by the inhibitory action of GCV upon viral replication 
(figure 4.20, figure 4.21), the combined viral and HSV1-sr39TK/GCV approach efficiently induced 
HSV1-sr39TK/GCV-mediated cytotoxicity in 3D spheroids and was stronger than both oncolytic effect 
and HSV1-sr39TK/GCV-mediated cytotoxicity alone (figure 4.19). The cell killing was therefore 
augmented by the bystander effect of GCV and not by adenoviral replication alone. However, 
evidence exist that HSV1-TK-expressing spheroids display lower GCV-bystander effect than 
monolayer culture [367]. Here, this finding was in accordance with the lower cytotoxicity of the 
replication-deficient Ad-sr39TK in spheroids than in 2D culture, presuming a role of the attenuated 
bystander effect. The potential bystander effect of GCV in spheroids was however enhanced by 
replication of the oncolytic adenoviruses at late time points and the difference in cell survival after 
the single viral approach and the combined viral and HSV1-sr39TK/GCV-approach was more 
prominent in 3D than in 2D. Due to the similarity of the 3D structure to tumour tissue, the results in 
3D are assumed to be more relevant for predicting the therapeutic efficacy of the suicide gene 
system in vivo.    
There are conflicting data in the literature regarding the efficacy of oncolytic adenoviruses combined 
with HSV1-TK/GCV suicide therapy. Some studies show that the HSV1-TK/GCV system enhances the 
oncolytic activity of replication-competent E1B55K-deleted adenoviruses [237, 238] or of replication-
competent adenoviruses with a deletion of the Mr 19.000 glycoprotein (gp19K) coding sequence in 
the E3 region [240], whereas other studies demonstrate no further enhancement of E1B-positive 
oncolytic adenoviruses, especially when the E1B55K protein is functional [368-371]. However, GCV 
was applied in the latter studies not earlier than two days after infection.  
It is suggested that the HSV1-TK/GCV system might still be suitable to enhance the cytoreductive 
effect of highly potent oncolytic vectors in clinical settings, because immune responses often limit 
viral spread [369]. Moreover, HSV1-TK/GCV administration might potentiate the oncolytic activity by 
immune-mediated mechanisms [372]. In this thesis it was demonstrated that the E1B55K-expressing 
HSV1-sr39TK-armed oncolytic adenovirus had a potent anti-tumour effect by oncolysis alone, 
especially in 2D glioma culture. Additionally, there was an enhancement of the oncolytic effect by the 
combination of oncolytic and HSV1-sr39TK/GCV activity, which was more distinctive in 3D spheroids 
than in 2D cell culture. It can be presumed that the impaired accessibility of cells within spheroids, 
even by replicating adenoviruses, leading to a delayed oncolytic effect compared to 2D culture, 
resembles the in vivo situation more precisely and can be substantially enhanced by the suicide gene 
system.  
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5.10. Combined effect of YB-1 dependent virotherapy, TMZ and HSV1-
sr39TK/GCV suicide system against GBM 
It was shown that TMZ, by enhancing the replication and thus oncolytic effect of Ad-delo-sr39TK-RGD 
via triggering the nuclear translocation of YB-1 [292] , acted in combination with the HSV1-sr39TK-
/GCV-system to potentiate the decrease of glioma cell survival both in 2D culture (figure 4.18) and 3D 
spheroids (figure 4.19). Compared to the sole combination of oncolysis and HSV1-sr39TK/GCV-
mediated cytotoxicity, additional TMZ-stimulation induced an earlier onset of cell killing and allowed 
the application of less viral load. In contrast, TMZ exerted rather cytostatic than cytotoxic effects in 
uninfected spheroids.  
The type of cell death, mediated by the combined experimental approach, and the mode of action of 
this treatment have to be elucidated in more detail. Replicating adenoviruses induce more than one 
type of cell death or a mixed type of cell death, according to the heterogeneous functions of the 
adenoviral gene products and the time point of their activation during the adenoviral life cycle [373, 
374]. The most commonly observed adenovirus-mediated cell death modes include apoptosis [375], 
necrosis-like cell death [376], cell lysis [165] and autophagy [377]. As shown in figure 4.18 C, YB-1 
dependent oncolytic adenoviruses induced probably an apoptotic cell death after c.p.e., which is in 
line with previous findings that Ad-delo3-RGD induces apoptosis in vivo [292]. The hypothesis that 
E1B19K-deleted adenoviruses, such as Ad-delo-sr39TK-RGD and Ad-delo3-RGD, induce apoptosis, at 
least in early stages of the viral life cycle, is corroborated by the finding that cells infected with an 
E1B19K mutant undergo apoptosis, because DNA damage caused by viral infection activates the 
proteosomal degradation of the anti-apoptotic Bcl-2 family member Myeloid Cell Leukemia 1. The 
Bcl-2 homologue E1B19K is then not at disposal to block this pathway and to counteract apoptosis 
mediated by E1A [378].  
The suggested apoptotic cell death upon TMZ treatment and infection with YB-1 dependent oncolytic 
adenoviruses (figure 4.18 C) needs to be analysed more thoroughly, since it has been shown that the 
combination of TMZ and conditionally-replicating adenoviruses elicits autophagic cell death in vitro in 
U87-MG cells, whereas both autophagy and apoptosis are observed in vivo in glioma models [379]. 
Moreover, TMZ induces apoptosis and senescence in GBM spheroids [380], but doses up to 100 µM 
TMZ do not lead to strong apoptosis [208]. Thus, it can be concluded that tumour cell eradication 
(figure 4.18, figure 4.19) resulted predominantly from the potentiation of the oncolytic effect by TMZ 
and the HSV1-sr39TK-/GCV-mediated cytotoxicity, and probably to a lower extent from induction of 
apoptosis by TMZ. As indicated by the difference in cellular morphology (figure 4.18 C), it can be 
assumed that the oncolytic effect elicited a different type of cell death than the HSV1-sr39TK/GCV 
system alone. The HSV1-TK/GCV suicide system has been shown to mediate apoptosis in U87-MG 
cells [70]. On the contrary, combined TMZ and GCV treatment of Ad-delo-sr39TK-RGD-infected GBM 
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cells resulted most likely in a mixed apoptotic and necrosis-like mode of cell death. More detailed 
examinations are necessary to determine the exact type of cell death induced by this triple 
combinatorial approach. 
It has been shown that inhibition of YB-1 sensitizes GBM cells to TMZ [381]. This finding could be one 
of the mechanisms underlying the additive effect of YB-1 dependent oncolysis and TMZ treatment, as 
YB-1 is not at disposal because of its function in activating viral replication.      
The mechanism of action of the HSV1-sr39TK/GCV-mediated cytotoxicity in potentiating viral 
oncolysis requires a more detailed elucidation. It has been shown that infection with oncolytic 
adenoviruses induces a profound overreplication of genomic DNA in permissive cell lines. The 
overreplication results from the transactivation of cdc25a phosphatase by E1A and the promotion of 
E1A-induced S phase entry by activated cdc25a [382]. Deregulated cdc25a activity during adenoviral 
infection induces uncontrolled genomic DNA replication via activation of cdc2. Consequently, DNA 
overreplication is associated with the occurrence of genomic DNA damage. As a result, the DNA 
homologous recombination repair pathway, involving the key kinase ataxia telangiectasia and Rad3-
related (ATR) and checkpoint kinase 1 (Chk1), is activated in order to maintain the integrity of the 
genome. Inhibition of the ATR-Chk1 pathway impairs DNA damage repair, which results in 
accumulation of cytotoxic lesions and consequently leads to cell death [382].  
The HSV1-TK/GCV system may interfere in the above described model in a dual mode. First, the 
incorporation rate of GCV-triphosphate into genomic DNA may be increased due to genomic DNA 
overreplication in adenovirus-infected cells, since GCV-triphosphate exerts its cytotoxicity upon 
rapidly dividing DNA. Second, GCV-triphosphate induces an irreversible arrest in late S-G2 phase 
through activation of the G2-M DNA damage checkpoint and inhibition of the activity of cdc2 [383]. 
During this irreversible late S-G2 phase arrest, unrepairable DNA double strand breaks may 
accumulate due to blocked Chk1-mediated homologous recombination repair [384], which adds to 
the deleterious effect of virus-induced DNA damage. Hence, through the incorporation of GCV-
triphosphate during virus-induced DNA overreplication and by interfering with the virus-mediated 
cell cycle progression and with DNA repair pathways, the HSV1-sr39TK/GCV system exerts additive 
effects in combination with viral replication for mediation of cell death.  
Rainov et al. already assessed the synergy between TMZ and GCV in mediating cytotoxicity in HSV1-
TK-expressing malignant glioma cells and elucidated the possible mechanism underlying this synergy 
[103]. Accordingly, GCV-triphosphate is supposed to inhibit the repair of TMZ-induced DNA-crosslinks 
by MGMT. According to a model of mutual synergism between chemotherapy and YB-1, defined as 
Mutually Synergistic Therapy (MUST), chemotherapy leads to increased levels of nuclear YB-1 and 
consequently enhances adenoviral replication, while viral-mediated nuclear translocation of YB-1 
leads to enhanced susceptibility of cells to chemotherapy [265]. Thus, there is strong evidence that 
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the combined effect of TMZ, YB-1 dependent oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity 
is based on the mutual synergism between these three components. In addition, the results of this 
thesis confirm the increased efficacy of YB-1 dependent virotherapy in multimodal over single-mode 
approaches against GBM in previous studies [289, 292]. 
5.11. Suitability of HSV1-sr39TK-armed YB-1 dependent oncolytic 
adenoviruses for non-invasive reporter gene imaging 
Multicellular spheroids had been already used as a relevant in vitro model to assess changes in cell 
viability after treatment with oncolytic adenoviruses by means of a PET scan using [18F]-labelled 
deoxyglucose [214]. To the author’s knowledge, no PET imaging of multicellular spheroids using 
HSV1-sr39TK has been performed by now. In this thesis, 3D glioma spheroids were used - along with 
2D cell culture - as a feasible model for the analysis of the cellular uptake and spatial distribution of 
PET radiotracer, specific for HSV1-sr39TK. The data demonstrate that Ad-delo-sr39TK-RGD mediated 
accumulation of radiotracer by the enzymatic activity of HSV1-sr39TK in 2D culture (figure 4.24) and 
in 3D spheroids (figure 4.25, figure 4.26). The activity of HSV1-sr39TK correlated positively with the 
amplification of the transgene by viral replication (figure 4.24 B). Although the replication-deficient 
vector Ad-sr39TK has been successfully applied for non-invasive radiotracer imaging in vivo [113, 
115], replication-competent adenoviruses may have an advantage over replication-deficient viruses 
in allowing the use of lower and non-toxic viral doses for in vivo imaging, which can be further 
amplified by replication.  
In future in vivo studies, progression of tumour cell killing as a result of oncolytic virotherapy in 
combination with cytostatic agents and the HSV1-sr39TK/GCV-mediated system could be monitored 
by non-invasive PET radiotracer imaging, having in mind that the accumulation rate correlates with 
cell viability. The use of the disseminating oncolytic adenovirus Ad-delo-sr39TK-RGD facilitates 
nuclear reporter gene delivery, as well as biodistribution, and provides first evidence that the 
therapeutic efficacy of the HSV1-sr39TK/GCV system could be easily monitored in vivo. Nevertheless, 
the radiotracer application should be well timed in order to achieve an equilibrium between the 
HSV1-sr39TK/GCV-mediated cytotoxicity, oncolytic killing and tracer accumulation. An optimal time 
point for uptake analysis would be three days post infection (figure 4.24 B), when the amount of 
oncolytic viral particles is significantly increased due to replication burst. In addition, imaging might 
be most successful if the radiotracer is applied before GCV treatment [126], because cell depletion by 
the HSV1-TK/GCV system would thus be circumvented. 
Regarding the issue of oncolytic toxicity, which could hamper imaging success, the replication-
deficient Ad-sr39TK has an advantage over Ad-delo-sr39TK-RGD for imaging, because of its non-lytic 
properties (figure 4.24 A). To circumvent the problem of off-target toxicity due to the action of 
DISCUSSION 107
 
armed oncolytic adenoviruses and as a safety regard, GCV can be applied in appropriate doses in 
order to abort the proliferation of HSV1-TK-expressing cells and thus attenuate adenoviral replication 
when necessary, but maintaining the therapeutic effect. The decrease in [18F]-FHBG accumulation 
upon dual and triple treatment approaches (figure 4.25, figure 4.26) reflected the enhanced 
cytoreduction by viral oncolysis in combination with TMZ and upon TMZ plus GCV treatment. These 
results point out the feasibility and sensitivity of HSV1-sr39TK/[18F]-FHBG reporter gene imaging for 
monitoring of minor differences in the viability of tumour cells after subjecting them to treatment. 
In respect of the technique for radiotracer detection in spheroids, gamma-counting allows a more 
precise quantification of absolute radiotracer amount on cellular level than PET imaging. Therefore, 
the determination of radiotracer accumulation by gamma-counting was more sensitive than PET 
measurement and was able to detect alterations between each of the TMZ, GCV or combined TMZ 
and GCV treatment approaches in Ad-delo-sr39TK-RGD-infected spheroids more accurately than PET 
(figure 4.25). Nevertheless, the ability of PET imaging to detect radiotracer accumulation in small 
tumour spheroids of size about 7 mm³ and consisting of about 4 x 105 cells (figure 4.26) proved the 
feasibility and the high sensitivity of this technique in combination with HSV1-sr39TK and [18F]-FHBG. 
The high imaging sensitivity when using this reporter gene and probe pair was in accordance with a 
previously estimated detection limit of 1 x 105 HSV1-sr39TK-transduced cells for tumours of size 
about 3 mm³ [385]. The preliminary results in 3D spheroids provide a first indication of the suitability 
of HSV1-sr39TK, delivered by an YB-1 dependent replicating adenovirus, in combination with [18F]-
FHBG for non-invasive in vivo PET imaging.     
5.12. Outlook and future perspectives of combined YB-1 dependent 
virotherapy and HSV1-sr39TK/GCV suicide gene system   
The combined approach of YB-1 dependent oncolytic virotherapy, HSV1-sr39TK/GCV suicide system 
and TMZ therapy proves to be promising, though some improvements are necessary for future 
application in preclinical studies. There is often a discrepancy between results obtained by in vitro 
and in vivo investigations, because monolayer cell culture does not reflect the tumour 
microenvironment [236]. Even 3D spheroid models, consisting of one cell type, are not able to 
constitute the complex interplay between tumours, vascularisation, tumour microenvironment and 
the immune system. Hence, a xenograft GBM in vivo model is needed to address the efficacy of the 
described therapeutic strategy, using the time- and dose-dependent treatment conditions, which 
were optimised in this study. Moreover, repetitive non-invasive microPET imaging can be performed 
after intratumoural injection of replicating HSV1-sr39TK-bearing adenoviruses and radiotracer 
application in order to explore the kinetics of viral replication, biodistribution and the tracer 
detection limits in respect of time and dosage in vivo. The tumour growth or regression after GCV 
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and TMZ addition, as well as possible toxicity of the combined treatment, can also be monitored by 
means of microPET imaging. Subtle differences in viral replication during GCV and TMZ treatment can 
be analysed by immunohistology and the correlation to biodistribution of radiotracer can be 
assessed. Considering that [18F]-FHBG has background leakage preferentially in the liver [115, 116], 
analysis of the biodistribution of the radiotracer in tumours and organs can be performed.   
An orthotopic GBM xenograft model can be used to examine the correlation between uptake of [18F]-
FHBG by HSV1-sr39TK-expressing GBM cells and 3'-deoxy-3'-[18F]-fluorothymidine uptake as a 
proliferation biomarker [386], in order to assess the effect of combined adenoviral, TMZ and HSV1-
sr39TK/GCV treatment on tumour growth and to predict survival outcome. Furthermore, the 
implantation of Ad-delo-sr39TK-RGD-infected GBM spheroids into established GBM models could 
result in a bystander effect of HSV1-sr39TK/GCV, induced from infected spheroids on uninfected 
GBM cells. This bystander effect can facilitate the application of low virus and GCV doses, and could 
help to avoid potential off-target effects. For all future in vivo studies, a GCV application at late time 
points of viral replication and a systemic TMZ addition should be preferred for enhancing the 
treatment efficacy and allowing control of virus spread.    
Future refinements of the current triple treatment approach may concern vector modifications, 
strategies for immune evasion, targeted delivery and improvement of the therapeutic efficacy. In 
order to target tumour cells with a low expression level or insufficient nuclear localisation of YB-1 
and in order to expand the application field of YB-1 dependent virotherapy and suicide gene therapy 
beyond the treatment of malignant gliomas, YB-1 can be cloned into a largely deleted E1 region of 
HSV1-sr39TK-armed oncolytic adenoviruses to ensure YB-1 overexpression. It has been 
demonstrated that YB-1 overexpression from an adenoviral vector can trigger the replication and 
oncolytic potential of E1-deficient adenoviruses [387]. The YB-1 gene can be inserted in place of 
E1B55K, as evidence exist that expression of this gene constitutes no further improvement of viral 
oncolysis by the HSV1-TK/GCV system. A critical issue hampering the success of virotherapy and 
suicide gene therapy in vivo is the presence of immune responses against the therapeutic vectors 
[175]. Therefore, virus shielding with polymers [388] or coupling of polymer-coated adenoviruses to 
therapeutic antibodies that bind to receptors on tumour cells, e.g. EGFR [389], can be considered as 
future mechanisms to improve systemic tumour transduction in vivo and to evade the immune 
system of the host. In addition, the targeted delivery and the potency of oncolytic adenoviruses in 
vivo can be improved by associating them with magnetic nanoparticles and a magnetic-field-guided 
infection [390]. Furthermore, the combined oncolytic- and suicide gene strategy can be improved in 
respect of efficacy and toxicity by the use of sustained intratumoural prodrug delivery systems, e.g. 
GCV-containing silicone formulations [391] or long-circulating PEGylated liposomes with 
encapsulated GCV [392]. The addition of immunostimulatory factors like interleukin-12 [393] or the 
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human soluble Fms-like tyrosine kinase 3 ligand [394] may help to improve the efficacy of combined 
oncolytic- and suicide gene therapy via stimulating an anti-tumour immunity.      
Regarding future preclinical or clinical application of RGD-modified oncolytic adenoviruses, it could 
be rather of disadvantage for the treatment efficacy when combining them with anti-angiogenic 
agents as the inhibitor of ανβ3/ανβ5 integrins cilentigide [395], because the inhibition of adenovirus-
binding integrins may attenuate adenoviral tumour targeting. 
 
Concluding the results of this thesis, the combination between low oncolytic virus, GCV and TMZ 
doses is as efficient as high doses of the single components for inducing glioma cell eradication. This 
combined approach might thus reduce the occurrence of potential treatment-induced side effects in 
vivo. Hence, combining YB-1 dependent oncolytic adenoviruses with suicide and reporter gene 
therapy, and classical anti-glioma chemotherapy, is promising in paving the way to an optimized 
therapeutic approach against solid cancers, which can be applied in vivo. 
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6. SUMMARY 
 
Glioblastoma multiforme (GBM) is the most common primary brain tumour, characterised with 
infiltrative growth, high recurrence rate and a fatal outcome. Suicide gene therapy, using the suicide 
and reporter gene Herpes simplex virus 1 thymidine kinase (HSV1-TK) with its prodrug Ganciclovir 
(GCV), and oncolytic virotherapy are promising tools to address the limitations of current anti-GBM 
treatment, arising from the aggressive nature of GBM and its resistance to therapy. Conditionally 
replicating oncolytic adenoviruses are gaining considerable influence in tumour gene therapy. Among 
them, adenoviruses, dependent in their replication on the oncogenic factor Y-box binding protein 1 
(YB-1), contain a manipulation of the essential E1A gene, which allows them to replicate in tumour 
cells with stress-induced nuclear accumulation of YB-1. Despite the success of the HSV1-TK/GCV 
suicide gene therapy and YB-1 dependent oncolytic virotherapy in the combat of GBM, single-mode 
approaches are often not as efficient as combined treatments to achieve a sustained therapeutic 
outcome.  
Therefore, based on the finding that YB-1 is overexpressed in GBM, it was of interest to characterise 
the therapeutic potential of an YB-1 dependent oncolytic adenovirus, armed with the HSV1-TK-
mutant HSV1-sr39TK, in combination with GCV and the standard anti-GBM chemotherapeutic agent 
Temozolomide (TMZ) in glioma cells in vitro, including a 3D multicellular spheroid model with tumour 
characteristics. The virus demonstrated strong replication competence, oncolytic potential and 
ability to produce infectious viral progeny. HSV1-sr39TK transgene expression correlated positively 
with viral replication, indicating a stable transgene expression despite oncolytic effect. Arming YB-1 
dependent oncolytic adenoviruses with a suicide gene was able to eradicate glioma cells more 
efficiently than oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity alone in the 3D spheroid 
model. In 2D culture, oncolysis was potentiated by the HSV1-sr39TK/GCV-mediated cytotoxicity only 
when GCV was applied at early time points post infection. The potent bystander effect of the suicide 
gene system in combination with viral replication contributed to the efficacy of the therapeutic 
approach and allowed for application of low viral load in order to minimise off-target toxicity in non-
malignant tissue. In addition, the inhibitory potential of GCV on viral replication at early stages of the 
viral life cycle represents a fail-safe means to control viral dissemination. Enhancement of YB-1 
dependent oncolysis by TMZ and combining this approach with HSV1-sr39TK/GCV-mediated 
cytotoxicity resulted in a potentiation of glioma cell killing, probably through a combined mode of 
cell death. In comparison to the oncolytic effect and the HSV1-sr39TK/GCV-mediated cytotoxicity 
alone, the triple treatment induced significant reduction of 3D spheroid growth. In contrast, viral 
oncolysis and the HSV1-sr39TK/GCV system exerted a diminished efficacy in the context of 
multidrug-resistance. Furthermore, HSV1-sr39TK-expressing oncolytic adenoviruses allowed for 
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radiotracer [18F]-FHBG accumulation in both 2D and 3D glioma models and thus proved to be suitable 
for non-invasive PET imaging of the therapeutic efficacy within a limited time frame. In conclusion, 
the results obtained in this thesis highlight the importance of combining YB-1-based virotherapy with 
conventional cancer treatment and suicide gene therapy for enhancing the therapeutic efficacy of 
anti-cancer approaches. The problem of impaired efficacy of the suicide gene therapy in many in vivo 
applications, caused by a low transduction efficiency of replication-deficient vectors, can be 
circumvented by applying replication-competent oncolytic adenoviruses. 
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7. ZUSAMMENFASSUNG 
 
Glioblastoma multiforme (GBM) ist der häufigste primäre Hirntumor, der sich durch infiltrierendes 
Wachstum, eine hohe Rezidivrate und eine schlechte Prognose auszeichnet. Die Suizidgentherapie 
mit dem Herpes simplex virus 1 Thymidinkinase (HSV1-TK)/Ganciclovir (GCV)-System, sowie 
onkolytische Virotherapie, sind vielversprechende Ansätze, um häufig auftretende Einschränkungen 
der gegenwärtigen Therapiemöglichkeiten für GBM aufzuheben. Diese Einschränkungen resultieren 
aus dem aggressiven Charakter und der Therapieresistenz von GBM. Tumorzellspezifische 
onkolytische Adenoviren gewinnen beträchtlich an Einfluss auf die Gentherapie von Tumoren. Unter 
ihnen befindet sich die Gruppe der Adenoviren, welche in ihrer Replikation von dem onkogenen 
Faktor Y-Box-bindendes Protein 1 (YB-1) abhängig sind und eine Mutation des essentiellen E1A-Gens 
enthalten. Diese E1A-Mutation ermöglicht den Viren die Replikation in Zellen, die eine Stress-
induzierte Kernlokalisation von YB-1 aufweisen. Trotz des Erfolges der HSV1-TK/GCV-
Suizidgentherapie und der Therapie mit YB-1-abhängigen onkolytischen Adenoviren gegen GBM, sind 
kombinierte Ansätze meistens effizienter als Monotherapien, um einen nachhaltigen Therapieerfolg 
zu erzielen.          
Basierend auf der Erkenntnis, dass YB-1 in GBM überexprimiert wird, war es daher von Interesse das 
therapeutische Potential eines HSV1-sr39TK-tragenden, YB-1-abhängigen onkolytischen Adenovirus 
in Kombination mit GCV und dem klassischen anti-GBM-Chemotherapeutikum Temozolomid (TMZ) 
zu charakterisieren. Die in vitro Analyse erfolgte in Gliomzellen, einschließlich eines 3D 
multizellulären Sphäroid-Modells mit Tumoreigenschaften. Das Virus zeichnete sich durch seine 
starke Replikationskompetenz, onkolytischen Potential und Fähigkeit zur Produktion von infektiösen 
viralen Nachkommen aus. Die Expression des Transgens HSV1-sr39TK korrelierte positiv mit der 
viralen Replikation, was auf eine stabile Expression trotz onkolytischen Effekts hindeutet. Die 
Kombination aus YB-1-abhängigen onkolytischen Adenoviren und einem Suizidgen ermöglichte ein 
effizienteres Abtöten von Gliomzellen im 3D Sphäroid-Modell als die Onkolyse und die HSV1-
sr39TK/GCV-vermittelte Zytotoxizität allein. Der onkolytische Effekt in 2D Zellkultur wurde durch die 
HSV1-sr39TK/GCV-vermittelte Zytotoxizität nur unter Zugabe von GCV zu frühen Zeitpunkten nach 
der Infektion verstärkt. Der starke Bystander-Effekt, induziert durch das Suizidgen-System in 
Kombination mit viraler Replikation, steuerte zur Wirksamkeit des Therapieansatzes bei und 
ermöglicht den Einsatz von niedriger Virusdosis, um „Off-target“-Toxizität in nicht-malignes Gewebe 
zu verhindern. Die Hemmung der viralen Replikation durch GCV in frühen Stadien des viralen 
Entwicklungszyklus stellt zusätzlich eine zuverlässige Methode dar, um die Ausbreitung des Virus zu 
kontrollieren. Die Steigerung des YB-1-abhängigen onkolytischen Effektes durch TMZ und die 
Kombination dieses Ansatzes mit der HSV1-sr39TK/GCV-vermittelten Zytotoxizität führte zu 
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verstärktem Abtöten von Gliomzellen. Dieses Abtöten kam möglicherweise durch eine kombinierte 
Art von Zelltod zustande. Im Vergleich zum onkolytischen Effekt und der HSV1-sr39TK/GCV-
vermittelten Zytotoxizität allein, erzeugte die dreifache Behandlung eine signifikante Reduktion des 
Wachstums von 3D Sphäroiden. Im Gegensatz dazu übten die virale Onkolyse und das HSV1-
sr39TK/GCV-System einen schwächeren Effekt auf multiresistente Zellen aus. Des Weiteren 
ermöglichten die HSV1-sr39TK-exprimierenden onkolytischen Adenoviren die Akkumulation des 
radioaktiven Tracers [18F]-FHBG sowohl in 2D, als auch in 3D Gliom-Modellen und zeigten dadurch 
ihre Eignung zum nicht-invasiven Imaging der therapeutischen Wirksamkeit im PET-System innerhalb 
eines begrenzten Zeitfensters. Die Ergebnisse dieser Arbeit heben die Bedeutung der Kombination 
aus YB-1-abhängiger Virotherapie, konventioneller Krebstherapie und  Suizidgentherapie zur 
Verstärkung der Wirksamkeit von Krebstherapien hervor. Mögliche Beeinträchtigung der 
Wirksamkeit von Suizidgentherapie in vivo, verursacht durch eine niedrige Transduktionseffizienz mit 
replikationsdefizienten Vektoren, könnte durch den Einsatz von replikationskompetenten 
onkolytischen Adenoviren umgangen werden. 
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9. APPENDIX 
 
9.1. Abbreviations 
’’ Inch 
°C Degree Celsius 
Δ Deletion 
ρ Volumetric mass density 
aa Amino acid 
ABC ATP-binding cassette 
ACV Acyclovir 
Ad5 Human adenovirus type 5 
ADP Adenovirus death protein 
Akt Protein kinase B 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
ATR Ataxia telangiectasia and Rad3-related 
Bcl-2 B cell lymphoma-2 
bp Base pair 
Bq Becquerel 
BSA Bovine Serum Albumin 
CaCl2 Calcium chloride 
CAR Coxsackie and adenovirus receptor 
CD Cluster of differentiation 
CD (b/y) Cytosine deaminase (from bacteria or yeast) 
Cdc(x) Cell division cycle (x=number) 
cDNA Complementary DNA 
Chk1 Checkpoint kinase 1 
C2H3NaO2 Sodium acetate 
cm Centimetre 
cm3 Cubic centimetre 
CMV Cytomegalovirus 
CNS Central nervous system 
CO2 Carbon dioxide 
CR Conserved region 
Cre Cyclization recombinase 
CsCl Cesium chloride 
Ct Cycle threshold 
CT Computed tomography 
c.p.e. Cytopathic effect 
cpm Counts per minute 
Cx43 Connexin 43 subunit 
Da Dalton 
DAPI 4´,6´-diamidino-2-phenylindole 
delo2/3 Deletion on 2/3 locations 
dH2O Distilled water 
DIG Digoxigenin 
DMEM Dulbecco's Modified Eagle’s Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
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dNTP Deoxynucleoside triphosphate 
ds Double-stranded 
dUTP 2´-deoxyuridine 5´-triphosphate 
EDTA Ethylenediamine-tetraacetic acid 
E2F E2 promoter binding factor 
e.g. For example 
eGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor  
FAM 6-carboxyfluorescein 
FBS Fetal bovine serum 
5-FC 5-fluorocytosine 
FHBG 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine 
FIAU 2’-fluoro-2’-deoxy-5-iodo-1-β-D-arabinofuranosyl 
FITC Fluorescein isothiocyanate 
5-FU 5-fluorouracil 
g Gravitational field strength 
g Gramme 
G Gauge 
G Giga 
GBM Glioblastoma multiforme 
GCV Ganciclovir 
h Hour 
HCl Hydrochloric acid 
HEK Human embryonic kidney 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
hNIS Human sodium-iodide symporter gene 
HNSCC Head and neck squamous cell carcinoma 
HRP Horseradish peroxidase 
HS Horse serum 
HSV Herpes simplex virus 
HSV1-TK Herpes simplex virus 1 thymidine kinase 
hTERT Human telomerase reverse transcriptase 
IC50 Half maximal inhibitory concentration 
IF Immunofluorescence 
ifu Infectious units 
Ig Immunoglobulin  
kb 1000 base pairs 
KCl Potassium chloride 
KH2PO4 Potassium dihydrogen phosphate 
kIU Kallikrein Inhibitor Units 
Km Michaelis constant 
l Litre 
loxP   Locus of X-over of P1 
M Mega 
M Molarity 
mA Milliampere 
mAU Milli-arbitrary unit 
mCMV Murine cytomegalovirus 
MDR1 Multidrug resistance gene 1 
MEM Minimum Essential Medium 
mg Milligramme 
MgCl2 Magnesium chloride 
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MGMT O6-methylguanine-DNA methyltransferase 
min Minute 
mJ Millijoule 
ml Millilitre 
mm Millimetre 
mM Millimolar (mmol/l) 
MOI Multiplicity of infection 
Mr Relative molecular mass 
mRNA Messenger RNA 
MTIC 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide 
mTOR Mammalian target of rapamycin 
µg Microgramme 
µl Microlitre 
µm Micrometre 
µM Micromolar (µmol/l) 
NaCl Sodium chloride 
NaHCO3 Sodium hydrogen carbonate 
Na2HPO4 Sodium phosphate 
NaOH Sodium hydroxide 
NEAA Non-essential amino acids 
ng Nanogramme 
NH4C2H3O2 Ammonium acetate 
(NH4)2SO4 Ammonium sulfate 
nm Nanometre 
nM Nanomolar (nmol/l) 
nt Nucleotide 
OD Optical density 
pIX Minor capsid protein IX 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEG Polyethyleneglycol 
PET Positron emission tomography 
pfu Plaque forming units 
pg Picogramme 
P-gp P-glycoprotein 
PI3K Phosphatidylinositide 3-kinase 
PKC Protein kinase C  
poly(A) Polyadenylation 
pRB Retinoblastoma protein 
PS Penicillin and streptomycin 
PVDF Polyvinylidene fluoride 
qPCR Quantitative PCR 
r Radius 
RCA Replication-competent adenoviruses 
RDB  Resistant to daunoblastin 
RGD Arginine-glycine-aspartic acid  
rGFP recombinant green fluorescent protein 
RIPA Radio-Immunoprecipitation Assay 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
RNase Ribonuclease 
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ROI Region of interest 
rpm Revolution per minute 
RT Room temperature 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
sec Second 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SPECT Single photon emission computed tomography 
SRB Sulforhodamine B 
ss Single-stranded 
SSC Sodium chloride-sodium citrate buffer 
SV40 Simian virus 40 
TAE Tris-acetate-EDTA 
TAMRA 6-carboxytertramethylrhodamine 
Taq Thermus aquaticus 
TCA Trichloroacetic acid 
Tm Melting temperature 
TMZ Temozolomide 
U Unit 
UV Ultraviolet  
V Volt 
V Volume 
VEGF Vascular endothelial growth factor  
VP Viral particles 
WB Western blot 
wt Wild-type 
w/v Weight/volume 
XTT Sodium 3´-[1-(phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro) 
benzene sulfonic acid hydrate 
YB-1 Y-box binding protein 1 
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